( (TITLE (NP (NP (JJ Persistent) (NN Amyloidosis)) (PP-TMP (VBG following) (NP (NP (NN Suppression)) (PP (IN of) (NP (NN Aβ) (NN Production))) (PP-LOC (IN in) (NP (NP (DT a) (JJ Transgenic) (NN Model)) (PP (IN of) (NP (NNP Alzheimer) (NN Disease))))))))) )
( (HEADING (NP (NN Abstract))) )
( (HEADING (NP (NN Background))) )
( (S (NP-SBJ (NP (DT The) (NML (NNS proteases) (-LRB- -LRB-) (NNS secretases)) (-RRB- -RRB-)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP cleave) (NP (NML (NML (NN amyloid) (HYPH -) (NN β)) (-LRB- -LRB-) (NML (NN Aβ))) (-RRB- -RRB-) (NN peptide)) (PP (IN from) (NP (NP (DT the) (NN amyloid) (NN precursor) (NN protein)) (-LRB- -LRB-) (NP (NN APP)))))))) (-RRB- -RRB-) (VP (VBP have) (VP (VBN been) (NP-PRD (NP (DT the) (NN focus)) (PP (IN of) (NP (NP (JJ considerable) (NN investigation)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNS treatments)) (PP (IN for) (NP (NNP Alzheimer) (NN disease)))))))))))) (. .)) )
( (S (NP-SBJ (DT The) (NN prediction)) (VP (VBZ has) (VP (VBN been) (SBAR-PRD (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG reducing) (NP (NN Aβ) (NN production)) (PP-LOC (IN in) (NP (DT the) (NN brain))))) (, ,) (PP-TMP (ADVP (RB even)) (IN after) (NP (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (JJ clinical) (NNS symptoms)))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (VBN associated) (NN pathology)))))) (, ,) (VP (MD will) (VP (VB facilitate) (NP (DT the) (NML (NML (NML (NN repair)) (PP (IN of) (NP (VBN damaged) (NN tissue)))) (CC and) (NML (NML (NN removal)) (PP (IN of) (NP (NN amyloid) (NNS lesions)))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (NP (DT no) (NML (JJ long) (HYPH -) (NN term)) (NNS studies)) (VP (VBG using) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NN amyloid) (NN pathology)))))) (VP (VBP have) (ADVP (RB yet)) (VP (VBN been) (VP (VBN performed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB test) (NP (DT this) (NN hypothesis)))))))) (. .)) )
( (HEADING (NP (NNS Methods) (CC and) (NNS Findings))) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN generated) (NP (NP (DT a) (JJ transgenic) (NN mouse) (NN model)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (ADVP (RB genetically)) (VP (VBZ mimics) (NP (NP (DT the) (NN arrest)) (PP (IN of) (NP (NP (NN Aβ) (NN production)) (VP (VBN expected) (NP (-NONE- *)) (PP (IN from) (NP (NP (NN treatment)) (PP (IN with) (NP (NN secretase) (NNS inhibitors))))))))))))))) (. .)) )
( (S (NP-SBJ (DT These) (NNS mice)) (VP (VBP overexpress) (NP (NN mutant) (NN APP)) (PP (IN from) (NP (NP (DT a) (NN vector)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD can) (VP (VB be) (VP (VBN regulated) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NN doxycycline))))))))))) (. .)) )
( (S (PP (IN Under) (NP (JJ normal) (NNS conditions))) (, ,) (NP-SBJ (NP (NML (JJ high) (HYPH -) (NN level)) (NN expression)) (PP (IN of) (NP (NN APP)))) (ADVP (RB quickly)) (VP (VBZ induces) (NP (JJ fulminant) (NN amyloid) (NN pathology))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN doxycycline) (NN administration)) (VP (VP (VBZ inhibits) (NP (JJ transgenic) (NN APP) (NN expression)) (PP (IN by) (NP (QP (JJR greater) (IN than) (CD 95)) (NN %)))) (CC and) (VP (VBZ reduces) (NP (NN Aβ) (NN production)) (PP (IN to) (NP (NP (NNS levels)) (VP (VBN found) (NP (-NONE- *)) (PP-LOC (IN in) (NP (JJ nontransgenic) (NNS mice))))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (JJ transgenic) (NN Aβ) (NN synthesis))) (PP (IN in) (NP (DT this) (NN model)))) (ADVP-MNR (RB abruptly)) (VP (VBZ halts) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN amyloid) (NN pathology))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (NP (NN formation) (CC and) (NN disaggregation)) (PP (IN of) (NP (NN amyloid) (NNS deposits)))) (VP (VBP appear) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (PP-PRD (IN in) (NP (NN disequilibrium))) (SBAR-PRP (IN as) (S (NP-SBJ-3 (DT the) (NNS plaques)) (VP (VBP require) (ADVP-TMP (ADVP (RB far) (RBR longer)) (SBAR-2 (-NONE- *ICH*))) (S (NP-SBJ-3 (-NONE- *PRO*)) (VP (TO to) (VP (VB disperse)))) (SBAR-2 (IN than) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB assemble)))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NNS Mice)) (SBAR (WHPP-2 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN APP) (NN synthesis)) (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (QP (RB as) (JJ long) (IN as) (CD 6)) (NN mo))) (PP-TMP (IN after) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NN Aβ) (NNS deposits))))) (PP-2 (-NONE- *T*))))))) (VP (VBP retain) (NP (DT a) (JJ considerable) (NN amyloid) (NN load)) (, ,) (PP (IN with) (NP (NP (JJ little) (NN sign)) (PP (IN of) (NP (JJ active) (NN clearance)))))) (. .)) )
( (HEADING (NP (NN Conclusion))) )
( (S (NP-SBJ (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP-SBJ (NP (NN amyloid) (NNS lesions)) (PP-LOC (IN in) (NP (JJ transgenic) (NNS mice)))) (VP (VBP are) (NP-PRD (NP (NP (ADJP (RB highly) (JJ stable)) (NNS structures)) (ADVP (FW in) (FW vivo))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP are) (ADJP-PRD (JJ slow) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB disaggregate))))))))))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG arresting) (NP (NN Aβ) (NN production)) (PP-LOC (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Alzheimer) (NN disease))))))) (VP (MD should) (VP (VB halt) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN pathology)))))))) (, ,) (CC but) (SBAR (IN that) (S (NP-SBJ (JJ early) (NN treatment)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ imperative)) (, ,) (SBAR-PRP (IN as) (S (NP-SBJ (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP-SBJ (NN amyloid) (NNS deposits)) (, ,) (SBAR-TMP (IN once) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN formed) (NP-2 (-NONE- *))))) (, ,) (VP (MD will) (VP (VB require) (NP (NP (JJ additional) (NN intervention)) (SBAR (WHNP-3 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB clear) (NP-3 (-NONE- *T*)))))))))))))))))))) (. .)) )
( (HEADING (NP (NN Introduction))) )
( (S (ADVP-TMP (NP (QP (IN Over) (DT a)) (NN decade)) (RB ago)) (NP-SBJ (DT the) (NML (NN amyloid) (NN cascade)) (NN hypothesis)) (VP (VBD predicted) (SBAR (IN that) (S (NP-SBJ (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NML (NML (NN amyloid) (HYPH -) (NN β)) (-LRB- -LRB-) (NML (NN Aβ))) (-RRB- -RRB-) (NN peptide)))) (VP (VBP lead) (PP (IN to) (NP (NP (JJ secondary) (NNS pathologies)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (ADVP (RB ultimately)) (VP (VBP culminate) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Alzheimer) (NN disease)) (-LRB- -LRB-) (NP (NN AD))))))))))) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 1)) (-RRB- ])))))) (. .)) )
( (S (NP-SBJ (NP (JJ Early) (NN support)) (PP (IN for) (NP (DT this) (NN hypothesis)))) (VP (VBD came) (PP (IN from) (NP (NP (JJ genetic) (NNS studies)) (VP (VBG linking) (NP (NML (JJ early) (HYPH -) (NN onset)) (NN AD)) (PP (IN to) (NP (NP (NNS mutations)) (PP-LOC (IN in) (NP (NP (NP (NP (DT the) (NN amyloid) (NN precursor) (NN protein)) (-LRB- -LRB-) (NP (NN APP))) (-RRB- -RRB-) (, ,) (SBAR (WHPP-1 (IN from) (WHNP (WDT which))) (S (NP-SBJ-2 (NN Aβ)) (VP (VBZ is) (VP (VBN derived) (NP-2 (-NONE- *)) (PP-1 (-NONE- *T*))))))) (, ,) (CC and) (NP (NP (NNS presenilins) (NML (CD 1) (CC and) (CD 2))) (, ,) (SBAR (WHNP-4 (WDT which)) (S (NP-SBJ-4 (-NONE- *T*)) (VP (VBP are) (NP-PRD (NP (JJ interchangeable) (NNS components)) (PP (IN of) (NP (NP (DT a) (NN endoprotease) (NN complex)) (SBAR (WHNP-3 (WDT that)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBZ releases) (NP (NN Aβ)) (PP (IN from) (NP (NN APP))) (PRN (-LRB- -LRB-) (S-IMP (PP (IN for) (NP (NN review))) (NP-SBJ (-NONE- *PRO*)) (VP (VBP see) (-LRB- [) (NP (CD 2) (, ,) (CD 3)))) (-RRB- ]) (-RRB- -RRB-)))))))))))))))))))) (. .)) )
( (S (SBAR-ADV (IN If) (, ,) (S (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN predicted) (NP-1 (-NONE- *))))) (, ,) (NP-SBJ (NP (NN overproduction)) (PP (IN of) (NP (NN Aβ)))) (VP (VBZ initiates) (NP (NP (DT the) (NN cascade)) (PP (IN of) (NP (NP (NNS events)) (VP (VBG leading) (PP (IN to) (NP (NN disease)))))))))) (, ,) (ADVP-TMP (RB then)) (NP-SBJ (NP (JJ therapeutic) (NNS strategies)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP lower) (NP (NN Aβ) (NNS levels)))))) (VP (MD should) (VP (CC either) (VB arrest) (CC or) (VB reverse) (NP (NP (DT the) (NN progression)) (PP (PP (IN from) (NP (NN peptide))) (PP (IN to) (NP (NN dementia))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Early) (NN evidence)) (PP (IN from) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NP (ADJP (NN antibody) (HYPH -) (VBN mediated)) (NN clearance)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ first) (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NNS approaches)) (VP (VBN tested) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NNS humans)))))))))))) (, ,) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP (NNS treatments)) (VP (VBN designed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB reduce) (NP (NN amyloid) (NN burden))))))) (VP (MD may) (ADVP (RB indeed)) (VP (VB be) (ADJP-PRD (JJ beneficial))))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ-1 (DT the) (NNS trials)) (VP (VBD were) (VP (VBN halted) (NP-1 (-NONE- *)) (PP-PRP (IN because) (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NNS volunteers))))))) (PRN (-LRB- [) (NP (CD 4) (, ,) (CD 5)) (-RRB- ])))))) (, ,) (NP-SBJ (NP (JJ further) (NN analysis)) (PP (IN of) (NP (JJ several) (NNS patients)))) (VP (VBD found) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ-2 (NP (NN amyloid) (NN pathology)) (, ,) (CC and) (NP (PP (IN to) (NP (DT a) (JJR lesser) (NN degree))) (JJ cognitive) (NN function))) (, ,) (VP (VBD was) (VP (VBN improved) (NP-2 (-NONE- *)) (PP (IN in) (NP (NP (NN proportion)) (PP (IN to) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN titer)) (PP (IN of) (NP (ADJP (NN Aβ) (HYPH -) (JJ specific)) (NN antibody))))))) (PRN (-LRB- [) (NP (CD 6) (, ,) (CD 7)) (-RRB- ])))))))) (. .)) )
( (S (SBAR-ADV (IN While) (S (NP-SBJ (DT this) (NN approach)) (VP (VBZ is) (ADJP-PRD (JJ promising))))) (, ,) (NP-SBJ (NP (JJ constant) (NN exposure)) (PP (IN to) (NP (NP (NNS antibodies)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP recognize) (NP (NP (DT an) (NN epitope)) (ADJP (RB highly) (VBN enriched) (PP-LOC (IN in) (NP (DT the) (NN brain))))))))))) (VP (MD may) (VP (VB have) (NP (NP (JJ unexpected) (NN side) (NNS effects)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD will) (VP (VB limit) (NP (PRP$ its) (NML (JJ long) (HYPH -) (NN term)) (NN use))))))))) (. .)) )
( (S (NP-SBJ-2 (NP (DT An) (JJ alternative) (NN approach)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (VP (VBG being) (ADVP-MNR (RB actively)) (VP (VBN pursued) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (JJ future) (NN treatment)) (PP (IN of) (NP (NN AD))))))))))) (VP (VBZ seeks) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (TO to) (VP (VB lower) (NP (NN Aβ) (NNS levels)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG limiting) (NP (PRP$ its) (NN production)) (PP (IN from) (NP (NP (DT the) (NN precursor) (NN protein)) (NP (NN APP))))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Peptide) (NN Aβ)) (VP (VBZ is) (VP (VBN released) (NP-1 (-NONE- *)) (PP (IN from) (NP (NN APP))) (PP (IN by) (NP-LGS (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NP (CD two) (NNS enzymes)) (, ,) (NP (NP (DT the) (NML (NML (ADJP (NP (NN β) (HYPH -) (NN APP)) (VBG cleaving)) (NN enzyme) (CD 1)) (-LRB- -LRB-) (NML (NN BACE1)))) (-RRB- -RRB-) (CC and) (NP (SYM γ) (HYPH -) (NN secretase)))) (, ,) (SBAR (WHNP-2 (WDT which)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP cleave) (NP (DT the) (NN holoprotein)) (PP-LOC (IN at) (NP (NP (DT the) (NML (NN N) (HYPH -) (CC and) (NN C)) (HYPH -) (NNS termini)) (PP (IN of) (NP (NN Aβ)))))))))))) (, ,) (ADVP (RB respectively)))) (. .)) )
( (S (S (NP-SBJ-2 (NP (JJ Several) (NNS inhibitors)) (PP (IN of) (NP (SYM γ) (HYPH -) (NN secretase)))) (VP (VBP have) (ADVP (RB already)) (VP (VBN been) (VP (VBN produced) (NP-2 (-NONE- *)) (PRN (-LRB- [) (NP (CD 8) (, ,) (CD 9)) (-RRB- ])))))) (, ,) (CC and) (S (NP-SBJ-1 (NP (JJ small) (NN molecule) (NNS inhibitors)) (PP (IN of) (NP (ADJP (NP (NN β) (HYPH -) (NN APP)) (VBG cleaving)) (NN enzyme) (CD 1)))) (VP (VBP are) (ADVP-TMP (RB currently)) (VP (VBG being) (VP (VBN developed) (NP-1 (-NONE- *)) (PRN (-LRB- [) (NP (CD 10) (, ,) (CD 11)) (-RRB- ])))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NML (JJ long) (HYPH -) (NN term)) (NN effectiveness)) (PP (IN of) (NP (DT this) (NN approach))) (PP-LOC (IN in) (NP (NP (CC either) (NNS humans)) (CC or) (NP (NN model) (NNS systems))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (NP-1 (-NONE- *))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (NP (NN loss)) (PP (IN of) (NP (ADJP (NP (NN β) (HYPH -) (NN APP)) (VBG cleaving)) (NML (NN enzyme) (CD 1)) (NN function)))) (VP (MD can) (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNS plaques)))) (PP-LOC (IN in) (NP (NP (JJ transgenic) (NN mouse) (NNS models)) (PP (IN for) (NP (NN AD))))) (CIT (-LRB- -LRB-) (NNP F.) (NNP Laird) (, ,) (NNP H.) (NNP Cai) (, ,) (NNP P.) (NNP C.) (NNP Wong) (, ,) (JJ personal) (NN communication) (-RRB- -RRB-)))))) (, ,) (NP-SBJ-1 (NP (PRP it)) (SBAR-3 (-NONE- *EXP*))) (VP (VBZ is) (RB not) (VP (VBN known) (NP-1 (-NONE- *)) (SBAR-3 (IN whether) (S (NP-SBJ (DT the) (NN brain)) (VP (MD can) (VP (VB clear) (NP (JJ pre-existing) (NN amyloid) (NNS deposits)) (SBAR-TMP (IN once) (S (NP-SBJ-2 (NP (NN production)) (PP (IN of) (NP (NN Aβ)))) (VP (VBZ has) (VP (VBN been) (VP (VBN suppressed) (NP-2 (-NONE- *))))))))))))) (. .)) )
( (S (ADVP (RB Clearly)) (, ,) (NP-SBJ-1 (DT the) (ADJP (NN amyloid) (HYPH -) (VBG lowering)) (NN approach)) (VP (MD should) (VP (VB be) (ADVP-MNR (RB rigorously)) (VP (VBN examined) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN animal) (NNS models))) (SBAR-TMP (IN before) (S (NP-SBJ-2 (DT these) (NNS reagents)) (VP (VBP are) (VP (VBN tested) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NNS patients)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (JJ chemical) (NN secretase) (NNS inhibitors)) (ADJP (RBS most) (JJ likely) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB reach) (NP (JJ human) (NNS trials))))))) (VP (VBP are) (ADVP-TMP (RB still)) (PP-PRD (IN in) (NP (NN development)))) (. .)) )
( (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD developed) (NP (NP (DT a) (NN mouse) (NN model)) (PP (IN of) (NP (NP (NML (NNP Alzheimer) (HYPH -) (NN type)) (NN amyloid)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ expresses) (NP (DT a) (JJ controllable) (NN APP) (NN transgene))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT This) (NN system)) (, ,) (VP (ADVP (RB commonly)) (VBN known) (NP (-NONE- *)) (PP (IN as) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN system))))) (, ,) (VP (MD can) (VP (VB be) (VP (VBN regulated) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NNS analogs)) (PP (IN of) (NP (NP (NN tetracycline)) (VP (VBN administered) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NN food) (CC or) (NN water)))))))) (PRN (-LRB- [) (NP (CD 12) (, ,) (CD 13)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ strong) (NN expression) (NNS levels)) (VP (VBN produced) (NP (-NONE- *)) (PP (IN with) (NP (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NNS vectors)) (, ,) (VP (VBN combined) (NP (-NONE- *)) (PP (IN with) (NP (DT the) (NN ability) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB reduce) (NP (DT this) (NN expression)) (PP-EXT (IN by) (NP (NP (JJ several) (NNS orders)) (PP (IN of) (NP (NN magnitude))))) (PP-MNR (IN with) (NP (NN tetracycline))) (PRN (-LRB- [) (NP (CD 14)) (-RRB- ])))))))))))) (, ,) (VP (VBD allowed) (PP (IN for) (NP (NP (DT a) (JJ stringent) (NN test)) (PP (IN of) (NP (SBAR-NOM (WHADVP-1 (WRB how)) (S (NP-SBJ (NP (DT a) (ADJP (RB highly) (JJ effective)) (JJ pharmaceutical) (NN inhibitor)) (PP (IN of) (NP (NN Aβ) (NN production)))) (VP (MD would) (VP (VB impact) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN amyloid) (NN pathology)))) (ADVP-MNR-1 (-NONE- *T*)))))) (CC and) (SBAR-NOM (IN whether) (S (NP-SBJ (NP (NN reversal)) (PP (IN of) (NP (DT these) (NNS lesions)))) (VP (MD might) (VP (VB be) (ADJP-PRD (JJ possible)) (PP-TMP (VBG following) (PP (JJ such) (NP (NN treatment))))))))))))) (. .)) )
( (HEADING (NP (NNS Methods))) )
( (HEADING (NP (NN Transgene) (NN Construction))) )
( (S (NP-SBJ (PRP We)) (VP (VBD created) (NP (DT a) (ADJP (NN tetracycline) (HYPH -) (JJ responsive)) (JJ chimeric) (NML (NN mouse) (HYPH /) (JJ human)) (NML (NML (NN APP695Swedish) (HYPH /) (NNP Indiana)) (-LRB- -LRB-) (NML (NN swe) (HYPH /) (NN ind))) (-RRB- -RRB-) (NN vector)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG replacing) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (NN moPrP.XhoI) (NN vector)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (-NONE- *PRO*)) (ADVP (RB also)) (VP (VBN known) (NP (-NONE- *)) (PP (IN as) (NP (NN pPrPpE1) (HYPH /) (NN E2) (, ,) (NN 3sal))) (PRN (-LRB- [) (NP (CD 15)) (-RRB- ])))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (ADJP (NN tetracycline) (HYPH -) (JJ responsive)) (NN promoter)) (PP (IN of) (NP (NN pTetSplice) (PRN (-LRB- -LRB-) (NP (NP (NNP Life) (NNP Technologies)) (, ,) (NP-LOC (NNP Rockville)) (, ,) (NP-LOC (NNP Maryland)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (ADVP-TMP (RB then)) (VBG ligating) (NP (NN mouse) (NN APP)) (PP-MNR (IN with) (NP (NML (NML (DT a) (JJ humanized) (NN Aβ) (NN domain)) (-LRB- -LRB-) (NML (NN mo) (HYPH /) (NN huAPP695))) (-RRB- -RRB-) (NN cDNA))) (PP-LOC (IN into) (NP (DT the) (JJ new) (NN vector)))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD began) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG cloning) (NP (DT the) (ADJP (NN tetracycline) (HYPH -) (JJ responsive)) (NN promoter) (PRN (-LRB- -LRB-) (NP (NN bp) (NML (NML (CD 6)) (PP (SYM –) (NP (CD 481))))) (-RRB- -RRB-))) (PP (IN from) (NP (NP (NN pTetSplice)) (PP (IN by) (NP (NP (NN PCR)) (VP (VBG using) (NP (NP (NNS primers)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VP (VBD added) (NP=3 (JJ external) (NML (NN BamHI) (CC and) (NN NotI)) (NNS sites)) (PP=2 (IN to) (NP (DT the) (NML (CD 5) (SYM ′)) (NN end)))) (CC and) (VP (NP=3 (DT a) (NN BamHI) (NN site)) (PP=2 (IN to) (NP (DT the) (NML (CD 3) (SYM ′)) (NN end)))))))))))))))) (, ,) (SBAR-ADV (IN while) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBG destroying) (NP (NP (NML (NN XhoI) (CC and) (NN BamHI)) (NNS sites)) (PP (IN within) (NP (DT the) (NN promoter)))) (PRN (-LRB- -LRB-) (FRAG (NP (NN forward)) (: :) (NP (NN GCC) (NN GGA) (NN TCC) (NN GCG) (NN GCC) (NN GCC) (NN GTC) (NN GAG) (NN TTT) (NN ACC) (NN ACT) (NN CCC) (NN TAT) (NN C))) (: ;) (FRAG (NP (NN reverse)) (: :) (NP (NN GCC) (NN GGA) (NN TCC) (NN ACT) (NN CTA) (NN GAA) (NN GAT) (NN CCC) (NN CGG) (NN GTA) (NN CCG))) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP-TMP (RB then)) (VP (VBD isolated) (NP (DT the) (NN moPrP.XhoI) (NN intron)) (PP-MNR (IN by) (NP (NP (NN amplification)) (PP (IN with) (NP (NP (NNS primers)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VP (VBD added) (NP (DT an) (JJ external) (NN BamHI) (NN site)) (PP (IN to) (NP (NP (DT the) (NML (CD 5) (SYM ′)) (NN end)) (PP (IN of) (NP (NN exon) (CD 1)))))) (CC and) (VP (VBD ran) (PP (IN through) (NP (NP (DT the) (NN Asp718) (NN site)) (PP (IN of) (NP (NN exon) (CD 2))) (PRN (-LRB- -LRB-) (FRAG (NP (NN forward)) (: :) (NP (NN GCC) (NN GGA) (NN TCC) (NN GAT) (NN CAG) (NN CAG) (NN ACC) (NN GAT) (NN TCT) (NN GG))) (: ;) (FRAG (NP (NN reverse)) (: :) (NP (NN GCC) (NN GGT) (NN ACC) (NN ACT) (NN AGG) (NN AAG) (NN GCA) (NN GAA) (NN TGC))) (-RRB- -RRB-))))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NML (CD 2) (HYPH -) (NN kb)) (NN intron) (NN fragment)) (VP (VBD was) (VP (VP (VP (VBN cloned) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (DT a) (NML (NN TA) (NN cloning)) (NN vector) (PRN (-LRB- -LRB-) (NP (NP (NNP Invitrogen)) (, ,) (NP-LOC (NNP Carlsbad)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))))) (, ,) (VP (ADVP-TMP (RB then)) (VBN excised) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN Asp718) (NN digestion)))) (CC and) (VP (VBN ligated) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NP (DT the) (NML (CD 6.8) (HYPH -) (NN kb)) (NN Asp718) (NN fragment)) (PP (IN of) (NP (NN moPrP.XhoI)))) (VP (VBG containing) (NP (NP (NN exon) (CD 2)) (, ,) (NP (NN exon) (CD 3)) (, ,) (NP (DT the) (NML (CD 3) (SYM ′)) (NN UTR)) (, ,) (CC and) (NP (NN pBluescript)))))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB generate) (NP (DT an) (JJ intermediate) (NN vector)) (PP-MNR (IN with) (NP (NP (NP (DT all) (CD three) (NNS exons)) (CC and) (NP (DT a) (JJ central) (NN intron))) (CC but) (NP (DT no) (NN promoter))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN vector)) (VP (VBD was) (ADVP-TMP (RB then)) (VP (VP (VBN opened) (NP-1 (-NONE- *)) (PP-LOC (IN at) (NP (NP (DT the) (NN BamHI) (NN site)) (VP (VBN introduced) (NP (-NONE- *)) (PP (IN by) (NP-LGS (DT the) (NN intron) (NN cloning) (NN primer))))))) (, ,) (CC and) (VP (VBN ligated) (NP-1 (-NONE- *)) (PP (IN to) (NP (DT the) (NML (CD 0.5) (HYPH -) (NN kb)) (NML (NN BamHI) (HYPH -) (NN cut)) (NML (NN tetracycline) (NN promoter)) (NN fragment)))))) (. .)) )
( (S (NP-SBJ (DT This) (NN ligation)) (VP (VBD generated) (NP (NP (DT a) (NML (CD 9.3) (HYPH -) (NN kb)) (NN vector)) (VP (VBG encoding) (NP (NP (DT the) (NN tetracycline) (NN promoter)) (PP (IN from) (NP (NN pTetSplice)))) (PP-MNR (IN with) (NP (NP (NP (CD two) (NNS exons)) (, ,) (NP (CD one) (NN intron)) (, ,) (CC and) (NP (NP (DT the) (JJ original) (NML (CD 3) (SYM ′)) (NN UTR)) (PP (IN of) (NP (DT the) (NN moPrP.XhoI) (NN vector))))) (, ,) (VP (RB all) (VBN carried) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NML (NNP pBluescript) (NN cloning)) (NN vector))))))))) (. .)) )
( (S (S (NP-SBJ (PRP We)) (VP (VBD incorporated) (NP (DT the) (ADJP (ADJP (NNP Swedish) (PRN (-LRB- -LRB-) (NP (NN KM570) (HYPH /) (NN 571NL)) (-RRB- -RRB-))) (CC and) (ADJP (NNP Indiana) (PRN (-LRB- -LRB-) (NP (NN V617F)) (-RRB- -RRB-)))) (NNS mutations)) (PP (IN into) (NP (NP (DT the) (NML (NN mo) (HYPH /) (NN huAPP695)) (NN cDNA)) (-LRB- -LRB-) (PP-LOC (IN in) (NP (NN BS) (HYPH -) (NN KS))))) (-RRB- -RRB-) (PP-MNR (IN by) (NP (NN PCR))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT a) (NML (CD four) (HYPH -) (NN primer)) (NN strategy)))))) (: :) (S (ADVP-TMP (RB first)) (, ,) (NP-SBJ-1 (CD two) (ADJP (RB partially) (VBG overlapping)) (NNS products)) (VP (VBD were) (VP (VBN generated) (NP-1 (-NONE- *)) (PP (IN in) (NP (JJ separate) (NNS reactions))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NNS primers)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP encode) (NP (DT the) (VBN desired) (NNS mutations)) (PRN (-LRB- -LRB-) (FRAG (FRAG (NP (NNP Swedish) (NN forward)) (: :) (NP (NN GGA) (NN GAT) (NN CTC) (NN TGA) (NN AGT) (NN GAA) (NN TCT) (NNP GGA) (NNP TGC) (NNP AGA) (NNP ATT) (NN CCG))) (HYPH /) (FRAG (NP (NNP Indiana) (NN reverse)) (: :) (NP (NN GGG) (NN TGA) (NN TGA) (NN AAA) (NN TCA) (NN CGG) (NN TTG) (NN C)))) (: ;) (FRAG (NP (NNP Indiana) (NN forward)) (: :) (NP (NN CAA) (NN CCG) (NN TGA) (NN TTT) (NN TCA) (NN TCA) (NN CCC) (NN TGG) (HYPH /) (NN M13) (RB reverse))) (-RRB- -RRB-))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (CD two) (NN PCR) (NNS products)) (VP (VP (VBD were) (VP (VBN ligated) (, ,) (VBN digested) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NN BglII) (CC and) (NN ApaI))))) (CC and) (VP (VBN cloned) (NP-1 (-NONE- *)) (ADVP (RB back)) (PP (IN into) (NP (DT the) (JJ original) (NML (NN mo) (HYPH /) (NN huAPP695) (HYPH -) (NN BS) (HYPH -) (NN KS)) (NN vector))))) (. .)) )
( (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-1 (DT the) (JJ new) (NN APP695swe) (HYPH /) (NN ind)) (VP (VBD was) (VP (VBN subcloned) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (NP (DT the) (NN XhoI) (NN site)) (PP (IN of) (NP (DT the) (NML (NN moPrP) (HYPH -) (NN tetP)) (NN vector))))) (PP-DIR (IN from) (ADVP (RB above))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB complete) (NP (DT the) (NN construct))))))) (. .)) )
( (HEADING (NP (NP (JJ Pronuclear) (NN Injection)) (, ,) (NP (NP (NN Screening)) (PP (IN of) (NP (NNS Founders)))) (, ,) (CC and) (NP (NP (NN Maintenance)) (PP (IN of) (NP (DT the) (NNS Lines)))))) )
( (S (S (NP-SBJ-1=3 (DT The) (NML (NN moPrP) (HYPH -) (NN tetP) (HYPH -) (NN mo) (HYPH /) (NN huAPP695swe) (HYPH /) (NN ind)) (NN vector)) (VP (VBD was) (VP=4 (VBN linearized) (NP-1 (-NONE- *))))) (CC and) (S (NP-SBJ-2=3 (DT the) (NNP pBluescript) (NN domain)) (VP=4 (VBN excised) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NN digestion)) (PP (IN with) (NP (NN NotI))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (VBN purified) (NN vector)) (VP (VBD was) (VP (VBN injected) (NP-1 (-NONE- *)) (PP-DIR (IN into) (NP (NP (DT the) (NN pronucleus)) (PP (IN of) (NP (NP (VBN fertilized) (NNS eggs)) (PP (IN from) (NP (NML (NN C57BL) (HYPH /) (NN 6J) (SYM ×) (NN C3HeJ)) (NN F1) (NNS matings))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Founder) (NNS animals)) (VP (VBD were) (VP (VBN screened) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (NN transgene))))) (PP-MNR (IN by) (NP (NML (CD three) (HYPH -) (NN way)) (NN PCR))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT the) (NML (NML (NN S36)) (CC and) (NML (NN PrP) (HYPH -) (NN S) (HYPH /) (NN PrP) (HYPH -) (NN AS))) (NNS primers)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB below)))))))) (. .)) )
( (S (NP-SBJ-1 (ADJP (NN Transgene) (HYPH -) (JJ positive)) (NNS founders)) (VP (VBD were) (VP (VBN bred) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NNS animals)) (VP (VBG expressing) (NP (NP (DT the) (NN tetracycline) (NN transactivator)) (-LRB- -LRB-) (NP (NN tTA)))))) (-RRB- -RRB-) (PP-MNR (IN under) (NP (NP (NN control)) (PP (IN of) (NP (NP (DT the) (NML (NML (NN calcium) (HYPH -) (NN calmodulin)) (NN kinase) (NN IIα)) (-LRB- -LRB-) (NML (NN CaMKIIα)) (-RRB- -RRB-) (NN promoter)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP (NNP Jackson) (NNP Laboratory) (PRN (-LRB- [) (NP (CD 16)) (-RRB- ])))) (PRN (-LRB- -LRB-) (NP (NP (NNP Bar) (NNP Harbor)) (, ,) (NP-LOC (NNP Maine)) (, ,) (NP-LOC (NNP United) (NNP States))) (: ;) (FRAG (NP (NN stock) (SYM #) (CD 3010)) (: ;) (NP (NN B6)) (: ;) (NP (NN CBA) (HYPH -) (NN TgN) (-LRB- [) (NN Camk2a) (HYPH -) (NN tTA) (-RRB- ]) (NN 1Mmay))) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NN colony)) (VP (VBD was) (ADVP-TMP (RB thereafter)) (VP (VBN maintained) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG crossing) (NP (JJ single) (JJ transgenic) (NML (NN tTA) (CC and) (NN APP)) (NN offspring)) (PP (IN for) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (CD four) (NN APP) (NNS lines)))))))))) (. .)) )
( (S (NP-SBJ-1 (DT All) (NNS mice)) (VP (VBD were) (VP (VBN provided) (NP-1 (-NONE- *)) (NP (JJ fresh) (NML (NN food) (CC and) (NN water))) (ADVP-MNR (FW ad) (FW libitum)))) (. .)) )
( (S (NP-SBJ-1 (NN Animal) (NNS protocols)) (VP (VBD were) (VP (VBN approved) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NML (DT both) (NML (DT the) (NNP Johns) (NNP Hopkins) (NNP University)) (CC and) (NML (NML (DT the) (NNP California) (NNP Institute)) (PP (IN of) (NP (NNP Technology))))) (NML (NML (NNP Institutional) (NNP Animal)) (NML (NNP Care) (CC and) (NNP Use))) (NNPS Committees))))) (. .)) )
( (HEADING (NP (NN Doxycycline) (NN Administration))) )
( (S (NP-SBJ-1 (NP (NN Doxycycline)) (-LRB- -LRB-) (NP (NN dox)) (-RRB- -RRB-)) (VP (VBD was) (VP (VBN administered) (NP-1 (-NONE- *)) (PP-MNR (IN through) (NP (ADJP (RB commercially) (JJ available)) (ADJP (NN dox) (HYPH -) (VBG containing)) (NN chow))) (PRN (-LRB- -LRB-) (NP (NP (NNP BioServ)) (, ,) (NP-LOC (NNP Frenchtown)) (, ,) (NP-LOC (NNP New) (NNP Jersey)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))) (. .)) )
( (S (S (NP-SBJ (DT The) (NN chow)) (VP (VBD contained) (NP (NP (CD 200) (NN mg)) (PP (SYM /) (NP (NN kg))) (PP (IN of) (NP (JJ antibiotic)))))) (: ;) (S (PP (VBN based) (PP (IN on) (NP (NP (VBN estimated) (NN consumption)) (PP (IN of) (NP (NP (CD 5) (NN g)) (PP (IN per) (NP (NN mouse))) (PP-TMP (IN per) (NP (NN day)))))))) (, ,) (NP-SBJ (NP (DT the) (VBN expected) (NN dose)) (PP (IN to) (NP (DT each) (NN animal)))) (VP (VBD was) (NP-PRD (NP (NML (CD 1) (NN mg)) (NN dox)) (PP-TMP (IN per) (NP (NN day)))))) (. .)) )
( (S (NP-SBJ (DT The) (JJ average) (NML (CD 25) (HYPH -) (NN g)) (NN animal)) (ADVP (RB therefore)) (VP (VBD received) (NP (NP (CD 40) (NN μg)) (PP (IN of) (NP (NN dox))) (PP (IN per) (NP (NN gram) (NN body) (NN weight))) (PP-TMP (IN per) (NP (NN day))))) (. .)) )
( (S (NP-SBJ-1 (NN Chow)) (VP (VBD was) (VP (VBN changed) (NP-1 (-NONE- *)) (NP-TMP (NP (QP (CD 1) (SYM –) (CD 2)) (NNS times)) (PP-TMP (IN per) (NP (NN week)))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB prevent) (NP (NP (NN breakdown)) (PP (IN of) (NP (DT the) (NN antibiotic))))))))) (. .)) )
( (HEADING (NP (NN Genotyping))) )
( (S (NP-SBJ-1 (NN Offspring)) (VP (VBD were) (VP (VBN genotyped) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT each) (NN transgene))))) (PP-MNR (IN by) (NP (NP (NN PCR) (NN amplification)) (PP (IN of) (NP (NP (JJ genomic) (NN DNA)) (VP (VBN extracted) (NP (-NONE- *)) (PP (IN from) (NP (DT a) (NML (CD 5) (HYPH -) (NN mm)) (NN tail) (NN biopsy)))))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Tails)) (VP (VBD were) (VP (VP (VBN heated) (NP-1 (-NONE- *)) (PP (IN to) (NP (CD 95) (NN °C))) (PP-TMP (IN for) (NP (CD 45) (NN min))) (PP-LOC (IN in) (NP (NP (CD 250) (NN μl)) (PP (IN of) (NP (NML (CD 50) (NN mM)) (NN NaOH)))))) (, ,) (VP (VBN vortexed) (NP-1 (-NONE- *))) (, ,) (VP (ADVP-TMP (RB then)) (VBN neutralized) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NML (CD 0.5) (NN M)) (NN Tris) (HYPH -) (NN HCl) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 5.5)) (-RRB- -RRB-))))))))) (. .)) )
( (S (S (NP-SBJ-1 (NN Debris)) (VP (VBD was) (VP (VBN sedimented) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN centrifugation)))))) (, ,) (CC and) (S (NP-SBJ-2 (NP (CD 3) (NN μl)) (PP (IN of) (NP (NN supernatant)))) (VP (VBD was) (VP (VBN used) (NP-2 (-NONE- *)) (PP-PRP (IN for) (NP (NN amplification)))))) (. .)) )
( (S (NP-SBJ-1 (NP (VBG Genotyping)) (PP (IN for) (NP (NML (NN APP) (CC and) (NN tTA)) (NNS transgenes)))) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT the) (JJ same) (NN PCR) (NN reaction))) (, ,) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (CD five) (JJ separate) (NNS primers)))))) (. .)) )
( (S (NP-SBJ-1 (NN APP)) (VP (VBD was) (VP (VBN amplified) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NP (RB forward) (NN primer) (NN S36)) (VP (VBN located) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NML (CD 3) (SYM ′)) (NN end)) (PP (IN of) (NP (DT the) (NN APP) (NN cDNA) (PRN (-LRB- -LRB-) (NP (NN CCG) (NN AGA) (NN TCT) (NN CTG) (NN AAG) (NN TGA) (NN AGA) (NN TGG) (NN ATG)) (-RRB- -RRB-)))))))) (CC and) (NP (NP (JJ reverse) (NN primer) (NN PrP) (HYPH -) (NN AS) (HYPH -) (NN J)) (VP (VBN located) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NML (CD 3) (SYM ′)) (NN UTR)) (PP (IN of) (NP (DT the) (NN vector))) (PRN (-LRB- -LRB-) (NP (NN CCA) (NN AGC) (NN CTA) (NN GAC) (NN CAC) (NN GAG) (NN AAT) (NN GC)) (-RRB- -RRB-))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NN tTA) (NN transgene)) (VP (VBD was) (VP (VBN detected) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT a) (NN primer) (NN set)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD amplified) (PP-LOC (IN across) (NP (PRP$ its) (CD two) (NNS subdomains))) (PP-MNR (IN with) (NP (NP (NP=3 (NN tet) (RB forward)) (VP (VBN located) (NP (-NONE- *)) (PP-LOC=4 (IN within) (NP (DT the) (NML (NN Tn10) (NN tetracycline)) (NN repressor) (PRN (-LRB- -LRB-) (NP (NN CGC) (NN TGT) (NN GGG) (NN GCA) (NN TTT) (NN TAC) (NN TTT) (NN AG)) (-RRB- -RRB-)))))) (CC and) (NP (NP=3 (NN tet) (JJ reverse)) (PP-LOC=4 (IN within) (NP (DT the) (NN HSV1) (NN VP16) (PRN (-LRB- -LRB-) (NP (NN CAT) (NN GTC) (NN CAG) (NN ATC) (NN GAA) (NN ATC) (NN GTC)) (-RRB- -RRB-))))))))))))))) (. .)) )
( (S (NP-SBJ (DT All) (NNS reactions)) (, ,) (SBAR-ADV (IN whether) (FRAG (ADJP (NN transgene) (HYPH -) (JJ positive)) (CC or) (VP (FRAG (RB not))))) (, ,) (VP (VBD amplified) (NP (NP (DT a) (NN segment)) (PP (IN of) (NP (DT the) (JJ endogenous) (NN prion) (NN protein) (NN gene)))) (PP (IN as) (NP (NP (DT a) (NN control)) (PP (IN for) (NP (NN DNA) (NN quality))))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NP (NP (DT a) (JJ forward) (NN primer)) (, ,) (NP (NN PrP) (HYPH -) (NN S) (HYPH -) (NN J))) (, ,) (ADJP (JJ specific) (PP (IN to) (NP (DT the) (NN mouse) (NN PrP) (NML (JJ open) (NN reading)) (NN frame) (PRN (-LRB- -LRB-) (NP (NN GGG) (NN ACT) (NN ATG) (NN TGG) (NN ACT) (NN GAT) (NN GTC) (NN GG)) (-RRB- -RRB-)))))) (CC and) (NP (NP (NP (DT a) (JJ reverse) (NN primer)) (, ,) (NP (NN PrP) (HYPH -) (NN AS) (HYPH -) (NN J))) (, ,) (VP (VBN shared) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NML (CD 3) (SYM ′)) (NN UTR)) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (NN PrP) (NN gene)) (CC and) (NP (DT the) (NN transgene) (NN vector)))))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Amplification) (NNS reactions)) (VP (VBD were) (VP (VP (VBN run) (NP-1 (-NONE- *)) (PP (IN for) (NP (CD 37) (NNS cycles))) (PP (IN at) (NP=2 (CD 94) (NN °C))) (PP-TMP=3 (IN for) (NP (CD 30) (NN s)))) (, ,) (VP (NP=2 (CD 64) (NN °C)) (PP-TMP=3 (IN for) (NP (CD 1) (NN min)))) (, ,) (CC and) (VP (NP=2 (CD 72) (NN °C)) (PP-TMP=3 (IN for) (NP (CD 1) (NN min)))))) (. .)) )
( (S (NP-SBJ (NP (DT All) (NNS samples)) (, ,) (UCP (ADJP (JJ transgenic)) (CC and) (NP (JJ wild) (HYPH -) (NN type)))) (, ,) (VP (VBD gave) (NP (NP (DT a) (NML (CD 750) (HYPH -) (NN bp)) (NN product)) (PP (IN from) (NP (DT the) (JJ endogenous) (NN PrP) (NN gene))))) (. .)) )
( (S (S (NP-SBJ (DT The) (NN APP) (NN transgene)) (VP (VBD yielded) (NP (NP (DT an) (JJ additional) (NN band)) (PP (IN at) (NP (CD 400) (NN bp)))))) (: ;) (S (NP-SBJ (DT the) (NN tTA) (NN product)) (VP (VBD fell) (ADVP (RB in) (RB between)) (PP-LOC (IN at) (NP (CD 480) (NN bp))))) (. .)) )
( (HEADING (NP (NN Immunoblotting) (HYPH /) (NN Quantitation))) )
( (S (NP-SBJ-1 (VBN Frozen) (UCP (ADJP (JJ cortical)) (CC or) (NML (JJ whole) (NN forebrain))) (NN tissue)) (VP (VBD was) (VP (VBN homogenized) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN sonication))) (PP-LOC (IN in) (NP (NP (CD five) (NNS volumes)) (PP (IN of) (NP (NP (ADJP (NN phosphate) (HYPH -) (VBN buffered)) (NN saline)) (-LRB- -LRB-) (NP (NN PBS)))))) (-RRB- -RRB-) (PP-MNR (IN with) (NP (NML (CD 5) (NN mM)) (NML (NN EDTA) (CC and) (NN protease)) (NNS inhibitors) (PRN (-LRB- -LRB-) (NP (NP (JJ Mammalian) (NN cell) (NN cocktail)) (, ,) (NP-ADV (NNP Sigma)) (, ,) (NP-LOC (NNP St.) (NNP Louis)) (, ,) (NP-LOC (NNP Missouri)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))) (, ,) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT a) (NN probe) (NN sonicator)) (VP (VBN set) (NP (-NONE- *)) (PP (IN to) (NP (NML (CD 50) (NN %)) (NN output)))) (PRN (-LRB- -LRB-) (NP (NP (NNP TEKMAR)) (, ,) (NP-LOC (NNP Cincinnati)) (, ,) (NP-LOC (NNP Ohio)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (NN dilution)) (PP (IN with) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NML (NN PBS) (HYPH /) (NN EDTA) (HYPH /) (NN protease)) (NN inhibitor))))))) (, ,) (S (S (NP-SBJ-1=4 (DT the) (NNS samples)) (VP (VBD were) (VP=3 (VBN centrifuged) (NP-1 (-NONE- *)) (ADVP-TMP (RB briefly))))) (CC and) (S (NP-SBJ-2=4 (DT the) (NN supernatant)) (VP=3 (VBN used) (NP-2 (-NONE- *)) (PP-PRP (IN for) (NP (NN analysis)))))) (. .)) )
( (S (NP-SBJ-1 (NP (NP (NML (CD Fifty) (NNS micrograms)) (-LRB- -LRB-) (NN 6E10) (CC and) (NN CT15) (-RRB- -RRB-)) (CC or) (NP (NML (CD 5) (NN μg)) (-LRB- -LRB-) (NN 22C11) (-RRB- -RRB-))) (PP (IN of) (NP (NN brain) (NN homogenate)))) (VP (VBD was) (VP (VP (VBN loaded) (NP-1 (-NONE- *)) (PP (IN per) (NP (NN lane))) (PP (IN onto) (NP (NML (NML (NML (CD 7.5) (NN %)) (, ,) (NML (NML (CD 10) (NN %)) (PP (SYM –) (NP (CD 20) (NN %)))) (, ,) (CC or) (NML (NML (CD 4) (NN %)) (PP (SYM –) (NP (CD 20) (NN %))))) (NN Tris) (HYPH -) (NN HCl) (NN PAGE)) (NNS gels) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP Bio) (HYPH -) (NNP Rad)) (NNP Laboratories)) (, ,) (NP-LOC (NNP Hercules)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))))) (CC and) (VP (VBN electrophoresed) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (JJ several) (NNS hours))) (PP-LOC (IN in) (NP (NP (NML (NML (QP (CD 1) (SYM ×)) (NN Tris) (HYPH -) (NN glycine) (HYPH –) (NN sodium) (NN dodecyl) (NN sulfate)) (-LRB- -LRB-) (NML (QP (CD 1) (SYM ×)) (NN TG) (HYPH -) (NN SDS))) (-RRB- -RRB-) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN 6E10) (CC and) (NN 22C11)) (: ;) (NP (NP (NNP Amresco)) (, ,) (NP-LOC (NNP Solon)) (, ,) (NP-LOC (NNP Ohio)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))) (CC or) (NP (QP (CD 1) (SYM ×)) (NML (NN Tris) (HYPH -) (NN tricine) (HYPH -) (NN SDS)) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN CT15)) (: ;) (NP (NP (NNP Invitrogen)) (, ,) (NP-LOC (NNP Carlsbad)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Proteins)) (VP (VBD were) (VP (VBN transferred) (NP-1 (-NONE- *)) (ADVP-TMP (RB overnight)) (PP (IN to) (NP (NML (CD 0.45) (HYPH -) (NN μm)) (NNP Optitran) (NN nitrocellulose) (PRN (-LRB- -LRB-) (NP (NP (NNP Schleicher) (CC and) (NNP Schuell)) (, ,) (NP-LOC (NNP Keene)) (, ,) (NP-LOC (NNP New) (NNP Hampshire)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))) (PP-LOC (IN in) (NP (QP (CD 1) (SYM ×)) (NN TG) (NN buffer) (PRN (-LRB- -LRB-) (NP (NNP Amresco)) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ-1 (NNS Blots)) (VP (VBD were) (VP (VP (VBN blocked) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN PBS)) (VP (VBG containing) (NP (NML (CD 5) (NN %)) (NML (JJ nonfat) (JJ dry) (NN milk)) (NN powder)))))) (, ,) (CC and) (VP (VBN incubated) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 3) (NN h))) (PP (IN at) (NP (NN room) (NN temperature))) (PP-LOC (IN in) (NP (NP (NN blocking) (NN solution)) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (VBG following) (NNS antibodies)) (: :) (NP (NP (NP (NN mouse) (JJ monoclonal) (NN 22C11) (PRN (-LRB- -LRB-) (NP (NP (JJ kind) (NN gift)) (PP (IN of) (NP (NP (NNP Konrad) (NNP Beyreuther)) (CC and) (NP (NNP Andreas) (NNP Weidemann))))) (: ;) (-LRB- [) (NP (CD 17)) (-RRB- ]) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 1,000)))))) (, ,) (NP (NP (NN mouse) (JJ monoclonal) (NN 6E10) (PRN (-LRB- -LRB-) (NP (NP (NNP Signet) (NNP Laboratories)) (, ,) (NP-LOC (NNP Dedham)) (, ,) (NP-LOC (NNP Massachusetts)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 2,500)))))) (, ,) (NP (NP (NN rabbit) (JJ polyclonal) (JJ anti-superoxide) (NN dismutase) (CD 1) (-LRB- -LRB-) (NN m) (HYPH /) (NN hSOD1) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 18)) (-RRB- ]))) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 2,500))) (PP (IN to) (NP (NP (CD 1)) (PP (SYM :) (NP (CD 4,000)))))))) (, ,) (CC or) (NP (NP (NN rabbit) (JJ polyclonal) (NN CT15) (PRN (-LRB- -LRB-) (NP (NP (JJ kind) (NN gift)) (PP (IN of) (NP (NNP Ed) (NNP Koo))) (: ;) (PRN (-LRB- [) (NP (CD 19)) (-RRB- ]))) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 1,000)))))))))))))))) (. .)) )
( (S (ADVP-TMP (RB Subsequently)) (, ,) (NP-SBJ-1 (DT the) (NNS blots)) (VP (VBD were) (VP (VP (VBN washed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NN PBS)) (VP (VBG containing) (NP (NML (CD 0.1) (NN %)) (NN Tween) (HYPH -) (CD 20)))))) (, ,) (CC and) (VP (ADVP-TMP (RB then)) (VBN incubated) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NML (CC either) (NML (NN goat) (JJ anti-mouse)) (HYPH –) (CC or) (NML (NN goat) (JJ anti-rabbit))) (HYPH –) (ADJP (NN HRP) (VBN conjugated)) (JJ secondary) (NN antibody)) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 1,000)))) (PP-LOC (IN in) (NP (NN blocking) (NN solution))))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (JJ several) (JJ additional) (NNS rinses)) (PP-LOC (IN in) (NP (NN PBS))) (PP (IN with) (NP (QP (CD 0.1) (NN %)) (NN Tween) (HYPH -) (CD 20))))) (, ,) (NP-SBJ-1 (NNS blots)) (VP (VBD were) (VP (VP (VBN developed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (VBN enhanced) (NN chemiluminescence) (NN reagent)))) (CC and) (VP (VBN imaged) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (DT the) (NML (NML (NNP Bio) (HYPH -) (NNP Rad)) (NNP Molecular) (NNP Imager) (NNP FX)) (NN system)))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Staining) (NN intensity)) (PP (IN within) (NP (DT each) (NN lane)))) (VP (VBD was) (VP (VBN quantified) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (NML (NNP Quantity) (CD One)) (NML (NN image) (NN analysis)) (NN software) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP Molecular) (NNP Imager)) (NNP FX)) (, ,) (NP-ADV (NML (NNP Bio) (HYPH -) (NNP Rad)) (NNP Laboratories))) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ-1 (NN Background)) (VP (VBD was) (VP (VP (VBN calculated) (NP-1 (-NONE- *)) (PP (IN from) (PP (IN across) (NP (DT the) (NN image))))) (CC and) (VP (VBN subtracted) (NP-1 (-NONE- *)) (PP (IN from) (NP (DT the) (JJ entire) (NN file)))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN signal) (NN intensity)) (PP (IN for) (NP (DT each) (NN band))) (PRN (-LRB- -LRB-) (NP (NP (VBN corrected) (NN signal) (NN intensity)) (SYM ×) (NP (NN pixel) (NN number))) (-RRB- -RRB-))) (VP (VBD was) (ADVP-TMP (RB then)) (VP (VBN calculated) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (NML (NN Volume) (NN report)) (NN tool)))))) (. .)) )
( (HEADING (NP (NML (NN Slot) (NN Blot)) (NN mRNA) (NN Analysis))) )
( (S (NP-SBJ-1 (NP (CD Five) (NNS micrograms)) (PP (IN per) (NP (NP (NN sample)) (PP (IN of) (NP (NP (JJ total) (NN RNA)) (VP (VBN extracted) (NP (-NONE- *)) (PP (IN from) (NP (ADJP (JJ fresh) (HYPH -) (VBN frozen)) (NML (NML (NN brain)) (, ,) (NML (NN liver)) (, ,) (NML (NN kidney)) (, ,) (NML (NN heart)) (, ,) (NML (NN lung)) (, ,) (NML (NN spleen)) (, ,) (CC and) (NML (JJ skeletal) (NN muscle))))))))))) (VP (VBD was) (VP (NN vacuum) (HYPH -) (VBN filtered) (NP-1 (-NONE- *)) (PP-MNR (IN through) (NP (NML (CD 0.45) (HYPH -) (NN μm)) (NNP Optitran) (NN nitrocellulose))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (JJ several) (NNS washes)) (PP (IN through) (NP (DT the) (NN manifold))) (PP (IN with) (NP (QP (CD 10) (SYM ×)) (NN SSC))))) (, ,) (NP-SBJ-1 (NNS blots)) (VP (VBD were) (VP (NN UV) (HYPH -) (VBN cross-linked) (NP-1 (-NONE- *))) (CC and) (VP (VBN probed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (DT a) (VBN radiolabeled) (NML (QP (SYM ∼) (CD 350)) (HYPH -) (NN bp)) (NML (NN BglII) (HYPH –) (NN XhoI)) (NN cDNA) (NN fragment)) (PP (IN of) (NP (NML (NN mo) (HYPH /) (NN huAPP695)) (NN cDNA))))))) (. .)) )
( (S (PP-TMP (IN After) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG hybridizing) (ADVP-TMP (RB overnight)) (PP (IN at) (NP (CD 65) (NN °C))) (PP-LOC (IN in) (NP (NP (NML (CD 1) (NN %)) (NN BSA)) (HYPH /) (NP (NML (CD 1) (NN mM)) (NN EDTA)) (HYPH /) (NP (NML (CD 0.5) (NN M)) (NN sodium) (NN phosphate) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.2)) (-RRB- -RRB-))) (HYPH /) (NP (NML (CD 7) (NN %)) (NN SDS) (PRN (-LRB- [) (NP (CD 20)) (-RRB- ])))))))) (, ,) (NP-SBJ-1 (DT the) (NNS blots)) (VP (VBD were) (VP (VBN washed) (NP-1 (-NONE- *)) (ADVP-TMP (RB twice)) (PP (IN at) (NP (CD 65) (NN °C))) (PP-TMP (IN for) (NP (NP (CD 30) (NN min)) (NP (DT each)))) (PP-LOC (IN in) (NP (NP (NML (CD 0.1) (NN %)) (NN BSA)) (HYPH /) (NP (NML (CD 1) (NN mM)) (NN EDTA)) (HYPH /) (NP (NP (CD 40) (NN mM)) (NN sodium) (NN phosphate) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.2)) (-RRB- -RRB-))) (HYPH /) (NP (NML (CD 5) (NN %)) (NN SDS)))) (PP-TMP (IN before) (NP (NP (CD two) (JJ final) (NML (CD 30) (HYPH -) (NN min)) (NNS washes)) (PP (IN at) (NP (CD 65) (NN °C))) (PP (IN with) (NP (NP (NML (CD 1) (NN mM)) (NN EDTA)) (HYPH /) (NP (NML (CD 40) (NN mM)) (NN sodium) (NN phosphate) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.2)) (-RRB- -RRB-))) (HYPH /) (NP (NML (CD 1) (NN %)) (NN SDS)))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Blots)) (VP (VBD were) (VP (VP (VBN wrapped) (NP-1 (-NONE- *)) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ wet)))) (CC and) (VP (VBN exposed) (NP-1 (-NONE- *)) (PP (IN to) (NP (NNS phosphorscreens))) (ADVP-TMP (RB overnight)) (PP (IN at) (NP (NN room) (NN temperature)))))) (. .)) )
( (HEADING (NP (NN Amyloid) (NN Histology))) )
( (S (S (NP-SBJ-1=3 (NNS Mice)) (VP (VBD were) (VP=2 (VBN euthanized) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN ether) (NN inhalation)))))) (CC and) (S (NP-SBJ-4=3 (NNS brains)) (VP=2 (VBN removed) (NP-4 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NN immersion) (NN fixation)) (PP-LOC (IN in) (NP (NP (NML (CD 4) (NN %)) (NN paraformaldehyde)) (HYPH /) (NP (NML (CD 1) (SYM ×)) (NN PBS)))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (CD 48) (NN h)) (PP (IN in) (NP (JJ fixative))) (PP (IN at) (NP (CD 4) (NN °C))))) (, ,) (NP-SBJ-1 (NNS brains)) (VP (VBD were) (VP (VP (VBN transferred) (NP-1 (-NONE- *)) (PP (IN to) (NP (NN PBS)))) (, ,) (VP (VBN dehydrated) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NNS alcohols)))) (, ,) (VP (VBN treated) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NN cedarwood) (NN oil)) (CC and) (NP (NN methylsalicylate))))) (, ,) (CC and) (VP (VBN embedded) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN paraffin))) (PP-PRP (IN for) (NP (VBG sectioning)))))) (. .)) )
( (HEADING (NP (NN Hirano) (NN silver) (NN stain))) )
( (S (NP-SBJ-1 (NN Silver) (NN impregnation) (NN histology)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (PP (IN on) (NP (NML (CD 10) (HYPH -) (NN μm)) (ADJP (NN paraffin) (HYPH -) (VBN embedded)) (NNS sections))) (PP-MNR (IN by) (NP (NP (NML (NNP Hirano) (POS 's)) (NN modification)) (PP (IN of) (NP (DT the) (NNP Bielschowsky) (NN method))))) (PRN (-LRB- [) (NP (CD 21)) (-RRB- ])))) (. .)) )
( (S (ADVP-TMP (RB Briefly)) (, ,) (NP-SBJ-1 (NNS sections)) (VP (VBD were) (VP (VBN deparaffinized) (NP-1 (-NONE- *)) (PP-MNR (IN through) (NP (NN xylene) (CC and) (NNS alcohols))) (PP-LOC (IN into) (NP (NN tap) (NN water))) (PP-TMP (IN before) (S-NOM (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBG being) (VP (VBN placed) (NP-2 (-NONE- *)) (PP-LOC (IN into) (NP (JJ fresh) (NML (CD 20) (NN %)) (NN silver) (NN nitrate) (NN solution))) (PP-TMP (IN for) (NP (CD 20) (NN min))))))))) (. .)) )
( (S (PP-TMP (IN After) (S-NOM (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBG being) (VP (VBN washed) (NP-1 (-NONE- *)) (ADVP-MNR (RB thoroughly)) (PP (IN with) (NP (JJ distilled) (NN water))))))) (, ,) (NP-SBJ-2 (NNS slides)) (VP (VBD were) (VP (VBN immersed) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NML (CD 20) (NN %)) (NML (NN silver) (NN nitrate)) (NN solution)) (VP (VBN titrated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (JJ fresh) (NN ammonium) (NN hydroxide)))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (CD 20) (NN min))) (, ,) (NP-SBJ-1 (NNS slides)) (VP (VBD were) (VP (VBN washed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NN ammonia) (NN water))) (PP-TMP (IN before) (S-NOM (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBG being) (ADVP-MNR (RB individually)) (VP (VBN developed) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NP (CD 100) (NN μl)) (PP (IN of) (NP (NN developer) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 20) (NN ml)) (PP (IN of) (NP (NML (CD 37) (NN %)) (NN formaldehyde)))) (, ,) (NP (NP (CD 100) (NN ml)) (PP (IN of) (NP (JJ distilled) (NN water)))) (, ,) (NP (NP (CD 50) (NN μl)) (PP (IN of) (NP (VBN concentrated) (JJ nitric) (NN acid)))) (, ,) (CC and) (NP (NP (CD 0.5) (NN g)) (PP (IN of) (NP (JJ citric) (NN acid))))) (-RRB- -RRB-))))) (VP (VBN added) (NP (-NONE- *)) (PP (IN to) (NP (NP (CD 50) (NN ml)) (PP (IN of) (NP (VBN titrated) (NML (NN silver) (NN nitrate)) (NN solution)))))))))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Slides)) (VP (VBD were) (ADVP-TMP (RB then)) (VP (VP (VBN rinsed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN tap) (NN water)))) (, ,) (VP (VBN fixed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NML (CD 5) (NN %)) (NN sodium) (NN thiosulfate)))) (, ,) (CC and) (VP (VBN dehydrated) (NP-1 (-NONE- *)) (PP-MNR (IN through) (NP (NNS alcohols) (CC and) (NN xylene)))))) (. .)) )
( (HEADING (NP (NML (NN Thioflavin) (HYPH -) (NN S)) (NN staining))) )
( (S (PP-TMP (VBG Following) (NP (NP (NN deparaffinization)) (PP (IN of) (NP (NNS sections))) (PP (IN through) (NP (NN xylene) (CC and) (NNS alcohols))))) (, ,) (NP-SBJ-1 (NP (NN amyloid) (NN impregnation)) (PP (IN with) (NP (NN thioflavin) (HYPH -) (NN S)))) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (PP (VBG according) (PP (IN to) (NP (NP (DT the) (NN Guntern) (NN modification)) (PP (IN of) (NP (DT the) (JJ standard) (NN protocol)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NNS Slides)) (VP (VBG holding) (NP (NML (CD 10) (HYPH -) (NN μm)) (NN paraffin) (NNS sections)))) (VP (VBD were) (VP (VP (VBN washed) (NP-1 (-NONE- *)) (ADVP-TMP (RB twice)) (PP-LOC (IN in) (NP (JJ distilled) (NN water)))) (, ,) (VP (ADVP-TMP (RB then)) (VBN immersed) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 5) (NN min))) (PP-LOC (IN in) (NP (DT a) (NML (CD 0.25) (NN %)) (NN potassium) (NN permanganate) (NN solution))) (, ,) (S-ADV (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN followed) (NP-2 (-NONE- *)) (PP (IN by) (NP-LGS (NP (CD 5) (NN min)) (PP-LOC (IN in) (NP (DT a) (NML (NML (NML (CD 1) (NN %)) (NN potassium) (NN metabisulfate)) (HYPH /) (NML (NML (CD 1) (NN %)) (JJ oxalic) (NN acid))) (NN solution)))))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (DT this) (NN preparation))) (, ,) (NP-SBJ-1 (NNS slides)) (VP (VBD were) (VP (VBN placed) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (DT a) (VBN filtered) (JJ aqueous) (NML (CD 0.02) (NN %)) (NML (NN thioflavin) (HYPH -) (NN S)) (NN solution) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP Chroma) (HYPH -) (NNP Gesellschaft)) (NNP Schmid)) (, ,) (NP-LOC (NNP Kongen)) (, ,) (NP-LOC (NNP Germany))) (-RRB- -RRB-)))) (PP-TMP (IN for) (NP (CD 8) (NN min))))) (. .)) )
( (S (NP-SBJ-1 (JJ Excess) (NN stain)) (VP (VBD was) (VP (VBN removed) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NP (NP (CD two) (JJ brief) (NNS rinses)) (PP (IN in) (NP (NML (CD 80) (NN %)) (NN ethanol)))) (, ,) (NP (ADVP-TMP (RB then)) (NP (CD two)) (PP-LOC (IN in) (NP (JJ distilled) (NN water))))) (, ,) (SBAR (WHPP-3 (IN after) (WHNP (WDT which))) (S (NP-SBJ-2 (NNS slides)) (VP (VBD were) (VP (VBN finished) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (JJ aqueous) (NN mounting) (NN medium))) (PP-PRP (IN for) (NP (NN florescence) (NN photomicrography))) (PP-TMP-3 (-NONE- *T*)))))))))) (. .)) )
( (HEADING (NP (NP (NN Ubiquitin)) (, ,) (NP (JJ glial) (JJ fibrillary) (JJ acidic) (NN protein)) (, ,) (CC and) (NP (NN Aβ) (NN immunohistochemistry)))) )
( (S (PP-TMP (JJ Prior) (PP (IN to) (NP (NN immunostaining)))) (, ,) (NP-SBJ-1 (NNS slides)) (VP (VBD were) (VP (VBN deparaffinized) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN oven) (NN heating))) (S-TMP (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN followed) (NP-2 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NN immersion)) (PP-LOC (IN in) (NP (NN xylene))))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (NN rehydration)) (PP (IN through) (NP (VBN graded) (NNS alcohols))) (PP-LOC (IN into) (NP (NN tap) (NN water))))) (, ,) (NP-SBJ-1 (JJ endogenous) (NN peroxidase) (NN activity)) (VP (VBD was) (VP (VBN quenched) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NN incubation)) (PP (IN with) (NP (NML (CD 3) (NN %)) (NN hydrogen) (NN peroxide))) (PP-LOC (IN in) (NP (NN methanol))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Slides)) (VP (VBD were) (VP (VP (VBN microwaved) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (QP (CD 5) (SYM –) (CD 7)) (NN min))) (PP-LOC (IN in) (NP (NN water)))) (, ,) (VP (VBN cooled) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 5) (NN min)))) (, ,) (VP (ADVP-TMP (RB then)) (VBN washed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN TBS)))))) (. .)) )
( (S (NP-SBJ-1 (JJ Nonspecific) (NN staining)) (VP (VBD was) (VP (VBN blocked) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 1) (NN h))) (PP-MNR (IN with) (NP (NP (NP (NML (CD 3) (NN %)) (JJ normal) (NN goat) (NN serum)) (CC and) (NP (NML (CD 0.1) (NN %)) (NN Triton) (HYPH -) (NN X) (CD 100))) (PP-LOC (IN in) (NP (NN TBS))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Slides)) (VP (VBD were) (ADVP-TMP (RB then)) (VP (VP (VBN placed) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (NP (JJ primary) (NN antibody) (PRN (-LRB- -LRB-) (NP (NP (NN rabbit) (JJ anti-Aβ) (NN peptide) (JJ polyclonal) (NN antibody)) (, ,) (NP-ADV (NNP Zymed) (NNP Laboratories)) (, ,) (NP-LOC (NNP South) (NNP San) (NNP Francisco)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (: ;) (NP (NP (NML (NML (NN rabbit) (JJ anti-ubiquitin)) (CC and) (NML (NN rabbit) (JJ anti–glial))) (NML (NML (JJ fibrillary) (JJ acidic) (NN protein)) (-LRB- -LRB-) (NML (NN GFAP))) (-RRB- -RRB-) (JJ polyclonal) (NNS antibodies)) (, ,) (NP-LOC (NNP Dako)) (, ,) (NP-LOC (NNP Carpinteria)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP-ADV (NP (CD 1)) (PP (SYM :) (NP (CD 500)))) (PP-LOC (IN in) (NP (NN TBS))) (PP-MNR (IN with) (NP (NML (CD 2) (NN %)) (JJ normal) (NN goat) (NN serum))))))) (CC and) (VP (VBN incubated) (NP-1 (-NONE- *)) (ADVP-TMP (RB overnight)) (PP (IN at) (NP (NN room) (NN temperature)))))) (. .)) )
( (S (PP-TMP (IN After) (S-NOM (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBG being) (VP (VBN washed) (NP-1 (-NONE- *)) (PP (IN of) (NP (JJ excess) (JJ primary) (NN antibody))) (PP-MNR (IN with) (NP (NP (JJ several) (NNS changes)) (PP (IN of) (NP (NN TBS))))))))) (, ,) (NP-SBJ-2 (NNS slides)) (VP (VBD were) (VP (VBN incubated) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (CC either) (NP (DT the) (NML (NNP Vectastain) (NNP Elite)) (JJ anti-rabbit) (JJ secondary) (NN system) (PRN (-LRB- -LRB-) (NP (JJ anti-Aβ)) (: ;) (NP (NP (NNP Vector) (NNP Laboratories)) (, ,) (NP-LOC (NNP Burlingame)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))) (CC or) (NP (NML (NN peroxidase) (HYPH /) (JJ anti-peroxidase)) (NNS reagents) (PRN (-LRB- -LRB-) (NP (JJ anti-ubitquitin) (CC and) (JJ anti-GFAP)) (: ;) (NP (NP (NNP Sternberger) (NNPS Monoclonals)) (, ,) (NP-LOC (NNP Lutherville)) (, ,) (NP-LOC (NNP Maryland)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-))))) (PP-MNR (VBG according) (PP (IN to) (NP (NP (DT the) (NNS manufacturers) (POS ')) (NNS directions)))))) (. .)) )
( (S (S (NP-SBJ-1 (NN Antibody) (NN binding)) (VP (VBD was) (VP (VBN visualized) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NN diaminobenzidene)))))) (, ,) (CC and) (S (NP-SBJ-2 (NNS sections)) (VP (VBD were) (VP (VBN counterstained) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (NN hematoxylin)))))) (. .)) )
( (HEADING (NP (NN Filter) (NN Trap) (NN Assay))) )
( (S (NP-SBJ-1 (NP (DT An) (NN aliquot)) (PP (IN of) (NP (NP (DT each) (JJ cortical) (NN homogenate)) (VP (VBN used) (NP (-NONE- *)) (PP-PRP (IN for) (NP (NNP Western) (NN blotting))) (ADVP (RB above)))))) (VP (VBD was) (ADVP (RB partially)) (VP (VBN solubilized) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN SDS))))) (PP (IN to) (NP (NP (DT a) (JJ final) (NN concentration)) (PP (IN of) (NP (CD 1) (NN %))))))) (. .)) )
( (S (S (NP-SBJ-1 (JJ Serial) (NML (NML (CD 1)) (PP (SYM :) (NP (CD 2)))) (NNS dilutions)) (VP (VBD were) (VP (VBN made) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NML (CD 1) (SYM ×)) (NN PBS)) (HYPH /) (NP (NML (CD 1) (NN %)) (NN SDS))))))) (, ,) (CC and) (S (NP-SBJ-2 (NP (CD 100) (NN μl)) (PP (IN of) (NP (DT each) (NN dilution)))) (VP (VBD was) (ADVP-TMP (RB then)) (VP (NN vacuum) (HYPH -) (VBN filtered) (NP-2 (-NONE- *)) (PP-DIR (IN through) (NP (DT a) (JJ pre-wet) (NML (CD 0.22) (HYPH -) (NN μm)) (NN cellulose) (NN acetate) (NN membrane) (PRN (-LRB- -LRB-) (NP (NNP Schleicher) (CC and) (NNP Schuell)) (-RRB- -RRB-)))) (PRN (-LRB- [) (NP (CD 22)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ-1 (DT Each) (NN well)) (VP (VBD was) (VP (VBN washed) (NP-1 (-NONE- *)) (NP (JJ several) (NNS times)) (PP-MNR (IN with) (NP (NN PBS))) (, ,) (SBAR-TMP (WHPP-3 (IN after) (WHNP (WDT which))) (S (NP-SBJ-2 (NNS blots)) (VP (VBD were) (VP (VBN incubated) (NP-2 (-NONE- *)) (ADVP-TMP (RB overnight)) (PP-TMP-3 (-NONE- *T*)) (PP-MNR (IN with) (NP (NP (JJ polyclonal) (JJ anti-Aβ) (NN antibody) (PRN (-LRB- -LRB-) (NP (NNP Zymed) (NNP Laboratories)) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP-EXT (NP (CD 1)) (PP (SYM :) (NP (CD 600)))) (PP-LOC (IN in) (NP (NP (DT a) (NN blocking) (NN solution)) (PP (IN of) (NP (NML (NML (NML (CD 1) (SYM ×)) (NN TBS)) (HYPH /) (NML (NML (CD 5) (NN %)) (JJ nonfat) (JJ dry) (NN milk))) (NN powder)))))))))))))) (. .)) )
( (S (PP-TMP (IN After) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG washing) (NP (DT the) (NNS blots)) (NP-TMP (CD three) (NNS times)) (PP (IN for) (NP (NP (CD 10) (NN min)) (NP (DT each)))) (PP-LOC (IN in) (NP (NP (NML (CD 1) (SYM ×)) (NN TBS)) (HYPH /) (NP (NML (CD 0.1) (NN %)) (NN Tween) (HYPH -) (CD 20))))))) (, ,) (NP-SBJ-1 (DT the) (NN membrane)) (VP (VBD was) (VP (VBN incubated) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (CD 1) (NN h))) (PP-MNR (IN with) (NP (NP (ADJP (NN HRP) (HYPH -) (VBN conjugated)) (NN protein) (NN A) (PRN (-LRB- -LRB-) (NP (NNP Sigma)) (-RRB- -RRB-))) (VP (VBN diluted) (NP (-NONE- *)) (NP (NP (CD 1)) (PP (SYM :) (NP (CD 5,000)))) (PP-LOC (IN in) (NP (NN blocking) (NN solution)))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NNS membranes)) (VP (VBD were) (ADVP-TMP (RB again)) (VP (VBN washed) (NP-1 (-NONE- *)) (NP-TMP (CD three) (NNS times)) (PP-MNR (IN with) (NP (NP (NML (CD 1) (SYM ×)) (NN TBS)) (HYPH /) (NP (NML (CD 0.1) (NN %)) (NN Tween) (HYPH -) (CD 20)))) (, ,) (SBAR-TMP (IN before) (S (NP-SBJ-2 (NN antibody) (NN binding)) (VP (VBD was) (VP (VBN detected) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (VBN enhanced) (NN chemiluminescence))) (PRN (-LRB- -LRB-) (NP (NP (NNP PerkinElmer)) (, ,) (NP-LOC (NNP Boston)) (, ,) (NP-LOC (NNP Massachusetts)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))))))) (. .)) )
( (S (S (NP-SBJ-1 (NP (JJ Digital) (NNS images)) (PP (IN of) (NP (DT each) (NN blot)))) (VP (VBD were) (VP (VBN captured) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (DT a) (NML (NML (JJ Molecular) (NNP Imager)) (NNP FX)) (NML (NN gel) (NN documentation)) (NN system)))))) (, ,) (CC and) (S (NP-SBJ-2 (NP (DT the) (NN intensity)) (PP (IN of) (NP (NN Aβ) (NN staining)))) (VP (VBD was) (VP (VBN quantified) (NP-2 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NML (NNP Quantity) (CD One)) (NML (NN image) (NN analysis)) (NN software))))))) (. .)) )
( (HEADING (NP (NN Aβ) (NN ELISA))) )
( (S (NP-SBJ-1 (NP (DT An) (NN aliquot)) (PP (IN of) (NP (NP (JJ cortical) (NN homogenate)) (VP (VBN generated) (NP (-NONE- *)) (PP-PRP (IN for) (NP (NP (NNP Western) (NN analysis)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB above))))))))) (VP (VBD was) (VP (VBN subjected) (NP-1 (-NONE- *)) (PP (IN to) (NP (DT a) (NML (CD three) (HYPH -) (NN step)) (JJ sequential) (NN extraction))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NN PBS)) (, ,) (NP (NML (CD 2) (NN %)) (NN SDS)) (, ,) (CC and) (NP (NML (CD 70) (NN %)) (NML (NML (JJ formic) (NN acid)) (-LRB- -LRB-) (NML (NN FA))))))))) (-RRB- -RRB-) (. .)) )
( (S (PP (IN At) (NP (DT each) (NN step))) (, ,) (NP-SBJ-1 (DT the) (NN sample)) (VP (VBD was) (VP (VP (VBN sonicated) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (JJ appropriate) (NN buffer)))) (CC and) (VP (VBN centrifuged) (NP-1 (-NONE- *)) (PP (IN at) (NP (CD 100,000g))) (PP-TMP (IN for) (NP (NP (CD 30) (NN min) (PRN (-LRB- -LRB-) (NP (NML (QP (CD 1) (HYPH -) (IN to) (CD 1.5)) (HYPH -) (NN mo)) (NNS samples)) (-RRB- -RRB-))) (CC or) (NP (CD 60) (NN min) (PRN (-LRB- -LRB-) (NP (NML (QP (CD 6) (HYPH -) (IN to) (CD 12)) (HYPH -) (NN mo)) (NNS samples)) (-RRB- -RRB-))))) (PP (IN at) (NP (CD 4) (NN °C))) (SBAR-MNR (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP-TMP (RB previously)) (VP (VBN described) (NP-2 (-NONE- *))))) (PRN (-LRB- [) (NP (NP (CD 23)) (PP (SYM –) (NP (CD 25)))) (-RRB- ]))))) (. .)) )
( (S (S (NP-SBJ-1 (DT The) (NN supernatant)) (VP (VBD was) (VP (VBN removed) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NN analysis)))))) (, ,) (CC and) (S (NP-SBJ-2 (DT the) (NN pellet)) (VP (VBD was) (VP (VBN sonicated) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (JJ next) (NN solution))) (PP-MNR (IN in) (NP (NN sequence)))))) (. .)) )
( (S (S (NP-SBJ-1=4 (DT The) (NML (CD 2) (NN %)) (NN SDS) (NNS extracts)) (VP (VBD were) (VP=3 (VBN diluted) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN EC) (NN buffer)))))) (, ,) (CC and) (S (NP-SBJ-2=4 (DT the) (NN FA) (NNS extracts)) (VP=3 (VP (VBN neutralized) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (NN 1M) (NN Tris) (HYPH -) (NN phosphate) (NN buffer) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 11)) (-RRB- -RRB-))))) (VP (ADVP-TMP (RB then)) (VBD diluted) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (NN EC) (NN buffer))) (PP-TMP (JJ prior) (PP (IN to) (NP (NN testing))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Human) (NN Aβ)) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT each) (NN fraction))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG using) (NP=2 (NN BAN50)) (PP=3 (IN for) (NP (NN capture) (PRN (-LRB- -LRB-) (NP (NN epitope) (NN Aβ1) (HYPH –) (NN 16)) (-RRB- -RRB-))))) (CC and) (VP (NP=2 (NN BA27) (CC and) (NN BC05)) (PP=3 (IN for) (NP (NN detection) (PRN (-LRB- -LRB-) (NP (NN Aβ40) (CC and) (NN Aβ42)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NNP Takeda) (NNP Chemical) (NNPS Industries)) (, ,) (NP-LOC (NNP Osaka)) (, ,) (NP-LOC (NNP Japan))) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Total) (NN Aβ) (PRN (-LRB- -LRB-) (NP (NN mouse) (SYM +) (JJ human)) (: ;) (NP (NP (NML (QP (CD 1) (HYPH -) (IN to) (CD 1.5)) (HYPH -) (NN mo)) (NNS samples)) (ADVP (RB only))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT each) (NN fraction))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG using) (NP=3 (NN BNT77)) (PP=2 (IN for) (NP (NN capture) (PRN (-LRB- -LRB-) (NP (NN epitope) (NN Aβ11) (HYPH –) (CD 28)) (-RRB- -RRB-))))) (CC and) (VP (NP=3 (NN BA27) (CC and) (NN BC05)) (PP=2 (IN for) (NP (NN detection)))))))) (. .)) )
( (S (NP-SBJ-1 (DT All) (NNS values)) (VP (VBD were) (VP (VBN calculated) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (NNS picomoles)) (PP (IN per) (NP (NN gram))))) (PP-PRP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ initial) (NN weight)) (PP (IN of) (NP (JJ cortical) (NN tissue)))))))) (. .)) )
( (HEADING (NP (NN Activity) (NN Monitoring))) )
( (S (NP-SBJ-1 (JJ Daily) (JJ basal) (NN activity)) (VP (VBD was) (VP (VBN studied) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (CD 28) (NML (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN tet) (HYPH -) (NN APPswe) (HYPH /) (NN ind)) (NML (NN line) (CD 107)) (NNS mice)) (NP-TMP (NP (QP (IN between) (CD 4) (CC and) (CD 5)) (NN mo)) (PP (IN of) (NP (NN age)))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Animals)) (VP (VBD were) (VP (VBN separated) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (JJ individual) (NNS cages))) (PP-TMP (ADVP (RB immediately)) (IN before) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT each) (NN experiment))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (NP (QP (CD 3) (SYM –) (CD 6))) (PP (IN per) (NP (NP (NN genotype)) (ADJP (JJ untreated))))) (, ,) (NP (NP (QP (CD 2) (SYM –) (CD 5))) (PP (IN per) (NP (NP (NN genotype)) (VP (NN dox) (HYPH -) (VBN reared) (NP (-NONE- *))))))))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NNS cages)) (VP (VBD were) (VP (VBN placed) (NP-1 (-NONE- *)) (PP-LOC (IN inside) (NP (NP (ADJP (NN activity) (HYPH -) (VBG monitoring)) (NNS frames)) (VP (VBN designed) (NP (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB count) (NP (NP (DT every) (NN time)) (SBAR (WHADVP-2 (-NONE- *0*)) (S (NP-SBJ (DT the) (NN animal)) (VP (VBN passed) (PP-DIR (IN through) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD three) (NNS photobeams)) (VP (VBG spanning) (NP (NP (DT the) (NN width)) (PP (IN of) (NP (DT the) (NN cage))))))))) (ADVP-TMP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP San) (NNP Diego)) (NNP Instruments)) (, ,) (NP-LOC (NNP San) (NNP Diego)) (, ,) (NP-LOC (NNP California)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))))))))))))) (. .)) )
( (S (S (NP-SBJ-1 (NNS Experiments)) (VP (VBD were) (VP (VBN started) (NP-1 (-NONE- *)) (PP-TMP (ADVP (RB midway)) (IN through) (NP (NP (DT the) (NN light) (NN phase)) (PP (IN of) (NP (DT the) (NN day)))))))) (, ,) (CC and) (S (NP-SBJ-2 (NNS data)) (VP (VBD were) (VP (VBN collected) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NML (CD 1) (HYPH -) (NN h)) (NNS bins))) (PP-TMP (IN for) (NP (DT the) (JJ following) (CD 48) (NN h)))))) (. .)) )
( (S (NP-SBJ-1 (NN Testing) (NNS rooms)) (VP (VP (VBD were) (VP (VBN maintained) (NP-1 (-NONE- *)) (PP (IN on) (NP (NP (DT the) (JJ same) (NML (NML (NML (CD 13)) (PP (SYM :) (NP (CD 11)))) (NN h)) (NML (NML (NN day)) (PP (SYM :) (NP (NN night)))) (NN cycle)) (PP (IN as) (NP (DT the) (JJ main) (NML (NN animal) (NN housing)) (NNS areas))))))) (CC and) (VP (VBD were) (VP (VBN closed) (NP-1 (-NONE- *)) (PP (IN to) (NP (NN entry))) (PP-TMP (IN during) (NP (DT the) (NN experiment)))))) (. .)) )
( (HEADING (NP (JJ Statistical) (NNS Analyses))) )
( (S (NP-SBJ-1 (NP (JJ Statistical) (NNS analyses)) (PP (IN of) (NP (NP (NN protein) (NN expression)) (, ,) (NP (NN ELISA) (NNS data)) (, ,) (CC and) (NP (NML (NN filter) (NN trap)) (NNS assays))))) (VP (VBD were) (VP (VBN performed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN ANOVA))) (PP-MNR (IN with) (NP (NP (NP (NNP Tukey) (POS 's)) (JJ honest) (JJ significant) (NN difference) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (JJ significant) (NML (NML (JJ main) (NNS effects)) (CC or) (NML (NNS interactions)))))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Statistica) (CD 6.0)) (, ,) (NP-ADV (NNP StatSoft)) (, ,) (NP-LOC (NNP Tulsa)) (, ,) (NP-LOC (NNP Oklahoma)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN In) (NP (NP (NNS cases)) (PP (IN of) (NP (ADJP (RB positively) (VBN skewed)) (NNS data) (NN distribution))))) (, ,) (NP-SBJ-1 (NML (NN log10) (-LRB- -LRB-) (NN x) (SYM +) (CD 0.5) (-RRB- -RRB-)) (NN transformation)) (VP (VBD was) (VP (VBN applied) (NP-1 (-NONE- *)) (PP (IN to) (NP (DT the) (JJ raw) (NNS data))) (PP-TMP (IN before) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG submitting) (NP (PRP them)) (PP (IN to) (NP (NN ANOVA)))))))) (. .)) )
( (HEADING (NP (NNS Results))) )
( (S (NP-SBJ (PRP We)) (VP (VBD used) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN transgene) (NN system)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB express) (NP (NP (NP (DT a) (JJ double) (NN mutant) (NN version)) (PP (IN of) (NP (JJ chimeric) (NN mo) (HYPH /) (NN huAPP695)))) (-LRB- -LRB-) (NP (NP (NN swe) (HYPH /) (NN ind) (NN KM570)) (, ,) (NP (NN 571NL)) (, ,) (CC and) (NP (NN V617F)))) (-RRB- -RRB-) (PP (IN from) (NP (DT a) (ADJP (NN tetracycline) (HYPH -) (JJ responsive)) (NN promoter))) (PRN (-LRB- [) (NP (CD 12) (, ,) (CD 13)) (-RRB- ])))))) (. .)) )
( (S (NP-SBJ-1 (NML (JJ Transgenic) (NN APP)) (NN expression)) (VP (VBD was) (VP (VBN activated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG crossing) (NP (DT the) (NML (NN APPswe) (HYPH /) (NN ind)) (NNS mice)) (PP (IN to) (NP (NP (NNS animals)) (VP (VBG producing) (NP (NN tTA)) (PP (IN under) (NP (NP (NN control)) (PP (IN of) (NP (DT the) (NN CaMKIIα) (NN promoter))))) (PRN (-LRB- [) (NP (CD 16)) (-RRB- ])))))))))) (. .)) )
( (S (PP-TMP (IN After) (NP (NP (JJ initial) (NN screening)) (PP (IN of) (NP (NNS founders))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD identified) (NP (NP (NP (CD four) (NNS lines)) (PP (IN of) (NP (NML (NN tet) (HYPH -) (NN APPswe) (HYPH /) (NN ind)) (NNS mice)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD produced) (NP (NP (ADJP (RB very) (JJ high)) (NNS levels)) (PP (IN of) (NP (NN transgene) (NN product)))) (PP-LOC (IN in) (NP (NP (NN offspring)) (VP (VBG coexpressing) (NP (NN tTA))))) (PRN (-LRB- -LRB-) (NP (NP (NNS Figures) (CD 1)) (CC and) (NP (NN Figure) (NN S1))) (-RRB- -RRB-))))))) (. .)) )
( (S (PP (VBN Compared) (PP (IN to) (NP (NP (DT a) (JJ standard) (NN APP) (JJ transgenic) (NN line)) (VP (VBN used) (NP (-NONE- *)) (PP-PRP (IN for) (NP (NP (JJ previous) (NN amyloid) (NNS studies)) (PP (IN by) (NP (PRP$ our) (NN laboratory))))) (PRN (-LRB- -LRB-) (NP (NN line) (NN C3) (HYPH –) (CD 3)) (: ;) (-LRB- [) (NP (CD 15) (, ,) (CD 26) (, ,) (CD 27)) (-RRB- ]) (-RRB- -RRB-)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD estimated) (SBAR (IN that) (S (NP-SBJ (DT the) (CD four) (JJ controllable) (NNS lines)) (VP (VBP produce) (NP (JJ transgenic) (NN APP) (NN protein)) (PP (IN at) (ADVP (QP (CD 10) (HYPH -) (IN to) (RB 30-fold)) (PP (IN over) (NP (JJ endogenous) (NNS levels))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S1)) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN estimate)) (VP (VBD was) (VP (VBN confirmed) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (JJ direct) (NN comparison)) (PP (IN of) (NP (NN APP) (NNS levels))) (PP-LOC (IN in) (NP (UCP (ADJP (JJ nontransgenic)) (CC and) (NML (NN tet) (HYPH -) (NN off))) (NN APP) (NNS mice))))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT an) (NN antibody)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBZ recognizes) (NP (NP (CC both) (NP (JJ endogenous) (NN APP)) (-LRB- -LRB-) (CC and) (NP (NN amyloid) (ADJP (NN precursor) (HYPH -) (JJ like)) (NN protein) (CD 2)) (-RRB- -RRB-)) (CC and) (NP (DT the) (JJ transgenic) (NN protein) (PRN (-LRB- -LRB-) (NP (JJ monoclonal) (NN antibody) (NN 22C11)) (: ;) (NP (NN Figure) (NN 1D)) (-RRB- -RRB-)))))))))))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (DT all) (CD four) (JJ new) (NNS lines)) (PP (IN of) (NP (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)))) (VP (VBD showed) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN suppression)) (PP (IN of) (NP (DT the) (NN transgene)))) (PP-TMP (VBG following) (NP (NN dox) (NN treatment))) (PRN (-LRB- -LRB-) (NP (NP (NNS Figures) (CD 1)) (CC and) (NP (NN Figure) (NN S1))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD focused) (PP (IN on) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (CD four) (NNS lines)))) (, ,) (NP (NN line) (CD 107)))) (, ,) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (PP (IN in) (NP (JJR more) (NN detail))) (NP (NP (DT the) (NML (NML (NN time) (NN dependence)) (CC and) (NML (NML (NN extent)) (PP (IN of) (NP (NN transgene) (NN suppression)))))) (PP-TMP (VBG following) (NP (NP (CC either) (ADJP (JJ acute) (CC or) (JJ chronic)) (NN treatment)) (PP (IN with) (NP (NN dox)))))))))) (. .)) )
( (S (S (NP-SBJ-1 (CD Two) (ADJP (NN dox) (HYPH -) (VBN treated)) (NNS groups)) (VP (VBD were) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (CD two) (JJ untreated) (NNS groups)))))) (: :) (S (NP-SBJ-2 (NP (CD one) (NN group)) (PP (IN of) (NP (NNS mice)))) (VP (VBD was) (VP (VBN born) (CC and) (VBN raised) (NP-2 (-NONE- *)) (PP (IN on) (NP (NN dox)))))) (, ,) (S (NP-SBJ-3 (DT a) (JJ second) (NN group)) (VP (VBD was) (VP (VBN treated) (NP-3 (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PP-TMP (IN for) (NP (CD 2) (NN wk))) (S-TMP (NP-SBJ (-NONE- *PRO*)) (VP (VBG starting) (PP (IN at) (NP (NP (CD 1) (NN mo)) (PP (IN of) (NP (NN age))))))) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN wk)) (SYM +) (NP (NML (CD 2) (NN wk)) (NN dox))) (-RRB- -RRB-))))) (: ;) (S (NP-SBJ-4 (NP (CD two) (JJ untreated) (NNS groups)) (VP (VBN kept) (NP (-NONE- *)) (PP (IN on) (NP (JJ normal) (NN chow))))) (VP (VBD were) (VP (VBN harvested) (NP-4 (-NONE- *)) (PP-TMP (IN at) (NP (NP (NML (CC either) (CD 4) (CC or) (CD 6)) (NN wk)) (PP (IN of) (NP (NN age)))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Animals)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))) (VP (VBD harbored) (NP (DT no) (JJ transgenic) (NN APP)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1A)) (-RRB- -RRB-))) (. .)) )
( (S (PP-TMP (VBG Following) (NP (NP (QP (RB as) (JJ little) (IN as) (CD 2)) (NN wk)) (PP (IN of) (NP (NN dox) (NN treatment))))) (, ,) (NP-SBJ-1 (JJ transgenic) (NN APP) (NN expression)) (VP (VBD was) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP-EXT (IN by) (NP (QP (JJR more) (IN than) (CD 95)) (NN %))) (PP (VBN compared) (PP (IN to) (NP (JJ pre-dox) (NNS levels)))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ residual) (NN expression)) (VP (VBG remaining) (PP-LOC (IN in) (NP (ADJP (RB acutely) (VBN treated)) (NNS mice))))) (VP (VP (VBZ represents) (NP (NP (QP (JJR less) (IN than) (CD 4)) (NN %)) (PP (IN of) (NP (NP (DT the) (JJ transgenic) (NN protein)) (VP (VBN produced) (NP (-NONE- *)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN dox))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1C)) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (ADVP (RB likely)) (VBZ results) (PP (IN from) (NP (NP (JJ slight) (NN leakage)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NNS data)) (RB not) (VP (VBN shown) (NP (-NONE- *)))) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (DT the) (JJ total) (NN amount)) (PP (IN of) (NP (NP (NN APP) (PRN (-LRB- -LRB-) (ADJP (JJ endogenous) (CC plus) (JJ transgenic)) (-RRB- -RRB-))) (CC and) (NP (JJ related) (NNS APLPs)))) (PP-LOC (IN in) (NP (ADJP (CC both) (ADJP (JJ acute)) (CC and) (ADJP (RB chronically) (VBN treated))) (NNS animals)))) (VP (VBD was) (ADJP-PRD (RB statistically) (JJ indistinguishable) (PP (IN from) (NP (NP (DT that)) (PP-LOC (IN in) (NP (JJ nontransgenic) (NNS mice)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1D)) (: ;) (S (NP-SBJ-1 (NP (JJ statistical) (NNS analyses)) (PP (IN for) (NP (NP (NNS experiments)) (PP (IN throughout) (NP (DT the) (NN study)))))) (VP (VBP are) (VP (VBN presented) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT the) (VBG accompanying) (NN figure) (NNS legends)))))) (-RRB- -RRB-))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB ensure) (SBAR (IN that) (S (NP-SBJ-1 (NN Aβ) (NN production)) (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN mediated)) (NN inhibition)) (PP (IN of) (NP (NP (PRP$ its) (NN precursor)) (NP (NN APPswe) (HYPH /) (NN ind))))))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD measured) (NP (NML (NN Aβ40) (CC and) (NN Aβ42)) (NNS levels)) (PP-MNR (IN by) (NP (NN ELISA))) (PP-LOC (IN in) (NP (NP (NN forebrain) (NNS homogenates)) (PP (IN from) (NP (JJ young) (NML (NN tet) (HYPH -) (NN off)) (NNS animals)))))) (. .)) )
( (S (PP-TMP (IN At) (NP (NP (CD 1) (NN mo)) (PP (IN of) (NP (NN age))))) (, ,) (NP-SBJ (DT the) (NNS mice)) (VP (VBD lacked) (NP (NP (JJ visible) (NN amyloid) (NNS aggregates)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD might) (VP (VB act) (PP (IN as) (NP (NP (NP (DT an) (JJ intractable) (NN reservoir)) (PP (IN of) (NP (NN peptide)))) (VP (VBG remaining) (PP-LOC (IN in) (NP (DT the) (NN brain))) (SBAR-TMP (WHADVP-3 (IN after)) (S (NP-SBJ-2 (DT the) (NN transgene)) (VP (VBD had) (VP (VBN been) (VP (VBN suppressed) (NP-2 (-NONE- *)) (ADVP-TMP-3 (-NONE- *T*)))))))))))))))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (ADVP (RB further)) (VP (VB ensure) (SBAR (-NONE- *0*) (S (NP-SBJ (PRP we)) (VP (MD could) (VP (VB detect) (NP (NP (DT any) (JJ such) (JJ insoluble) (NNS aggregates)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD might) (VP (VB bias) (NP (NP (PRP$ our) (NN measure)) (PP (IN of) (NP (NNS changes)))) (PP (IN in) (NP (NN peptide) (NN synthesis))))))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD performed) (NP (NP (NP (DT a) (JJ sequential) (NML (CD three) (HYPH -) (NN step)) (NN extraction)) (PP (IN with) (NP (NP (NN PBS)) (, ,) (NP (NML (CD 2) (NN %)) (NN SDS)) (, ,) (CC and) (NP (NML (CD 70) (NN %)) (NN FA))))) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD would) (VP (VB separate) (NP (NNS peptides)) (PP-MNR (IN by) (NP (NN solubility))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (ADJP (NP (JJ human) (NN transgene)) (HYPH -) (VBN derived)) (NML (NN Aβ40) (CC and) (NN Aβ42)))) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice))) (PP-TMP (IN at) (NP (NP (NML (CD 4) (CC and) (CD 6)) (NN wk)) (PP (IN of) (NP (NN age)))))) (PP (IN to) (NP (NP (NNS animals)) (SBAR (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD had) (CC either) (VP (VBN been) (VP (VBN born) (CC and) (VBN raised) (NP-2 (-NONE- *)) (PP (IN on) (NP (NN dox)))))))) (CC or) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD had) (VP (VBN been) (VP (VP (VBN left) (NP-1 (-NONE- *)) (S-CLR (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ untreated))) (PP-TMP (IN for) (NP (CD 4) (NN wk)))) (CC and) (VP (ADVP-TMP (RB then)) (VBN placed) (NP-1 (-NONE- *)) (PP (IN on) (NP (NN dox) (NN chow))) (PP-TMP (IN for) (NP (NP (CD 2) (NN wk)) (PP-TMP (JJ prior) (PP (IN to) (NP (NN harvest)))))) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ same) (NNS groups)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB above)) (PP (IN for) (NP (NP (NN immunoblot) (NN analysis)) (PP (IN of) (NP (NML (NN APPswe) (HYPH /) (NN ind)) (NNS levels))))))) (, ,) (NP (NN line) (CD 107)) (-RRB- -RRB-)))))))))))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NML (JJ full) (HYPH -) (NN length)) (NML (NN APPswe) (HYPH /) (NN ind)) (NN synthesis)))) (VP (VBN shown) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN immunoblot)))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (CD 1)))) (-RRB- -RRB-)))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-1 (ADJP (NN transgene) (HYPH -) (VBN derived)) (NN Aβ) (NNS levels)) (VP (VP (VBD were) (ADVP (RB completely)) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS animals)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox)))))))) (, ,) (CC and) (VP (VBD were) (ADVP (RB sharply)) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP-TMP (VBG following) (NP (ADJP (JJ acute) (PRN (-LRB- -LRB-) (NP (CD 2) (NN wk)) (-RRB- -RRB-))) (JJ antibiotic) (NN treatment))))))))) (. .)) )
( (S (PP (VBN Compared) (PP (IN to) (NP (NP (DT the) (NNS levels)) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS mice)))))) (, ,) (NP-SBJ (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN Aβ42)) (VP (VP (VBD dropped) (PP-EXT=1 (IN by) (NP (CD 95.2) (NN %))) (PP-TMP (VBG following) (NP (NP (CD 2) (NN wk)) (PP (IN of) (NP (NN dox) (NN treatment)))))) (CC and) (VP (PP-EXT=1 (IN by) (NP (CD 99.2) (NN %))) (PP (IN with) (NP (JJ chronic) (NN treatment))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2A)) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ (ADJP (NN SDS) (HYPH -) (JJ soluble)) (NN Aβ42)) (VP (VBD decreased) (PP-EXT (IN by) (NP (NP (CD 75.2) (NN %)) (CC and) (NP (CD 94.8) (NN %)))) (PP (VBG following) (NP (UCP (NP (CD 2) (HYPH -) (NN wk)) (CC or) (ADJP (JJ lifelong))) (NN dox) (NN treatment))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2B)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (RB Only) (DT the) (NN FA) (NN fraction)) (VP (VBD revealed) (NP (NP (NP (DT a) (JJ small) (ADJP (NN dox) (HYPH -) (JJ resistant)) (NN pool)) (PP (IN of) (NP (NN peptide))) (PP-LOC (IN in) (NP (ADJP (RB acutely) (VBN treated)) (NNS animals)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ (PRP we)) (VP (VBP believe) (SBAR (-NONE- *0*) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ represents) (NP (NP (JJ stable) (JJ predeposit) (NNS aggregates)) (SBAR (WHNP-4 (WDT that)) (S (NP-SBJ-4 (-NONE- *T*)) (VP (VBP have) (ADVP (RB already)) (VP (VBN accumulated) (PP-TMP (IN by) (NP (NP (CD 4) (NN wk)) (PP (IN of) (NP (NN age))))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-3 (NN treatment)) (VP (VBD was) (VP (VBN begun) (NP-3 (-NONE- *)) (ADVP-TMP-2 (-NONE- *T*)))))))))))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2C)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Indeed)) (, ,) (NP-SBJ (NP (NNS animals)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD were) (VP (VBN born) (CC and) (VBN raised) (NP-1 (-NONE- *)) (PP (IN on) (NP (NN dox)))))))) (VP (VBD did) (RB not) (VP (VB harbor) (NP (NP (DT this) (NN reservoir)) (PP (IN of) (NP (ADJP (NN treatment) (HYPH -) (JJ resistant)) (NN peptide)))) (, ,) (PP (IN with) (NP (NP (ADJP (NP (CD 96.3) (NN %)) (JJR less)) (NN Aβ42)) (PP (IN than) (NP (JJ untreated) (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS mice))))))) (. .)) )
( (S (NP-SBJ (NP (NN Measurement)) (PP (IN of) (NP (JJ total) (NN Aβ))) (PP-LOC (IN in) (NP (ADJP (RB chronically) (VBN treated)) (NNS mice))) (, ,) (PP (VBG including) (NP (ADJP (ADJP (JJ endogenous)) (CC and) (ADJP (NN transgene) (HYPH -) (VBN derived))) (NN peptide)))) (, ,) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN Aβ) (NNS levels)) (PP-LOC (IN in) (NP (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)))) (VP (VBD were) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ endogenous) (NN peptide)))) (VP (VBN found) (NP (-NONE- *)) (PP-LOC (IN in) (NP (JJ nontransgenic) (NNS animals)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2D)) (-RRB- -RRB-))))))) (. .)) )
( (S (S-ADV (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN Taken) (NP-1 (-NONE- *)) (ADVP (RB together)) (PP (IN with) (NP (NP (DT the) (NN immunoblotting) (NNS data)) (PP (IN for) (NP (NML (JJ full) (HYPH -) (NN length)) (NN APPswe) (HYPH /) (NN ind))))))) (, ,) (NP-SBJ (DT the) (NN ELISA) (NNS measurements)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (ADJP (NN dox) (HYPH -) (VBN mediated)) (NN suppression)) (PP (IN of) (NP (JJ transgenic) (NML (NN APPswe) (HYPH /) (NN ind)) (NN synthesis)))) (VP (VBZ leads) (PP (IN to) (NP (NP (JJ parallel) (NN reduction)) (PP (IN of) (NP (NN Aβ) (NNS levels))))))))) (. .)) )
( (S (NP-SBJ (DT The) (NN ELISA) (NNS data)) (ADVP (RB also)) (VP (VBD confirmed) (SBAR (IN that) (S (NP-SBJ (NP (NN incorporation)) (PP (IN of) (NP (DT the) (ADJP (JJ Swedish) (CC and) (NNP Indiana)) (NNS mutations)))) (VP (VBD led) (PP (IN to) (NP (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN Aβ42)))) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ (PRP we)) (VP (VBD predicted) (SBAR (-NONE- *0*) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD would) (VP (VB induce) (NP (JJ rapid) (NN plaque) (NN formation)) (PP-LOC (IN in) (NP (JJ untreated) (NNS animals)))))))))))))))) (. .)) )
( (S (NP-SBJ (NP (PRN (JJ Histological)) (NN characterization)) (PP (IN of) (NP (JJ double) (JJ transgenic) (PRN (-LRB- -LRB-) (NP (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN tet) (HYPH -) (NN APPswe) (HYPH /) (JJ ind)) (-RRB- -RRB-)) (NNS mice)))) (VP (VBD revealed) (NP (NML (JJ early) (HYPH -) (NN onset)) (NN amyloid) (NN formation)) (PP (IN in) (NP (DT all) (CD four) (JJ new) (NNS lines)))) (. .)) )
( (S (NP-SBJ-1 (NN Amyloid) (NNS plaques)) (VP (VBD were) (VP (VBN seen) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS mice)) (ADJP (ADJP (RB as) (JJ young)) (PP (IN as) (NP (NP (CD 8) (NN wk)) (PP (IN of) (NP (NN age)))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NNS data)) (RB not) (VP (VBN shown) (NP (-NONE- *)))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (NNS Plaques)) (VP (VBD were) (VP (VBN limited) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NP (DT the) (NN forebrain)) (, ,) (PP (VBG including) (NP (DT the) (NML (NML (NN cortex)) (, ,) (NML (NN hippocampus)) (, ,) (NML (JJ olfactory) (NN bulb)) (, ,) (CC and) (NML (NN striatum)))))) (, ,) (SBAR (WHADVP-2 (WRB where)) (S (NP-SBJ-3 (DT the) (NN CaMKIIα) (NN promoter)) (VP (VBZ is) (VP (VBN known) (S (NP-SBJ-3 (-NONE- *)) (VP (TO to) (VP (VB be) (ADJP-PRD (RBS most) (JJ active)) (ADVP-LOC-2 (-NONE- *T*))))) (PRN (-LRB- [) (NP (CD 16) (, ,) (CD 28)) (-RRB- ])))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S2)) (-RRB- -RRB-)))) (. .)) )
( (S (PP-TMP (IN By) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age))))) (, ,) (NP-SBJ (NN amyloid) (NN burden)) (VP (VBD became) (ADJP-PRD (JJ severe)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG covering) (NP (NP (JJ large) (NNS areas)) (PP (IN of) (NP (DT the) (NML (NN cortex) (CC and) (NN hippocampus))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S3)) (-RRB- -RRB-))))) (. .)) )
( (S (NP-SBJ-1 (DT No) (NNS lesions)) (VP (VBD were) (VP (VBN seen) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NML (NML (NN cerebellum)) (CC or) (NML (NN brain) (NN stem))))) (PP-TMP (ADVP (RB even)) (IN at) (NP (JJ late) (NNS ages))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (ADJP (NN CaMKIIα) (HYPH -) (VBN controlled)) (NN transgene) (NN expression))))))) (. .)) )
( (S (PP (IN Unlike) (SBAR-NOM (WHNP-1 (WP what)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ is) (VP (VBN thought) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB occur) (PP-LOC (IN in) (NP (DT the) (JJ human) (NN disease))))))))))) (, ,) (NP-SBJ (NP (DT the) (JJ first) (JJ visible) (NNS plaques)) (PP-LOC (IN in) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)))) (VP (VBP are) (NP-PRD (ADJP (JJ fibrillar) (HYPH -) (VBN cored)) (NNS deposits))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN noted) (NP (NP (DT the) (JJ same) (JJ early) (NN appearance)) (PP (IN of) (NP (VBN cored) (NNS deposits))) (PP-LOC (IN in) (NP (NP (NP (JJ other) (NNS lines)) (PP (IN of) (NP (NN APP) (JJ transgenic) (NNS mice)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP harbor) (NP (DT the) (JJ Swedish) (NN mutation)))))))) (PRN (-LRB- [) (NP (CD 27)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NN Diffuse) (NNS plaques)) (VP (VP (VBD were) (ADJP-PRD (JJ apparent)) (PP-LOC (IN in) (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))) (, ,) (CC and) (VP (VBD became) (ADJP-PRD (RB relatively) (JJ abundant)) (PP-TMP (IN by) (NP (NP (CD 9) (NN mo)) (PP (IN of) (NP (NN age))))))) (. .)) )
( (S (PP-TMP (IN At) (NP (NP (JJR older) (NNS ages)) (-LRB- -LRB-) (NP (QP (CD 9) (SYM –) (CD 12)) (NN mo)))) (-RRB- -RRB-) (NP-SBJ (NN amyloid) (NNS deposits)) (VP (VBD were) (ADJP-PRD (JJ visible)) (PP-LOC (IN in) (NP (NP (DT the) (NN thalamus)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN observed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS mice)) (VP (VBG expressing) (NP (NN mutant) (NN APP)) (PP-MNR (IN via) (NP (DT the) (NML (NN Thy) (HYPH -) (CD 1)) (NN promoter)))))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN presence)) (PP (IN of) (NP (NN amyloid) (NN pathology))) (PP-LOC (IN in) (NP (DT this) (NN region)))) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (JJ axonal) (NN transport)) (PP (IN of) (NP (NN APP) (HYPH /) (NN Aβ))) (PP (IN to) (NP (NP (DT the) (NNS terminals)) (PP (IN of) (NP (JJ cortical) (NNS neurons))) (PP-LOC (IN in) (NP (DT the) (NN thalamus))))))) (PRN (-LRB- [) (NP (CD 29)) (-RRB- ]))))) (. .)) )
( (S (ADVP (RBS Most) (RB importantly)) (, ,) (NP-SBJ (NP (RB only) (ADJP (JJ double) (JJ transgenic)) (NNS mice)) (, ,) (VP (VBG expressing) (NP (CC both) (DT the) (NML (NN tTA) (CC and) (NN APP)) (NNS transgenes)))) (, ,) (VP (VBD developed) (NP (NN amyloid) (NNS lesions))) (. .)) )
( (S (NP-SBJ (NP (ADJP (JJ Single) (JJ transgenic)) (NNS mice)) (NP-TMP (NP (QP (IN up) (IN to) (CD 15)) (NN mo)) (PP (IN of) (NP (NN age))))) (VP (VBD showed) (NP (NP (DT no) (NN sign)) (PP (IN of) (NP (NN pathology)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S3)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ-1 (NN amyloid) (NN pathology)) (VP (MD can) (VP (VB be) (ADVP (RB completely)) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (ADJP (JJ double) (JJ transgenic)) (NNS animals)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))))))) (. .)) )
( (S (NP-SBJ (NP (NP (NNS Animals)) (PP (IN from) (NP (NP (PRP$ our) (ADJP (JJS highest) (VBG expressing)) (NN line)) (-LRB- -LRB-) (NP (NN line) (CD 885))))) (-RRB- -RRB-) (VP (VBN maintained) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))) (PP-TMP (IN for) (PP (IN up) (PP (IN to) (NP (CD 1) (NN y))))))) (VP (VBD harbored) (NP (DT no) (NN amyloid) (NN pathology) (PRN (-LRB- -LRB-) (S (NP-SBJ (NNS data)) (RB not) (VP (VBN shown) (NP (-NONE- *))))) (-RRB- -RRB-)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (JJ residual) (NN leakage)) (PP (IN of) (NP (NN transgene) (NN expression))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN dox)))))) (VP (VBZ does) (RB not) (VP (VB provide) (NP (JJ sufficient) (NN Aβ) (NN peptide) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB induce) (NP (NN amyloid) (NN formation)) (PP-TMP (ADVP (RB even)) (IN over) (NP (JJ long) (NNS periods)))))))))))))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB mimic) (NP (JJ therapeutic) (NN intervention)) (PP-MNR (IN with) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN Aβ) (NN production)))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD raised) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (CD 25) (ADJP (JJ double) (JJ transgenic)) (NNS mice) (PRN (-LRB- -LRB-) (NP (NML (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN APP)) (NML (NN line) (CD 107))) (-RRB- -RRB-))))) (PP (IN on) (NP (JJ normal) (NN food))) (PP-TMP (IN until) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age))))) (, ,) (SBAR-TMP (WHADVP-1 (WRB when)) (S (NP-SBJ (PRP we)) (VP (VBD knew) (SBAR (-NONE- *0*) (S (NP-SBJ (NN amyloid) (NN formation)) (VP (VBD was) (ADVP (RB already)) (ADJP-PRD (RB well) (JJ underway)) (PP-LOC (IN in) (NP (DT the) (NN brain)))))) (ADVP-TMP-1 (-NONE- *T*)))))) (. .)) )
( (S (PP-TMP (IN At) (NP (CD 6) (NN mo))) (, ,) (NP-SBJ-1 (NP (NN half)) (PP (IN of) (NP (DT the) (NNS animals)))) (VP (VBD were) (VP (VBN switched) (NP-1 (-NONE- *)) (PP (IN from) (NP (JJ normal) (NN chow))) (PP (IN to) (NP (NP (NN food)) (VP (VBG containing) (NP (NN dox)) (PP (IN at) (NP (NP (CD 200) (NN mg)) (PP (SYM /) (NP (NN kg)))))))) (SBAR-TMP (IN until) (S (NP-SBJ-2 (PRP they)) (VP (VBD were) (VP (VBN sacrificed) (NP-2 (-NONE- *)) (PP-TMP (IN at) (NP (NP (NML (CD 9) (CC or) (CD 12)) (NN mo)) (PP (IN of) (NP (NN age))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (VBG remaining) (NN control) (NNS animals)) (VP (VBD were) (VP (VBN kept) (NP-1 (-NONE- *)) (PP (IN on) (NP (JJ standard) (NN chow))) (PRN (-LRB- -LRB-) (ADJP (JJ untreated)) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN In) (NP (DT all))) (, ,) (NP-SBJ-1 (NP (CD four) (NNS cohorts)) (NP-2 (-NONE- *ICH*))) (VP (VBD were) (VP (VBN created) (NP-1 (-NONE- *)) (: :) (NP-2 (NP (NML (CD 6) (NN mo)) (JJ untreated) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 7)))) (-RRB- -RRB-))) (, ,) (NP (NML (CD 9) (NN mo)) (JJ untreated) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-))) (, ,) (NP (NML (NML (CD 6) (NN mo)) (SYM +) (NML (CD 3) (NN mo))) (VBN treated) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 8)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NML (NML (CD 6) (NN mo)) (SYM +) (NML (CD 6) (NN mo))) (VBN treated) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Full) (NN suppression) (PRN (-LRB- -LRB-) (NP (QP (SYM >) (CD 95)) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ transgenic) (NML (NN APPswe) (HYPH /) (NN ind)) (NNS levels)) (PP-LOC (IN in) (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN treated)) (NNS animals)))))) (VP (VBD was) (VP (VBN confirmed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN immunoblot))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 3)) (-RRB- -RRB-)))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB ensure) (SBAR (IN that) (S (NP-SBJ-1 (DT the) (NN transgene)) (VP (MD could) (VP (VB be) (VP (VBN suppressed) (NP-1 (-NONE- *)) (ADVP (ADVP (RB as) (RB rapidly)) (SBAR-2 (-NONE- *ICH*))) (PP-LOC (IN in) (NP (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)) (PP (IN with) (NP (JJ fulminant) (NN pathology))))) (SBAR-2 (IN as) (S (NP-SBJ (PRP it)) (VP (MD can) (PP-LOC (IN in) (NP (JJ young) (, ,) (JJ predeposit) (NNS animals)))))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD treated) (NP (NP (DT an) (JJ additional) (NN set)) (PP (IN of) (NP (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS animals)) (PP (IN with) (NP (NN dox))))) (PP-TMP (IN for) (NP (CD 1) (NN wk))) (PP-TMP (JJ prior) (PP (IN to) (NP (NN harvest)))))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (NP-SBJ-1 (ADJP (NP (CC both) (NP (NN APPswe) (HYPH /) (NN ind)) (CC and) (NP (NN APP) (HYPH –) (NN C))) (HYPH -) (JJ terminal)) (NN fragment) (NNS levels)) (VP (VBD were) (ADVP (RB fully)) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP (IN after) (NP (NP (RB only) (CD 1) (NN wk)) (PP (IN of) (NP (NN treatment))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (NP (DT the) (ADJP (FW in) (FW vivo)) (NN half) (HYPH -) (NN life)) (PP (IN of) (NP (NN APPswe) (HYPH /) (NN ind)))) (CC and) (NP (PRP$ its) (VBN processed) (ADJP (NN C) (HYPH -) (JJ terminal)) (NNS fragments))) (VP (VBP are) (ADJP-PRD (RB relatively) (JJ short))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3D)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Tissue) (NNS sections)) (PP (IN from) (NP (NP (DT each) (NN animal)) (PP-LOC (IN in) (NP (DT the) (CD four) (NN treatment) (NNS groups)))))) (VP (VBD were) (VP (VBN stained) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NN amyloid) (NN pathology))) (PP (IN by) (NP-LGS (NP (NNP Hirano) (NN silver)) (, ,) (NP (NML (NNP Campbell) (HYPH -) (NNP Switzer)) (NN silver)) (, ,) (NP (NN thioflavin) (HYPH -) (NN S)) (, ,) (CC and) (NP (NN Aβ) (NN immunohistochemistry)))))) (. .)) )
( (S (S (SBAR-ADV (IN As) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN expected) (NP-1 (-NONE- *))))) (, ,) (NP-SBJ (DT the) (NML (CD 6) (NN mo)) (JJ untreated) (NN cohort)) (VP (VBD displayed) (NP (JJ moderate) (NN amyloid) (NN pathology)))) (, ,) (CC and) (S (NP-SBJ (DT the) (NML (CD 9) (NN mo)) (JJ untreated) (NN cohort)) (VP (VBD progressed) (PP (IN to) (NP (DT a) (JJ severe) (NN amyloid) (NN burden))))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (DT the) (NN extent)) (PP (IN of) (NP (NN amyloid) (NN pathology))) (PP-LOC (IN in) (NP (NP (NNS mice)) (PP (IN from) (NP (DT the) (ADJP (ADJP (NP (NP (CD 6) (NN mo)) (SYM +) (NP (CD 3) (NN mo))) (VBN treated)) (CC or) (ADJP (NP (NP (CD 6) (NN mo)) (SYM +) (NP (CD 6) (NN mo))) (VBN treated))) (NNS cohorts)))))) (ADVP (RB closely)) (VP (VBD resembled) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (ADJP (NP (CD 6) (NN mo)) (JJ untreated)) (NN cohort)))) (, ,) (PP (IN despite) (NP (NP (DT the) (JJ significant) (NN age) (NN difference)) (PP (IN between) (NP (DT the) (ADJP (VBN treated) (CC and) (JJ untreated)) (NNS groups))))) (PRN (-LRB- -LRB-) (NP (NP (NNS Figures) (CD 4)) (CC and) (NP (NN Figure) (NN S3))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (ADJP (RB Well) (HYPH -) (VBN formed)) (NNS plaques)) (VP (VBD remained) (PP-LOC (IN in) (NP (DT the) (VBN treated) (NNS animals))) (PP-TMP (IN after) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN transgene) (NN suppression))))) (, ,) (SBAR-ADV (ADVP (RB even)) (IN though) (S (NP-SBJ-2 (NP (ADJP (RB as) (JJ much)) (NN time)) (SBAR-1 (-NONE- *ICH*))) (VP (VBD was) (VP (VBN given) (NP-2 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB clear) (NP (DT the) (NNS lesions))))) (SBAR-1 (IN as) (S (NP-SBJ (PRP they)) (VP (VBD had) (VP (VBN taken) (NP (-NONE- *?*)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB form))))))))))))) (. .)) )
( (S (ADVP (RB Moreover)) (, ,) (NP-SBJ (NP (NP (DT both) (NNS types)) (PP (IN of) (NP (NN amyloid)))) (, ,) (ADJP (JJ diffuse) (CC and) (JJ fibrillar))) (, ,) (VP (VBD remained) (ADJP-PRD (JJ intact)) (PP-TMP (IN throughout) (NP (NN treatment)))) (. .)) )
( (S (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG Using) (NP (DT the) (NML (NNP Campbell) (HYPH -) (NNP Switzer)) (NN silver) (NN stain)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB distinguish) (NP (NP (JJ different) (NNS forms)) (PP (IN of) (NP (NN amyloid))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (-NONE- *0*) (S (NP-SBJ (JJ diffuse) (NNS plaques)) (VP (VBD were) (ADJP-PRD (ADJP (RB as) (JJ persistent)) (PP (IN as) (NP (VBN cored) (NNS deposits))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S4)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBD was) (ADVP (RB nevertheless)) (ADJP-PRD (JJ clear)) (SBAR-1 (IN that) (S (NP-SBJ (NP (ADJP (NN dox) (HYPH -) (VBN induced)) (NN suppression)) (PP (IN of) (NP (JJ transgenic) (NN APP)))) (VP (VBD had) (ADVP (RB completely)) (VP (VBN halted) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN pathology))))))))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB confirm) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN arrest)) (PP (IN of) (NP (NNS plaques))) (PP (IN without) (NP (NP (DT any) (NN sign)) (PP (IN of) (NP (NN clearance)))))) (VP (VBD was) (RB not) (ADJP-PRD (JJ unique) (PP (IN to) (NP (DT the) (NML (NN line) (CD 107)) (NNS mice)))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD repeated) (NP (DT the) (NML (NN dox) (HYPH -) (NN suppression)) (NN experiment)) (PP-LOC (IN in) (NP (NP (DT a) (JJ second) (NN line)) (PP (IN of) (NP (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NML (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN tet) (HYPH -) (NN APPswe) (HYPH /) (NN ind)) (NN line) (CD 18)) (: ;) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 22)))) (-RRB- -RRB-))) (. .)) )
( (S (S (ADVP (RB Again)) (, ,) (NP-SBJ-1 (NML (JJ long) (HYPH -) (NN term)) (NN dox) (NN treatment)) (VP (VBD was) (VP (VBN begun) (NP-1 (-NONE- *)) (PP-TMP (IN at) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age)))))))) (, ,) (CC and) (S (NP-SBJ-2 (NNS mice)) (VP (VBD were) (VP (VBN harvested) (NP-2 (-NONE- *)) (PP-TMP (IN after) (NP (NP (CD 3) (NN mo)) (PP (IN of) (NP (NN transgene) (NN suppression))))) (PRN (-LRB- -LRB-) (FRAG (ADJP (NP (CD 6) (NN mo)) (JJ untreated)) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 8))))) (: ;) (FRAG (ADJP (NML (CD 9) (NN mo)) (JJ untreated)) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 6))))) (: ;) (FRAG (ADJP (NP (CD 6) (NN mo) (SYM +) (CD 3) (NN mo)) (VBN treated)) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 8))))) (-RRB- -RRB-))))) (. .)) )
( (S (NP-SBJ (NP (NN Immunoblotting)) (PP (IN for) (NP (NN APP)))) (VP (VBD confirmed) (NP (JJ full) (NN transgene) (NN suppression)) (PP-LOC (IN in) (NP (DT the) (VBN treated) (NNS animals))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S5) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN As) (PP (IN in) (NP (NP (DT the) (NML (NN line) (CD 107)) (NNS mice)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB above)))))) (, ,) (NP-SBJ (NN amyloid) (NN burden)) (VP (VBD worsened) (ADVP (RB substantially)) (PP-LOC (IN in) (NP (NP (DT the) (JJ untreated) (NNS mice)) (PP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age)))))))) (. .)) )
( (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (NN transgene) (NN expression)))) (ADVP (RB abruptly)) (VP (VBD arrested) (NP (NP (NN progression)) (PP (IN of) (NP (NN pathology)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S6)) (-RRB- -RRB-)) (, ,) (NAC (CC but) (PP (ADVP-TMP (RB again)) (IN without) (NP (NP (DT any) (NN sign)) (PP (IN of) (NP (NN reduction))))))) (. .)) )
( (S (NP-SBJ-1 (ADJP (NP (CC Both) (NP (NN silver)) (HYPH -) (CC and) (NP (NN thioflavin) (HYPH -) (NN S))) (HYPH -) (JJ positive)) (NNS plaques)) (VP (MD could) (ADVP (RB still)) (VP (VB be) (VP (VBN found) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN treated)) (NNS animals)))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB biochemically)) (VP (VBD measured) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (VBN aggregated) (NN Aβ)))) (PP-LOC (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (PRP$ our) (NNS mice))))) (PP-TMP (IN before) (CC and) (IN after) (NP (NN transgene) (NN suppression))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NML (NN filter) (NN trap)) (NN analysis)) (PP (IN of) (NP (NP (JJ cortical) (NN tissue)) (PP (IN from) (NP (DT each) (NN animal))))))))) (. .)) )
( (S (S (PP (IN In) (NP (DT this) (NN assay))) (, ,) (NP-SBJ-1 (NP (JJ serial) (NNS dilutions)) (PP (IN of) (NP (NN protein) (NN homogenate)))) (VP (VBP are) (VP (VBN passed) (NP-1 (-NONE- *)) (PP-DIR (IN through) (NP (DT a) (NN cellulose) (NN acetate) (NN filter)))))) (: ;) (S (NP-SBJ-2 (NP (NNS particles)) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT the) (NN pore) (NN size)) (PP (IN of) (NP (DT the) (NN filter))))))) (VP (VP (VBP become) (ADJP-PRD (JJ trapped) (PP-LOC (IN in) (NP (DT the) (NN membrane))))) (CC and) (VP (VBP are) (VP (VBN revealed) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (NN immunoblotting))) (PRN (-LRB- [) (NP (CD 22)) (-RRB- ])))))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (NP (PRP$ our) (JJ visual) (NN analysis)) (PP (IN of) (NP (DT the) (JJ histological) (NNS sections))))))) (, ,) (NP-SBJ (NP (NML (NN line) (CD 107)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)) (VP (VBN treated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PP-TMP (IN for) (NP (CD 3) (CC or) (CD 6) (NN mo))))) (VP (VBD had) (NP (NP (DT the) (JJ same) (NN amount)) (PP (IN of) (NP (VBN aggregated) (NN Aβ))) (PP (IN as) (SBAR-NOM (WHADVP-1 (WRB when)) (S (NP-SBJ (PRP they)) (VP (VBD started) (NP (NN treatment)) (PP-TMP (IN at) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age))))) (ADVP-TMP-1 (-NONE- *T*))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 4A) (CC and) (NN 4B))) (-RRB- -RRB-))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (JJ untreated) (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)) (VP (VBD had) (NP (NP (ADJP (ADVP (RB almost) (RB twice)) (RB as) (JJ much)) (VBN aggregated) (NN Aβ)) (PP (IN as) (NP (NP (DT either)) (PP (IN of) (NP (DT the) (VBN treated) (NNS groups))))))) (. .)) )
( (S (S (NP-SBJ (NP (NN Filter) (NN trap) (NN analysis)) (PP (IN of) (NP (NML (NN line) (CD 18)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))) (VP (VBD yielded) (NP (JJ similar) (NNS results)))) (: :) (S (NP-SBJ-1 (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (VBN aggregated) (NN Aβ)))) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (JJ untreated) (NNS animals)) (PP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age))))))))) (VP (VBD was) (ADVP (RB completely)) (VP (VBN arrested) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NN transgene) (NN suppression))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN S5C) (CC and) (NN S5D))) (-RRB- -RRB-))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP-TMP (RB next)) (VP (VBD used) (NP (NN ELISA)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB measure) (NP (JJ total) (NN Aβ)) (PP-LOC (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (DT each) (NN group))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NP (DT any) (NN change)) (PP (IN in) (NP (NP (DT the) (NML (NN amount) (CC or) (NN solubility))) (PP (IN of) (NP (NN peptide)))))) (VP (VBD occurred) (SBAR-TMP (IN while) (S (NP-SBJ-1 (NML (NN APPswe) (HYPH /) (NN ind)) (NN expression)) (VP (VBD was) (VP (VBN suppressed) (NP-1 (-NONE- *)))))))))))))))) (. .)) )
( (S (S (NP-SBJ-2 (JJ Cortical) (NNS homogenates)) (VP (VBD were) (ADVP-MNR (RB sequentially)) (VP (VBN extracted) (NP-2 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB separate) (NP (NN peptide)) (PP (IN into) (NP (ADJP (NP (NP (NN PBS)) (HYPH -) (, ,) (NP (NN SDS)) (HYPH -) (, ,) (CC and) (NP (NN FA))) (HYPH -) (JJ soluble)) (NNS fractions))))))))) (, ,) (S (ADVP-TMP (RB then)) (NP-SBJ-1 (ADJP (NN transgene) (HYPH -) (VBN derived)) (NML (NN Aβ40) (CC and) (NN Aβ42))) (VP (VBD were) (VP (VBN measured) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (ADJP (JJ human) (HYPH -) (JJ specific)) (NN ELISA))) (PRN (-LRB- [) (NP (CD 23)) (-RRB- ]))))) (. .)) )
( (S (PP (IN In) (NP (NP (DT all) (NNS animals)) (VP (VBG harboring) (NP (NN amyloid) (NNS deposits))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-1 (NP (DT the) (JJ vast) (NN majority)) (PP (IN of) (NP (NN Aβ) (PRN (-LRB- -LRB-) (NP (QP (SYM >) (CD 99)) (NN %)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN extracted) (NP-1 (-NONE- *)) (PP-LOC (IN into) (NP (DT the) (NML (NN SDS) (CC and) (NN FA)) (NNS fractions))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 5A) (CC and) (NN 5B))) (-RRB- -RRB-))))))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (NP (DT the) (NN filter) (NN trap) (NNS results)) (VP (VBN presented) (NP (-NONE- *)) (ADVP (RB above))))))) (, ,) (NP-SBJ (EX there)) (VP (VBD were) (NP-PRD (NP (DT no) (JJ significant) (NNS differences)) (PP-LOC (IN in) (NP (ADJP (NP (NN SDS) (HYPH -) (CC or) (NN FA)) (HYPH -) (JJ soluble)) (NN Aβ))) (PP (IN between) (NP (NP (DT the) (NML (CD 6) (NN mo)) (JJ untreated) (NN cohort)) (CC and) (NP (CC either) (DT the) (NML (NML (NML (CD 6) (NN mo)) (SYM +) (NML (NML (CD 3) (NN mo)) (VP (VBN treated) (NP (-NONE- *))))) (CC or) (NML (NML (NML (CD 6) (NN mo)) (SYM +) (NML (NML (CD 6) (NN mo)) (VP (VBN treated) (NP (-NONE- *))))))) (NNS cohorts)))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NNS brains)) (PP (IN of) (NP (ADJP (NP (CC both) (NP (NP (CD 6) (NN mo)) (SYM +) (NP (CD 3) (NN mo))) (CC and) (NP (NP (CD 6) (NN mo)) (SYM +) (NP (CD 6) (NN mo)))) (VBN treated)) (NNS cohorts)))) (VP (VBD contained) (NP (NP (ADJP (ADVP (RB roughly) (RB twice)) (RB as) (JJ much)) (NN PBS) (HYPH -) (JJ soluble) (NN Aβ40)) (PP (IN as) (NP (JJ untreated) (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5C)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NNS Levels)) (PP (IN of) (NP (NN Aβ42)))) (VP (VP (VBD showed) (NP (DT a) (JJ similar) (NN trend))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance))))) (. .)) )
( (S (PP (IN In) (NP (NN fact))) (, ,) (NP-SBJ (NP (NNS levels)) (PP (IN of) (NP (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NML (NN Aβ40) (CC and) (NN Aβ42)))) (PP (IN in) (NP (DT the) (NML (NML (NML (CD 6) (NN mo)) (SYM +) (NML (NML (CD 3) (NN mo)) (VP-1 (-NONE- *RNR*)))) (CC and) (NML (NML (CD 6) (NN mo)) (SYM +) (NML (NML (CD 6) (NN mo)) (VP-1 (-NONE- *RNR*)))) (VP-1 (VBN treated) (NP (-NONE- *)))) (NNS cohorts)))) (VP (VBD were) (ADJP-PRD (RBS most) (JJ similar) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NML (CD 9) (NN mo)) (JJ untreated) (NN cohort)))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (NN age)) (, ,) (PP (IN as) (PP (VBN opposed) (PP (IN to) (NP (NP (JJ synthetic) (NN rate)) (-LRB- -LRB-) (SBAR (WHNP-2 (WDT which)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD would) (VP (VB be) (ADJP-PRD (JJ negligible)) (PP-LOC (IN in) (NP (DT the) (VBN treated) (NNS animals)))))))))))) (-RRB- -RRB-) (, ,) (VP (MD may) (VP (VB determine) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN Aβ)))) (PP-LOC (IN in) (NP (DT these) (NNS animals)))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBD assessed) (NP (NP (ADJP (JJ neuritic) (CC and) (JJ glial)) (NN pathology)) (VP (VBG surrounding) (NP (DT the) (NNS plaques)))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (EX there)) (VP (VBD were) (NP-PRD (NP (DT any) (NNS changes)) (PP-LOC (IN in) (NP (JJ nearby) (NN tissue)))) (PP-TMP (VBG following) (NP (NML (JJ long) (HYPH -) (NN term)) (NN transgene) (NN suppression)))))))))) (. .)) )
( (S (NP-SBJ (CC Both) (NP (NNP Hirano) (NN silver) (NN stain)) (CC and) (NP (NN ubiquitin) (NN immunostaining))) (VP (VBD showed) (NP (JJ neuritic) (NN pathology)) (PP-LOC (IN in) (NP (DT all) (NN treatment) (NNS groups))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 6)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ-1 (NP (VBN activated) (NNS astrocytes)) (VP (VBN immunostained) (NP (-NONE- *)) (PP (IN for) (NP (NN GFAP))))) (VP (VBD were) (VP (VBN found) (NP-1 (-NONE- *)) (PP-LOC (IN near) (NP (NNS plaques))) (PP-LOC (IN in) (NP (DT all) (NNS animals))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 6)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (ADJP (JJ Neuritic) (CC and) (JJ glial)) (NN pathology)) (VP (VBD were) (ADJP-PRD (RBR more) (JJ severe)) (PP-LOC (IN in) (NP (DT the) (JJR older) (JJ untreated) (NNS mice)))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NN transgene) (NN suppression)) (VP (VP (VBD prevented) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (NP (JJ individual) (NNS deposits)) (RRC (ADJP-PRD (JJ apparent)) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice)))))))) (, ,) (CC and) (VP (VBD limited) (NP (DT the) (VBG surrounding) (NN pathology)) (PP (IN to) (SBAR-NOM (WHNP-1 (WP what)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD was) (ADVP (RB already)) (ADJP-PRD (JJ present)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ (NN treatment)) (VP (VBD began) (ADVP-TMP-2 (-NONE- *T*))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT An) (JJ obvious) (NN question)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ-5 (PRP we)) (VP (VBD sought) (S (NP-SBJ-5 (-NONE- *PRO*)) (VP (TO to) (VP (VB address) (NP-1 (-NONE- *T*))))))))) (VP (VBD was) (NP-PRD (SBAR-NOM (IN whether) (S (NP-SBJ (NP (DT the) (NN deposition)) (PP (IN of) (NP (NN Aβ)))) (VP (VBD diminished) (NP (NP (JJ cognitive) (NN ability)) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice))))))) (, ,) (CC and) (SBAR-NOM (WHNP-2 (WP what)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD might) (VP (VB happen) (PP (IN to) (NP (NN cognition))) (SBAR-TMP (WHADVP-3 (WRB when)) (S (NP-SBJ-4 (DT the) (NN process)) (VP (VBD was) (VP (VBN interrupted) (NP-4 (-NONE- *)) (ADVP-TMP-3 (-NONE- *T*)))))))))))) (. .)) )
( (S (ADVP (RB Unfortunately)) (, ,) (NP-SBJ-1 (NNS efforts) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB characterize) (NP (JJ cognitive) (NN behavior)))))) (VP (VBD were) (VP (VBN compromised) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (JJ severe) (NN hyperactivity)) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (JJ double) (JJ transgenic)) (NNS mice))))))) (. .)) )
( (S (S (NP-SBJ-1 (DT The) (NML (NN tTA) (HYPH /) (NN APP)) (NNS animals)) (VP (VBD were) (ADVP-TMP (RB often)) (VP (VBN seen) (NP-1 (-NONE- *)) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG running) (PP (IN in) (NP (NNS circles))) (PP-DIR (IN around) (NP (NP (DT the) (NN perimeter)) (PP (IN of) (NP (PRP$ their) (NNS cages)))))))))) (, ,) (CC and) (S (NP-SBJ-2 (DT a) (JJ similar) (NN swimming) (NN pattern)) (VP (VBD was) (VP (VBN noted) (NP-2 (-NONE- *)) (SBAR-TMP (WHADVP-4 (WRB when)) (S (NP-SBJ-3 (DT the) (NNS mice)) (VP (VBD were) (VP (VBN tested) (NP-3 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NNP Morris) (NN water) (NN maze))) (ADVP-TMP-4 (-NONE- *T*))))))))) (. .)) )
( (S (PP-LOC (IN In) (NP (DT the) (JJ radial) (NN water) (NN maze))) (, ,) (NP-SBJ-1 (JJ repetitive) (NN swim) (NNS patterns)) (VP (VBD were) (VP (VBN noted) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (ADJP (NN choice) (HYPH -) (VBN motivated)) (NNS actions))))))) (. .)) )
( (S (NP-SBJ (JJ Other) (NNS studies)) (VP (VBP have) (VP (VBN dealt) (PP (IN with) (NP (JJ similar) (NNS problems))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG excluding) (NP (NP (NNS animals)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP do) (RB not) (VP (VB show) (NP (NP (JJ adequate) (NN attention)) (PP (IN to) (NP (DT the) (NN task)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG retaining) (NP (NP (RB only) (DT those) (NNS mice)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP meet) (NP (JJ certain) (NN performance) (NNS criteria)))))))))))))))) (PRN (-LRB- [) (NP (CD 30)) (-RRB- ])))) (. .)) )
( (S (PP (IN In) (NP (PRP$ our) (NN case))) (, ,) (NP-SBJ (NP (DT the) (NN penetrance)) (PP (IN of) (NP (NN hyperactivity)))) (VP (VBD was) (NP-PRD (QP (JJ close) (IN to) (CD 100)) (NN %)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG leaving) (NP (PRP us)) (PP (IN with) (NP (DT no) (JJ testable) (NNS animals)))))) (. .)) )
( (S (NP-SBJ (DT This) (NN phenotype)) (VP (VBZ has) (RB not) (VP (VBN affected) (NP (NP (NP (NP (NP (JJ previous) (NNS lines)) (PP (IN of) (NP (NN APPswe) (NNS mice)))) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN produced) (NP-1 (-NONE- *T*))))))) (, ,) (PP (JJ such) (IN as) (NP (NNS lines) (NML (NML (NN E1) (HYPH –) (CD 2)) (CC or) (NML (NN C3) (HYPH –) (CD 3)))))) (, ,) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP express) (NP (NP (JJR lower) (NNS levels)) (PP (IN of) (NP (JJ transgenic) (NN protein)))))))))) (. .)) )
( (S (ADVP (RB Indeed)) (, ,) (PP (IN in) (NP (NP (JJ past) (NNS studies)) (SBAR (WHADVP-1 (WRB where)) (S (NP-SBJ (NN hyperactivity)) (VP (VBD was) (RB not) (NP-PRD (DT a) (NN factor)) (ADVP-1 (-NONE- *T*))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD established) (NP (NP (DT a) (JJ clear) (NN relationship)) (PP (IN between) (NP (NP (NN amyloid) (NN load)) (CC and) (NP (JJ cognitive) (NN ability))))) (PRN (-LRB- [) (NP (CD 31)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT the) (JJ current) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBP feel) (SBAR (IN that) (S (SBAR-ADV (IN although) (S (NP-SBJ-1 (NP (DT the) (JJ poor) (NN performance)) (PP (IN of) (NP (DT the) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice))) (PP (IN in) (NP (DT the) (NN maze) (NNS tests)))) (VP (MD could) (ADVP-MNR (RB technically)) (VP (VB be) (VP (VBN scored) (NP-1 (-NONE- *)) (PP (IN as) (NP (JJ cognitive) (NN impairment)))))))) (, ,) (NP-SBJ (NP (DT the) (NNS animals) (POS ')) (JJ severe) (NN hyperactivity)) (VP (VBD made) (S (NP-SBJ (NP (NN interpretation)) (PP (IN of) (NP (DT the) (JJ cognitive) (NNS tasks)))) (ADJP-PRD (JJ impossible))))))) (. .)) )
( (S (PP-PRP (IN In) (NP (NN order) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NML (NN nature) (CC and) (NN extent))) (PP (IN of) (NP (NP (NN hyperactivity)) (PP-LOC (IN in) (NP (DT the) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD quantified) (NP (NP (JJ daily) (NN activity) (NNS levels)) (PP-LOC (IN in) (NP (ADJP (JJ double) (JJ transgenic)) (NNS animals))) (PP (IN along) (PP (IN with) (NP (NP (PRP$ their) (ADJP (ADJP (JJ single) (JJ transgenic)) (CC and) (ADJP (JJ nontransgenic))) (NNS siblings)) (VP (VBG using) (NP (NP (NML (CD four) (HYPH -) (NN beam)) (NNS frames)) (VP (VBN designed) (NP (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB monitor) (NP (NN ambulation)) (PP-LOC (IN within) (NP (DT an) (VBN enclosed) (NN cage)))))))))))))) (. .)) )
( (S (SBAR-ADV (IN As) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (NP (NN Figure) (CD 7)))))) (, ,) (NP-SBJ (DT the) (NML (JJ double) (JJ transgenic)) (NNS mice)) (VP (VBD were) (ADJP-PRD (ADJP (QP (IN up) (IN to) (RB 10-fold)) (RBR more) (JJ active)) (PP-1 (-NONE- *ICH*))) (PP-TMP (IN during) (NP (NP (DT the) (NN dark) (NN phase)) (PP (IN of) (NP (DT the) (NML (NN day) (HYPH –) (NN night)) (NN cycle))))) (PP-1 (IN than) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN control) (NNS groups)))))) (. .)) )
( (S (NP-SBJ-1 (NN Activity) (NNS levels)) (VP (VBD appeared) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB follow) (NP (DT a) (ADJP (RB relatively) (JJ normal)) (JJ diurnal) (NN cycle)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG decreasing) (ADVP-MNR (RB substantially)) (PP-TMP (IN during) (NP (DT the) (NN daylight) (NNS hours))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP-TMP (ADVP (RB even)) (IN during) (NP (DT the) (NN light) (NN phase))) (, ,) (NP-SBJ (DT the) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)) (VP (VBD remained) (ADJP-PRD (ADJP (ADVP (RB many-fold) (RBR more)) (JJ active)) (PP (IN than) (NP (JJ normal) (NNS controls))))) (. .)) )
( (S (NP-SBJ-2 (DT This) (NN behavior)) (VP (VBD was) (ADVP-MNR (RB partially) (, ,) (CONJP (CC but) (RB not)) (RB consistently)) (, ,) (VP (VBN reversed) (NP-2 (-NONE- *)) (PP-TMP (IN by) (NP (NP (NP (CD 1) (NN mo)) (PP (IN of) (NP (NN transgene) (NN suppression)))) (VP (VBG beginning) (PP-TMP (IN at) (NP (NP (QP (CD 4) (SYM –) (CD 5)) (NN mo)) (PP (IN of) (NP (NN age)))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ-1 (NNS data)) (RB not) (VP (VBN shown) (NP-1 (-NONE- *)))) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-1 (NN hyperactivity)) (VP (VBD was) (ADVP (RB completely)) (VP (VBN abolished) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG rearing) (NP (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)) (PP (IN on) (NP (NN dox)))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Animals)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))) (VP (VBD showed) (NP (NP (NN activity) (NNS levels)) (ADJP (JJ similar) (PP (IN to) (NP (DT the) (JJ untreated) (NNS controls))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 7C)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Intriguingly)) (, ,) (NP-SBJ (NP (NP (DT all)) (PP (IN of) (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN reared)) (NNS animals)))) (, ,) (UCP (CC both) (ADJP (JJ transgenic)) (CC and) (NML (JJ wild) (HYPH -) (NN type)))) (, ,) (VP (VBD showed) (NP (NP (VBN altered) (JJ circadian) (NNS rhythms)) (PP (IN with) (NP (NP (ADJP (RB far) (JJR less)) (NN distinction)) (PP (IN between) (NP (PRP$ their) (NML (NN day) (HYPH -) (CC and) (NN nighttime)) (NN activity) (NNS levels))))))) (. .)) )
( (HEADING (NP (NN Discussion))) )
( (S (NP-SBJ (PRP We)) (VP (VBP present) (NP (NP (NP (DT a) (JJ new) (NN mouse) (NN model)) (PP (IN for) (NP (NN AD)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD was) (VP (VBN designed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB test) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG inhibiting) (NP (NN Aβ) (NN production)) (PP-TMP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN amyloid) (NN pathology)))))))))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NP (JJ New) (NNS lines)) (PP (IN of) (NP (JJ transgenic) (NNS mice)))) (SBAR-2 (-NONE- *ICH*))) (VP (VBD were) (VP (VBN developed) (NP-1 (-NONE- *)) (PP (IN for) (NP (DT this) (NN study))) (SBAR-2 (WHNP-3 (WDT that)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBP express) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN APPswe) (HYPH /) (NN ind)))) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT a) (ADJP (NN tetracycline) (HYPH -) (JJ responsive)) (NN promoter)))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN treatment)) (PP (IN with) (NP (NN dox)))) (VP (VBZ suppresses) (NP (NP (NML (JJ steady) (HYPH -) (NN state)) (NNS levels)) (PP (IN of) (NP (CC both) (NP (NN APPswe) (HYPH /) (NN ind)) (CC and) (NP (PRP$ its) (NN C) (HYPH -) (JJ terminal) (NNS fragments))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (DT the) (NN mutant) (NN proteins)) (VP (VBP have) (NP (DT a) (ADJP (RB relatively) (JJ short)) (NN half) (HYPH -) (NN life)) (ADVP (FW in) (FW vivo))))))))))) (. .)) )
( (S (NP-SBJ (NP (NP (JJ Transgenic) (NN expression)) (PP (IN of) (NP (NN APPswe) (HYPH /) (NN ind)))) (CC and) (NP (NP (JJ consequent) (NN overproduction)) (PP (IN of) (NP (NN Aβ42))))) (VP (VBP cause) (NP (NML (JJ early) (HYPH -) (NN onset)) (NN amyloid) (NN deposition)) (PP-LOC (IN in) (NP (NP (JJ untreated) (NNS mice)) (, ,) (SBAR (WHPP-1 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NNS deposits)) (VP (VBP appear) (PP-LOC-1 (-NONE- *T*)) (ADVP-TMP (ADVP (RB as) (RB early)) (PP (IN as) (NP (NP (CD 2) (NN mo)) (PP (IN of) (NP (NN age)))))))))))) (. .)) )
( (S (S (NP-SBJ (NN Amyloid) (NN burden)) (VP (VBZ worsens) (ADVP (RB significantly)) (PP (IN with) (NP (NN age))))) (, ,) (CC and) (S (PP (IN by) (NP (CD 9) (NN mo))) (, ,) (NP-SBJ-1 (NP (DT the) (NML (NN hippocampus) (CC and) (NN cortex))) (PP (IN of) (NP (JJ untreated) (NNS mice)))) (VP (VBP are) (ADVP (RB largely)) (VP (VBN filled) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (VBN aggregated) (NN peptide)))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP-SBJ (NP (NN suppression)) (PP (IN of) (NP (JJ transgenic) (NN APP))) (PP (IN by) (NP (QP (JJR more) (IN than) (CD 95)) (NN %)))) (ADVP (RB abruptly)) (VP (VBZ halts) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN amyloid) (NN pathology)))))))) (. .)) )
( (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (DT this) (NN outcome)) (VP (VBZ occurs) (PP-LOC (IN in) (NP (NP (NNS animals)) (VP (ADVP (RB already)) (VBG harboring) (NP (JJ considerable) (NN amyloid) (NN pathology))))) (, ,) (NP-ADV (NP (DT a) (NN situation)) (ADJP (JJ similar) (PP (IN to) (SBAR-NOM (WHNP-2 (WP what)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD might) (VP (VB be) (VP (VBN expected) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS patients)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (TO to) (VP (VB be) (VP (VBN treated) (NP-1 (-NONE- *)) (PP (IN with) (NP (NN secretase) (NNS inhibitors))))))))))))))))))) (. .)) )
( (S (ADVP (RB Somewhat) (RB unexpectedly)) (, ,) (NP-SBJ (PRP we)) (VP (VBP observe) (NP (NP (DT no) (JJ appreciable) (NN clearance)) (PP (IN of) (NP (VBN deposited) (NN amyloid)))) (PP-TMP (ADVP (RB even)) (VBG following) (NP (NP (NP (NNS periods)) (PP (IN of) (NP (NN transgene) (NN suppression)))) (ADJP (JJ equal) (PP (IN to) (NP (NP (DT the) (NN time)) (SBAR (WHADVP-1 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBN taken) (ADVP-1 (-NONE- *T*)) (SBAR-TMP (IN for) (S (NP-SBJ (NNS plaques)) (VP (TO to) (VP (VB form)))))))))))))) (. .)) )
( (S (NP-SBJ (DT This) (JJ latter) (NN finding)) (VP (VBZ indicates) (SBAR (IN that) (S (PP (VBN compared) (PP (IN to) (NP (NP (JJ other) (ADJP (NN disease) (HYPH -) (VBN associated)) (NN protein) (NNS aggregates)) (PP (JJ such) (IN as) (NP (NP (NN mutant) (NN huntingtin)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP clear) (PP-TMP (IN in) (NP (QP (JJR less) (IN than) (CD 3)) (NN mo))) (PRN (-LRB- [) (NP (CD 32)) (-RRB- ])))))))))) (, ,) (NP-SBJ (NP (DT the) (NN disaggregation)) (PP (IN of) (NP (JJ extracellular) (NN amyloid)))) (VP (VBZ is) (ADJP-PRD (RB relatively) (JJ slow)))))) (. .)) )
( (S (ADVP (RB Notably)) (, ,) (NP-SBJ (NP (JJ pharmaceutical) (NML (SYM γ) (HYPH -) (NN secretase)) (NNS inhibitors)) (VP (VBN published) (NP (-NONE- *)) (PP-TMP (IN to) (NP (NN date))))) (VP (VBP show) (NP (NP (ADJP (RBR less) (JJ strict)) (NN regulation)) (PP (IN of) (NP (NN Aβ) (NN production))) (PP-TMP (VBG following) (NP (JJ chronic) (NN administration))) (SBAR (IN than) (S (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN attained) (ADVP (RB here)))))))) (. .)) )
( (S (NP-SBJ (NP (CD Two) (JJ independent) (NNS compounds)) (VP (VBN tested) (NP (-NONE- *)) (PP-LOC (IN in) (NP (ADJP (NP (NP (NN Tg2576) (PRN (-LRB- [) (NP (CD 33)) (-RRB- ]))) (CC and) (NP (NN TgCRND8) (PRN (-LRB- [) (NP (CD 34)) (-RRB- ])))) (JJ transgenic)) (NNS mice))))) (VP (VBP show) (NP (NP (NP (NML (QP (RB no) (JJR more) (IN than) (CD 85)) (NN %)) (NN suppression)) (PP (IN of) (NP (NN Aβ40) (NNS levels)))) (, ,) (CC and) (NP (SBAR-LOC (WHADVP-2 (WRB where)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN measured) (NP-1 (-NONE- *)) (ADVP-LOC-2 (-NONE- *))))) (, ,) (NP (ADJP (RB even) (JJR less)) (NN suppression)) (PP (IN of) (NP (NN Aβ42) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 60)) (NN %)) (-RRB- -RRB-)))))) (PRN (-LRB- [) (NP (CD 35) (, ,) (CD 36)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (PP-TMP (ADVP (RB even)) (IN after) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG accounting) (PP (IN for) (NP (NP (DT the) (ADJP (RB much) (JJR higher)) (NN APP) (NN expression) (NNS levels)) (PP-LOC (IN in) (NP (PRP$ our) (NNS mice))) (PP (IN than) (PP-LOC (IN in) (NP (DT the) (NML (NN Tg2576) (CC and) (NN TgCRND8)) (NNS lines))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN achieved) (NP (NP (RBR better) (JJ absolute) (NN suppression)) (PP (IN of) (NP (NN Aβ) (NN production))) (PP (IN with) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN system))) (SBAR (IN than) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBZ is) (ADVP-TMP (RB currently)) (ADJP-PRD (JJ possible)) (PP (IN with) (NP (VBN published) (NML (SYM γ) (HYPH -) (NN secretase)) (NNS inhibitors))))))))) (. .)) )
( (S (SBAR-PRP (IN Since) (S (NP-SBJ-2 (RB even) (DT the) (ADJP (RBS most) (JJ advanced)) (JJ future) (JJ pharmaceutical) (NNS agents)) (VP (VBP are) (ADJP-PRD (JJ unlikely) (S (NP-SBJ-2 (-NONE- *)) (VP (TO to) (VP (VB attain) (NP (NP (ADJP (RBR more) (JJ complete)) (NN control)) (PP (IN of) (NP (NN Aβ) (NN production))) (SBAR (IN than) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN achieved) (NP-1 (-NONE- *)) (ADVP (RB here))))))))))))) (, ,) (NP-SBJ (DT this) (NN system)) (VP (VBZ provides) (NP (NP (DT a) (JJ salient) (NN test)) (PP (IN of) (NP (NP (JJ therapeutic) (NN intervention)) (PP (IN with) (NP (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NNS compounds))))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ-1 (NP (DT the) (NN progression)) (PP (IN of) (NP (NN amyloid) (NN deposition)))) (VP (VBD was) (ADVP (RB sharply)) (VP (VBN arrested) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (DT this) (NN approach))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (DT a) (JJ substantial) (NN amyloid) (NN burden)) (VP (VBD remained) (PP-TMP (ADVP (RB even)) (IN after) (NP (NP (JJ long) (NNS periods)) (PP (IN of) (NP (NN transgene) (NN suppression))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VP (VBD examined) (NP (NP (DT a) (JJ small) (NN number)) (PP (IN of) (NP (NNS animals)))) (PP-TMP (IN after) (NP (NP (CD 12) (NN mo)) (PP (IN of) (NP (NP (NN dox) (NN treatment)) (-LRB- -LRB-) (VP (VBG beginning) (PP-TMP (IN at) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age)))))) (-RRB- -RRB-)))))) (, ,) (CC and) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NN amyloid) (NNS deposits)) (VP (VBD were) (ADVP-TMP (RB still)) (ADJP-PRD (RB relatively) (JJ abundant))))))) (. .)) )
( (S (NP-SBJ (NML (JJ Longer) (HYPH -) (NN term)) (NNS treatments)) (VP (VBP are) (ADVP-TMP (RB now)) (PP-PRD (IN in) (NP (NN progress)))) (. .)) )
( (S (PP (IN At) (NP (NP (DT the) (JJS latest) (NN treatment) (NN interval)) (VP (VBN analyzed) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN ELISA)))))) (, ,) (NP-SBJ (NP (NNS animals)) (VP (VBN administered) (NP (-NONE- *)) (NP (NN dox)) (PP-TMP (IN for) (NP (CD 6) (NN mo))))) (VP (VBD showed) (NP (NP (NP (VBN elevated) (NNS levels)) (PP (IN of) (NP (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN Aβ) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (CD 5)))) (-RRB- -RRB-))))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD could) (VP (VB be) (VP (VBN interpreted) (NP-1 (-NONE- *)) (PP (IN as) (NP (DT an) (NN indication) (SBAR (IN that) (S (NP-SBJ (DT the) (NNS plaques)) (VP (VP (VBP are) (ADVP-TMP (RB slowly)) (VP (VBG releasing) (NP (NP (NN peptide)) (-LRB- -LRB-) (CC or) (NP (JJ oligomeric) (NN Aβ)) (-RRB- -RRB-)) (PP-LOC (IN into) (NP (DT the) (JJ soluble) (NN pool))))) (CC and) (VP (MD might) (ADVP-TMP (RB eventually)) (VP (VB dissolve))))))))))))))) (. .)) )
( (S (S (SBAR-NOM-SBJ (IN Whether) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG inhibiting) (NP (NN Aβ) (NN production)) (ADVP-TMP (ADVP (RBR longer)) (PP (IN than) (NP (NML (CD 6) (-LRB- -LRB-) (CC or) (CD 12)) (-RRB- -RRB-) (NN mo)))))) (VP (MD may) (ADVP (RB ultimately)) (VP (VB result) (PP (IN in) (NP (NP (NN clearance)) (PP (IN of) (NP (NN amyloid))))))))) (VP (VBZ is) (PP-PRD (IN under) (NP (NN investigation))))) (: ;) (S (ADVP (RB unfortunately)) (, ,) (NP-SBJ (NP (DT the) (NN life) (NN span)) (PP (IN of) (NP (DT the) (NN model)))) (ADVP-TMP (RB eventually)) (VP (VBZ limits) (NP (DT this) (NN experiment)))) (. .)) )
( (S (NP-SBJ (NP (NNS Therapeutics)) (VP (VBN used) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NNS humans))))) (VP (MD will) (VP (VB have) (NP (NP (NP (ADJP (RB considerably) (JJR more)) (NN time)) (SBAR (WHADVP-1 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB act) (ADVP-TMP-1 (-NONE- *T*))))))) (SBAR (IN than) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBZ is) (ADJP-PRD (JJ possible)) (PP (IN within) (NP (NP (DT the) (NN life) (NN span)) (PP (IN of) (NP (NN rodent) (NNS models))))))))))) (. .)) )
( (S (NP-SBJ (NML (JJ Long) (HYPH -) (NN term)) (NNS treatments)) (VP (VP (MD would) (ADVP (RB certainly)) (VP (VB be) (ADJP-PRD (JJ possible)))) (CC and) (VP (MD could) (VP (VB be) (NP-PRD (NP (DT a) (NN key)) (PP (IN to) (NP (JJ effective) (NN therapy))))))) (. .)) )
( (S (ADVP (RB Overall)) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ (PRP we)) (VP (VBP interpret) (NP (PRP$ our) (NNS findings)) (PP (IN as) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NN AD) (NNS therapies)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (ADVP (RB significantly)) (VP (VBP lower) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN Aβ)))) (-LRB- -LRB-) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (CC either) (VP (VBG inhibiting) (NP (NN secretase) (NN activity))) (CC or) (VP (VBG inhibiting) (NP (NN APP) (NN expression)))))) (-RRB- -RRB-))))) (VP (VP (MD may) (RB not) (ADVP-TMP (RB quickly)) (VP (VB reverse) (NP (JJ preexisting) (NN pathology)))) (, ,) (CC but) (VP (MD should) (ADVP (RB effectively)) (VP (VB halt) (NP (NP (JJ further) (NN deposition)) (PP (IN of) (NP (NN amyloid)))))))))))) (. .)) )
( (S (PP (IN In) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG interpreting) (NP (PRP$ our) (NN study))))) (, ,) (NP-SBJ-1 (NP (PRP it)) (SBAR-3 (-NONE- *EXP*))) (VP (MD should) (VP (VB be) (VP (VBN remembered) (NP-1 (-NONE- *)) (SBAR-3 (IN that) (S (NP-SBJ (NP (NP (DT the) (JJS earliest) (NNS plaques)) (SBAR (WHNP-4 (-NONE- *0*)) (S (NP-SBJ-4 (-NONE- *T*)) (VP (TO to) (VP (VB appear) (PP-LOC (IN in) (NP (DT these) (NNS mice)))))))) (, ,) (PP (IN like) (NP (NP (JJ other) (NN APP) (NNS transgenics)) (VP (VBG harboring) (NP (DT the) (JJ Swedish) (NN mutation)) (PRN (-LRB- [) (NP (CD 27)) (-RRB- ])))))) (, ,) (VP (VBP are) (ADVP (RB predominantly)) (NP-PRD (NP (JJ fibrillar) (NNS deposits)) (, ,) (SBAR (WHNP-2 (WDT which)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (MD may) (VP (VB be) (ADJP-PRD (ADJP (RBR less) (JJ tractable)) (PP (IN than) (NP (NP (DT the) (JJ diffuse) (NNS aggregates)) (VP (VBN thought) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB come) (ADVP-TMP (RB first)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (JJ human) (NN disease))))))))))))))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR-TMP (IN once) (S (NP-SBJ-1 (JJ diffuse) (NNS deposits)) (VP (VBP are) (VP (VBN formed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT these) (NNS mice))))))) (, ,) (NP-SBJ-2 (PRP they)) (VP (VBP are) (ADVP-MNR (ADVP (ADVP (RB no) (RBR more)) (RB easily)) (PP-3 (-NONE- *ICH*))) (VP (VBN cleared) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (PRP$ our) (NN system))) (PP-3 (IN than) (NP (VBN cored) (NNS plaques))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (NN S4)))) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ (NP (DT An) (JJ additional) (NN consideration)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ (PRP we)) (VP (VBP recognize) (NP-1 (-NONE- *T*)))))) (VP (VBZ is) (SBAR-PRD (SBAR (IN that) (S (NP-SBJ (NP (DT a) (JJ small) (NN amount)) (PP (IN of) (NP (NN transgene) (NN expression)))) (VP (VBZ continues) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN dox)))))))) (CC and) (SBAR (IN that) (S (NP-SBJ-2 (JJ endogenous) (NN mouse) (NN Aβ)) (VP (VBZ continues) (S (NP-SBJ-2 (-NONE- *)) (VP (TO to) (VP (VB be) (VP (VBN produced) (NP-2 (-NONE- *))))))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ possible)) (SBAR-1 (IN that) (S (NP-SBJ-2 (NP (DT the) (VBN combined) (JJ low) (NNS levels)) (PP (IN of) (NP (NML (NML (JJ endogenous) (NN mouse) (NN Aβ)) (CC and) (NML (JJ nonsuppressed) (JJ human))) (NN peptide)))) (VP (VBP are) (ADJP-PRD (JJ sufficient) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (TO to) (VP (VB maintain) (NP (VBG existing) (NNS deposits)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (NP (DT these) (JJ low) (NNS levels)) (PP (IN of) (NP (NN peptide)))) (VP (VBP are) (RB not) (ADJP-PRD (JJ sufficient) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB induce) (NP (JJ new) (NN amyloid) (NN formation)))))) (, ,) (SBAR-PRP (IN as) (S (NP-SBJ (NP (NML (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN tetAPPswe) (HYPH /) (NN ind)) (NNS mice)) (VP (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))) (PP-TMP (IN for) (NP (QP (IN up) (IN to) (DT a)) (NN year))))) (VP (VBP do) (RB not) (VP (VB develop) (NP (NN amyloid) (NNS lesions)) (PRN (-LRB- -LRB-) (S (NP-SBJ-2 (NNS data)) (RB not) (VP (VBN shown) (NP-2 (-NONE- *)))) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADVP (RB also)) (ADJP-PRD (JJ clear)) (SBAR-1 (IN that) (S (PP (IN in) (NP (DT this) (JJ genetic) (NN system))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN raised) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN Aβ)))) (PP (IN to) (NP (NP (NNS levels)) (VP (RB not) (VBN found) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NNS humans)))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB accelerate) (NP (NN pathology)) (PP (IN into) (NP (DT an) (ADJP (RB experimentally) (JJ feasible)) (NN time) (NN frame))))))))))) (. .)) )
( (S (S (NP-SBJ (DT This) (NN system)) (VP (VBD allowed) (S (NP-SBJ (PRP us)) (VP (TO to) (VP (VB create) (NP (NP (DT an) (ADJP (RB approximately) (JJ 20-fold)) (NN differential)) (PP (IN between) (NP (NML (NN APP) (HYPH /) (NN Aβ)) (JJ synthetic) (NNS rates)))) (PP-TMP (IN before) (CC and) (IN after) (NP (NN treatment)))))))) (, ,) (S (ADVP (RB yet)) (NP-SBJ (NP (DT the) (ADJP (FW in) (FW vivo)) (NN equilibrium)) (PP (IN between) (NP (NP (ADJP (VBN aggregated) (CC and) (VBN disaggregated)) (NNS states)) (PP (IN of) (NP (NN Aβ)))))) (ADVP (RB still)) (VP (VBD favored) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NN amyloid) (NNS deposits)))))) (. .)) )
( (S (PP (IN In) (NP (PRP$ our) (NN opinion))) (, ,) (NP-SBJ-2 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ seems) (S (NP-SBJ-2 (-NONE- *)) (ADJP-PRD (JJ unlikely))) (SBAR-1 (IN that) (S (NP-SBJ (NP (NN amyloid) (NNS deposits)) (PP-LOC (IN in) (NP (JJ human) (NN brain)))) (VP (MD would) (VP (VB be) (ADVP (RB inherently)) (ADJP-PRD (ADJP (DT any) (RBR less) (JJ stable)) (PP (IN than) (NP (NP (DT those)) (VP (VBN formed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NN mouse) (NN brain)))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (JJ human) (NN brain)) (VP (MD may) (VP (VB harbor) (NP (NP (NP (NN clearance) (NNS mechanisms)) (VP (RB not) (VBN shared) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NNS mice))))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD would) (VP (VB allow) (NP (NP (ADJP (RBR more) (JJ efficient)) (NN removal)) (PP (IN of) (NP (VBG preexisting) (NN amyloid))))))))))) (. .)) )
( (S (NP-SBJ (NP (CD One) (JJ potential) (NN mechanism)) (SBAR (WHPP-2 (IN by) (WHNP (WDT which))) (S (NP-SBJ-1 (NN amyloid)) (VP (MD may) (VP (VB be) (ADVP (RBR more) (RB efficiently)) (VP (VBN removed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (JJ human) (NN disease))) (PP (IN than) (PP-LOC (IN in) (NP (DT the) (NN mouse) (NNS models)))) (PP-MNR-2 (-NONE- *T*)))))))) (VP (VBZ is) (PP-MNR-PRD (IN through) (NP (JJ microglial) (NN phagocytosis)))) (. .)) )
( (S (NP-SBJ (NP (JJ Resident) (NNS microglia)) (PP-LOC (IN in) (NP (JJ transgenic) (NN mouse) (NNS models)))) (VP (VP (VBP localize) (PP (IN to) (NP (NP (NN tissue)) (VP (VBG surrounding) (NP (NNS plaques)))))) (CC but) (VP (VBP show) (NP (NP (JJ little) (NN evidence)) (PP (IN of) (NP (NN amyloid) (NN engulfment)))) (PRN (-LRB- [) (NP (NP (CD 37)) (PP (SYM –) (NP (CD 40)))) (-RRB- ])))) (. .)) )
( (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NNS microglia)) (VP (VBG surrounding) (NP (NN amyloid) (NNS plaques)) (PP-LOC (IN in) (NP (JJ human) (NN brain))))) (VP (VBP show) (NP (NP (DT a) (ADJP (RB much) (JJR higher)) (NN state)) (PP (IN of) (NP (NN activation)))) (PP (IN with) (NP (NP (JJR greater) (NN expression)) (PP (IN of) (NP (NN complement) (NN receptor))))) (PRN (-LRB- [) (NP (CD 40)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (DT the) (NN role)) (PP (IN of) (NP (NNS microglia))) (PP (IN in) (NP (NN amyloid) (NN metabolism)))) (VP (VBZ is) (ADJP-PRD (JJ minor)) (PP-LOC (IN in) (NP (JJ transgenic) (NNS models))) (PP (VBN compared) (PP (IN to) (NP (DT the) (JJ human) (NN condition))))) (. .)) )
( (S (ADVP (RB Somewhat) (RB paradoxically)) (, ,) (NP-SBJ (JJ several) (NNS studies)) (ADVP (RB further)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN treatment)) (PP (IN with) (NP (JJ anti-inflammatory) (NNS drugs))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB reduce) (NP (JJ microglial) (NN activation)))))) (ADVP (RB actually)) (VP (VBZ lowers) (NP (NN amyloid) (NN load)) (PP-LOC (IN in) (NP (ADJP (NN APP) (JJ transgenic)) (NNS mice))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN mouse) (NNS microglia))) (PP (IN in) (NP (NP (DT the) (NML (NN formation) (CC and) (NN maintenance))) (PP (IN of) (NP (NN amyloid) (NNS aggregates)))))))) (PRN (-LRB- [) (NP (NP (CD 41)) (PP (SYM –) (NP (CD 43)))) (-RRB- ])))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (DT this) (NN outcome)) (VP (MD may) (VP (VB be) (ADVP (RB alternatively)) (VP (VBN explained) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (JJ direct) (NNS effects)) (PP (IN of) (NP (JJ many) (JJ anti-inflammatory) (NNS drugs))) (PP (IN on) (NP (NML (SYM γ) (HYPH -) (NN secretase)) (NN cleavage))))) (PRN (-LRB- [) (NP (NP (CD 44)) (PP (SYM –) (NP (CD 47)))) (-RRB- ]))))) (. .)) )
( (S (S (ADVP (RB Nonetheless)) (, ,) (NP-SBJ (NP (DT the) (NN role)) (PP (IN of) (NP (NNS microglia))) (PP (IN in) (NP (CC both) (NP (DT the) (JJ human) (NN condition)) (CC and) (NP (DT the) (NN mouse) (NNS models))))) (VP (VBZ is) (ADJP-PRD (RB poorly) (VBN understood)))) (, ,) (CC and) (S (NP-SBJ (NP (NNS differences)) (PP (IN in) (NP (JJ microglial) (NN reactivity))) (PP (IN between) (NP (DT the) (CD two)))) (VP (MD could) (VP (VB lead) (PP (IN to) (NP (NP (ADJP (RB significantly) (JJR faster)) (NN amyloid) (NN clearance)) (PP-LOC (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN AD))))))) (SBAR (IN than) (S (NP-SBJ (PRP we)) (VP (VBP observe) (NP (-NONE- *?*)) (PP-LOC (IN in) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice))))))))))) (. .)) )
( (S (PP (VBN Given) (NP (NP (DT the) (ADJP (RB relatively) (JJ minor)) (NN role)) (VP (VBN played) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NNS microglia))) (PP-LOC (IN in) (NP (NP (JJ other) (NN mouse) (NNS models)) (PP (IN of) (NP (NN amyloidosis)))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP think) (SBAR (-NONE- *0*) (S (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (ADJP-PRD (JJ unlikely)) (SBAR-1 (IN that) (S (NP-SBJ (DT these) (NNS cells)) (VP (VBP have) (VP (VBN influenced) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN amyloid) (NN clearance)))) (PP-LOC (IN in) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)))))))))) (. .)) )
( (S (ADVP (RB Even) (RB so)) (, ,) (NP-SBJ (PRP we)) (VP (VBD considered) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP-SBJ (JJ chronic) (NN dox) (NN treatment)) (VP (MD may) (VP (VB have) (VP (VBN altered) (NP (NP (DT the) (NN activation) (NN state)) (PP (IN of) (NP (NNS microglia)))) (PP-LOC (IN in) (NP (PRP$ our) (VBN treated) (NNS mice)))))))))) (. .)) )
( (S (NP-SBJ (NN Dox)) (VP (VBZ is) (ADJP-PRD (RB structurally) (JJ similar) (PP (IN to) (NP (NP (NN minocycline)) (, ,) (NP (NP (DT a) (VBN reported) (JJ anti-inflammatory) (NN drug)) (CC and) (NP (NP (NN inhibitor)) (PP (IN of) (NP (JJ microglial) (NN activation)))))))) (PRN (-LRB- [) (NP (CD 48)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB However)) (, ,) (SBAR-ADV (IN if) (S (NP-SBJ (NN dox)) (VP (VBZ does) (VP (VB have) (NP (JJ anti-inflammatory) (NN activity)))))) (, ,) (ADVP-TMP (RB then)) (, ,) (PP-PRP (VBN based) (PP (IN on) (NP (NP (JJ previous) (NNS studies)) (PP (IN with) (NP (JJ other) (NNS anti-inflammatories)))))) (, ,) (NP-SBJ-1 (PRP we)) (VP (MD would) (VP (VB have) (VP (VBN expected) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB find) (NP (RBR less) (NN amyloid)) (PP-LOC (IN in) (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN treated)) (NNS animals))))))))) (. .)) )
( (S (ADVP (RB Clearly)) (, ,) (NP-SBJ (DT that)) (VP (VBD was) (RB not) (NP-PRD (DT the) (NN case))) (. .)) )
( (S (SBAR-ADV (IN While) (S (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ possible)) (SBAR-1 (IN that) (S (NP-SBJ (NN dox)) (VP (VBZ acts) (PP-MNR (IN in) (NP (DT some) (JJ other) (NN way))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB slow) (NP (NN amyloid) (NN clearance))))))))))) (, ,) (NP-SBJ (NP (NNS data)) (PP (IN from) (NP (JJ multiple) (NNS studies)))) (VP (VBP demonstrate) (SBAR (IN that) (S (S (NP-SBJ (JJ microglial) (NNS responses)) (VP (VBP are) (ADVP (RB normally)) (ADJP-PRD (JJ weak)) (PP-LOC (IN in) (NP (DT the) (NN mouse) (NN AD) (NNS models))) (PRN (-LRB- [) (NP (NP (CD 37)) (PP (SYM –) (NP (CD 40)))) (-RRB- ])))) (, ,) (CC and) (S (ADVP (RB thus)) (NP-SBJ (NP (PRP it)) (SBAR-2 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ doubtful)) (SBAR-2 (IN that) (S (NP-SBJ (ADJP (NN dox) (HYPH -) (VBN mediated)) (JJ microglial) (NN inhibition)) (VP (VBD affected) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (PRP$ our) (NN study)))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NML (NN persistence) (CC and) (NN stability))) (PP (IN of) (NP (NN amyloid) (NNS deposits))) (PP-LOC (IN in) (NP (PRP$ our) (NN system)))) (VP (VBZ is) (ADJP-PRD (JJ unexpected)) (PP (VBN given) (NP (NP (DT the) (NN speed)) (SBAR (WHPP-2 (IN with) (WHNP (WDT which))) (S (NP-SBJ-1 (NN Aβ) (NNS aggregates)) (VP (VBP are) (VP (VBN cleared) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (JJ other) (NN mouse) (NNS models)) (PP (IN of) (NP (JJ therapeutic) (NN intervention))))) (PP-MNR-2 (-NONE- *T*))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Anti-Aβ) (NNS antibodies)) (VP (VBN injected) (NP (-NONE- *)) (ADVP (RB directly)) (PP-LOC (IN into) (NP (DT the) (NN brain))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB eliminate) (NP (NN amyloid) (NNS deposits)) (PP-TMP (IN in) (NP (NP (QP (RB as) (JJ little) (IN as) (CD 1)) (NN wk)) (PP (IN after) (NP (NN treatment))))) (PRN (-LRB- [) (NP (NP (CD 49)) (PP (SYM –) (NP (CD 51)))) (-RRB- ])))))))) (. .)) )
( (S (NP-SBJ (JJ Peripheral) (NN antibody) (NN injection)) (VP (VP (VBZ decreases) (NP (NN amyloid) (NN load)) (ADVP (RBR more) (RB broadly))) (, ,) (CC and) (VP (SBAR-ADV (IN although) (S (NP-SBJ-1 (PRP it)) (VP (VBZ does) (RB not) (VP (VB appear) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB act) (ADVP-TMP (ADVP (RB as) (RB quickly)) (PP (IN as) (NP (JJ local) (NN injection))))))))))) (, ,) (MD can) (ADVP (RB significantly)) (VP (VB reduce) (NP (NN amyloid) (NN load)) (PP-TMP (IN within) (NP (NP (CD 2) (NN mo)) (PP (IN of) (NP (JJ initial) (NN treatment))))) (PRN (-LRB- [) (NP (CD 52) (, ,) (CD 53)) (-RRB- ]))))) (. .)) )
( (S (ADVP-TMP (RBR More) (RB recently)) (, ,) (NP-SBJ (DT an) (JJ alternative) (NN approach)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NP (JJ lentiviral) (NN transfer)) (PP (IN of) (NP (NN neprilysin)))) (VP (MD can) (ADVP (RB also)) (VP (VB reduce) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS aggregates)))) (PP-LOC (IN in) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (DT the) (NN injection) (NN site))))) (PRN (-LRB- [) (NP (CD 54)) (-RRB- ])))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Careful) (NN study)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN behind) (NP (NP (JJ several)) (PP (IN of) (NP (DT the) (ADJP (NN antibody) (HYPH -) (VBN mediated)) (NNS therapies)))))))) (VP (VBZ has) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (VBN activated) (NNS microglia)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN removal)) (PP (IN of) (NP (JJ fibrillar) (NNS plaques))))) (PP-TMP (IN after) (NP (NN immunization)))))) (PRN (-LRB- [) (NP (CD 50) (, ,) (CD 52) (, ,) (CD 55)) (-RRB- ])))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (NP (PRP it)) (SBAR-2 (-NONE- *EXP*))) (VP (VBZ has) (VP (VBN been) (VP (VBN noted) (NP-1 (-NONE- *)) (SBAR-2 (IN that) (S (NP-SBJ (NP (NN deletion)) (PP (IN of) (NP (NP (DT the) (NN Fc) (NN receptor)) (-LRB- -LRB-) (NP (NP (DT the) (JJ primary) (NN receptor)) (PP (IN for) (NP (NP (JJ microglial) (NN opsinization)) (PP (IN of) (NP (NML (NN antibody) (HYPH –) (NN antigen)) (NNS complexes)))))))) (-RRB- -RRB-) (PP-LOC (IN in) (NP (ADJP (NN APP) (JJ transgenic)) (NN mouse) (NNS models)))) (VP (VBZ has) (NP (NP (DT no) (NN impact)) (PP (IN on) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (ADJP (NN antibody) (HYPH -) (VBN mediated)) (NN therapy)))))) (PRN (-LRB- [) (NP (CD 56) (, ,) (CD 57)) (-RRB- ])))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (, ,) (ADVP (RB nevertheless)) (, ,) (ADJP-PRD (JJ possible)) (SBAR-1 (IN that) (S (NP-SBJ (NP (NN lack)) (PP (IN of) (NP (NNS microglia) (NN activation)))) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ major) (NN difference)) (PP (IN between) (NP (NP (NP (NP (DT the) (JJ slow) (NN clearance)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB here)))) (, ,) (SBAR (WHADVP-3 (WRB where)) (S (NP-SBJ-2 (NP (DT no) (NN perturbation)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))) (VP (VBZ is) (VP (VBN expected) (NP-2 (-NONE- *)) (ADVP-LOC-3 (-NONE- *T*))))))) (, ,) (CC and) (NP (NP (DT the) (JJ rapid) (NN clearance)) (VP (VBN described) (NP (-NONE- *)) (PP (IN in) (NP (NP (NNS studies)) (VP (VBG involving) (NP (UCP (NN antibody) (CC or) (JJ viral)) (NN injection)))))))))))))) (. .)) )
( (S (S (PP (IN In) (NP (NN isolation))) (, ,) (NP-SBJ (NP (JJ mild) (NN activation)) (PP (IN of) (NP (NNS microglia))) (PP (IN by) (NP (NP (NN injection) (NN damage)) (CC or) (NP (NN opsinization))))) (VP (MD may) (RB not) (VP (VB be) (ADJP-PRD (JJ adequate)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB induce) (NP (JJ substantial) (NN phagocytosis)))))))) (, ,) (CC but) (S (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN combined) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (DT an) (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NN agent)) (, ,) (PP (JJ such) (IN as) (NP (ADJP (NP (NN neprilysin) (CC or) (NN Aβ)) (HYPH -) (VBN targeted)) (NNS antibodies))))) (ADVP-TMP-2 (-NONE- *T*))))) (, ,) (NP-SBJ (DT the) (CD two)) (VP (MD may) (VP (VB work) (PP-MNR (IN in) (NP (NN concert))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB clear) (NP (NN peptide) (NNS deposits)))))))) (. .)) )
( (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (DT this) (NN hypothesis))))) (, ,) (NP-SBJ (NP (JJ strong) (NN activation)) (PP (IN of) (NP (NNS microglia))) (PP (IN through) (NP (NP (NP (JJ transgenic) (NN expression)) (PP (IN of) (NP (NN TGFβ) (PRN (-LRB- [) (NP (CD 58)) (-RRB- ]))))) (CC or) (NP (NP (JJ central) (NN injection)) (PP (IN of) (NP (NN lipopolysaccharide) (PRN (-LRB- [) (NP (CD 59) (, ,) (CD 60)) (-RRB- ])))))))) (VP (MD can) (PP-MNR (IN by) (NP (PRP itself))) (ADVP (RB substantially)) (VP (VB reduce) (NP (NN plaque) (NN burden)) (PP-LOC (IN in) (NP (ADJP (NN APP) (JJ transgenic)) (NNS mice))))) (. .)) )
( (S (CC But) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (JJ acute) (ADJP (NP (NN antibody) (HYPH -) (CONJP (CC and) (HYPH /) (CC or)) (NN injury)) (HYPH -) (VBN mediated)) (NN activation))))) (, ,) (SBAR-TMP (IN once) (S (S (NP-SBJ (DT the) (NN inflammation)) (VP (VBZ has) (VP (VBN passed)))) (, ,) (CC and) (S (NP-SBJ-1 (DT the) (NML (NML (NN antibody)) (CC and) (NML (VBN bound) (NN peptide)))) (VP (VBP have) (VP (VBN been) (VP (VBN cleared) (CC and) (VBN degraded) (NP-1 (-NONE- *)))))))) (, ,) (S (S (NP-SBJ (DT the) (VBG remaining) (NN Aβ)) (ADVP-TMP (RB quickly)) (VP (VBZ reaggregates))) (CC and) (S (NP-SBJ-2 (NN amyloid) (NN pathology)) (VP (VBZ is) (VP (VBN reestablished) (NP-2 (-NONE- *)) (PRN (-LRB- [) (NP (CD 49)) (-RRB- ])))))) (. .)) )
( (S (NP-SBJ (DT This) (NN finding)) (VP (VBZ reinforces) (NP (DT the) (NN notion) (SBAR (IN that) (S (PP (IN without) (NP (VBN continued) (NN stimulation))) (, ,) (NP-SBJ (NP (NNS microglia)) (PP (IN in) (NP (NN mouse) (NNS models)))) (VP (VBP do) (RB not) (VP (VB maintain) (NP (NP (NP (DT the) (JJ same) (NN level)) (PP (IN of) (NP (VBN sustained) (NN activation)))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD may) (VP (VB occur) (PP-LOC (IN in) (NP (NNS humans)))))))))))))) (. .)) )
( (S (NP-SBJ (NP (NNP SantaCruz)) (ADVP-ETC (FW et) (FW al.))) (ADVP-TMP (RB recently)) (VP (VBD published) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (NNS mice)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP express) (NP (NN P301L) (JJ human) (NN tau)) (PP (IN via) (NP (DT a) (JJ similar) (NN vector) (NN system))))))))) (PRN (-LRB- [) (NP (CD 61)) (-RRB- ]))) (. .)) )
( (S (PP (IN As) (PP-LOC (IN in) (NP (PRP$ our) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)))) (, ,) (NP-SBJ (NP (NNP SantaCruz)) (ADVP-ETC (FW et) (FW al.))) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN tau) (JJ neurofibrillary) (NNS tangles)) (, ,) (PP (IN like) (NP (NN amyloid) (NNS plaques)))) (, ,) (VP (VBP are) (RB not) (VP (VBN cleared) (NP-1 (-NONE- *)) (ADVP-MNR (RB efficiently)) (PP-TMP (VBG following) (NP (NN transgene) (NN suppression)))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN lack)) (PP (IN of) (NP (NN clearance))) (PP (IN in) (NP (NP (DT both) (NNS models)) (PP (IN of) (NP (NN AD) (NN pathology)))))) (VP (VBZ comes) (PP (IN as) (NP (NP (DT a) (JJ stark) (NN contrast)) (PP (IN to) (NP (NP (NP (DT the) (JJ rapid) (NN removal)) (PP (IN of) (NP (NN protein) (NNS aggregates)))) (VP (VBN found) (NP (-NONE- *)) (PP (IN in) (NP (NP (JJ similar) (NML (NN tet) (HYPH -) (NN off)) (NN mouse) (NNS models)) (PP (IN of) (NP (NML (NML (NNP Huntington) (PRN (-LRB- [) (NP (CD 32)) (-RRB- ]))) (CC and) (NML (NN prion))) (NN disease) (PRN (-LRB- [) (NP (CD 62)) (-RRB- ])))))))))))) (. .)) )
( (S (PP (IN In) (NP (DT these) (NNS cases))) (, ,) (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG disrupting) (NP (NP (DT the) (NN input)) (PP (IN of) (NP (JJ new) (NN monomer))) (PP (IN to) (NP (DT the) (NN system)))) (PP-MNR (IN via) (NP (ADJP (NN dox) (HYPH -) (VBN mediated)) (NN transgene) (NN suppression))))) (VP (VBD led) (PP (IN to) (NP (NP (ADJP (RB relatively) (JJ rapid)) (NN clearance)) (PP (IN of) (NP (NN protein) (NNS aggregates)))))) (. .)) )
( (S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ (NP (PRP$ our) (NN study)) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNP SantaCruz)) (ADVP-ETC (FW et) (FW al.)))))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NN protein) (NNS aggregates)) (PP-LOC (IN in) (NP (NN AD)))) (VP (MD may) (VP (VB be) (ADJP-PRD (ADJP (RBR more) (JJ tenacious)) (PP (IN than) (PP-LOC (IN in) (NP (JJ other) (JJ neurodegenerative) (NNS disorders)))))))))) (. .)) )
( (S (ADVP (RB Perhaps)) (SBAR-TMP (IN once) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN aggregated) (NP-1 (-NONE- *))))) (, ,) (NP-SBJ (NN Aβ) (CC and) (NN tau)) (VP (VBP are) (ADJP-PRD (RB either) (ADJP (ADJP (ADVP (RB inherently)) (RBR more) (JJ stable)) (PP (IN than) (NP (JJ other) (NN protein) (NNS aggregates)))) (CC or) (ADJP (RBR more) (JJ resistant) (PP (IN to) (NP (ADJP (AFX intra) (HYPH -) (CC and) (JJ extracellular)) (NN clearance) (NNS mechanisms)))))) (. .)) )
( (S (NP-SBJ (NP (CD One) (NN question)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ-2 (PRP we)) (VP (VBD were) (RB not) (ADJP-PRD (JJ able) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (TO to) (VP (VB address) (NP-1 (-NONE- *T*)) (PP (IN in) (NP (DT this) (NN study))))))))))) (VP (VBZ is) (SBAR-PRD (IN whether) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG abrogating) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ new) (NN Aβ)))))) (VP (VBZ halts) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (JJ cognitive) (NN decline)))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Studies)) (PP (IN from) (NP (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN tau) (NNS mice)))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-1 (NN protein) (NN clearance)) (VP (MD may) (PP (IN in) (NP (NN fact))) (RB not) (VP (VB be) (VP (VBN required) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (JJ cognitive) (NN improvement))) (PP-TMP (VBG following) (NP (NN transgene) (NN suppression))) (PRN (-LRB- [) (NP (CD 61)) (-RRB- ])))))))) (. .)) )
( (S (PP-TMP (IN At) (ADJP (JJ present))) (, ,) (PP (IN because) (IN of) (NP (JJ unexpected) (JJ noncognitive) (JJ behavioral) (NNS abnormalities))) (, ,) (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ clear)) (SBAR-1 (IN whether) (S (NP-SBJ-2 (DT the) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice)) (VP (MD can) (VP (VB be) (VP (VBN used) (NP-2 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB address) (NP (DT the) (JJ same) (NN question)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NN amyloid) (NN pathology)))))))))))))) (. .)) )
( (S (NP-SBJ (NP (NP (DT Both) (NNS lines)) (PP (IN of) (NP (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ (PRP we)) (VP (VBN studied) (NP-1 (-NONE- *T*)) (ADVP-LOC (RB here)))))) (VP (VBP display) (NP (NP (JJ extreme) (NN hyperactivity)) (UCP (ADJP (JJ visible) (PP (IN as) (NP (NN cage) (NN circling)))) (CC and) (VP (VBN quantified) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN activity) (NN monitoring)))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (CD 7)))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (JJ Many)) (PP (IN of) (NP (DT the) (ADJP (JJ double) (JJ transgenic)) (NNS mice)))) (VP (VBD showed) (NP (NP (JJ similar) (JJ circular) (NNS patterns)) (PP (IN of) (NP (NN swimming))) (PP-LOC (IN near) (NP (NP (DT the) (NN edge)) (PP (IN of) (NP (DT the) (NN tank)))))) (SBAR-TMP (WHADVP-1 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN tested) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NNP Morris) (NN water) (NN maze))) (ADVP-TMP-1 (-NONE- *T*)))))) (. .)) )
( (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (DT this) (NN phenotype)))) (VP (VBZ makes) (S (NP-SBJ (NP (JJ standard) (NNS tests)) (PP (IN of) (NP (NN learning) (CC and) (NN memory)))) (ADJP-PRD (JJ uninterpretable)))) (. .)) )
( (S (NP-SBJ (NN Hyperactivity)) (ADVP-MNR (RB nonspecifically)) (VP (VBZ inhibits) (NP (NP (NP (ADJP (NN choice) (HYPH -) (VBN driven)) (NNS changes)) (PP (IN in) (NP (NN movement)))) (, ,) (NP (NP (DT the) (JJ key) (NN element)) (PP (IN behind) (NP (DT all) (JJ cognitive) (JJ behavioral) (NNS paradigms)))))) (. .)) )
( (S (NP-SBJ-1 (PRP We)) (VP (VBP are) (ADVP-TMP (RB currently)) (VP (VBG working) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NN hyperactivity)) (VP (VBZ correlates) (PP (IN with) (NP (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NML (NN APPswe) (HYPH /) (NN ind)) (NN holoprotein)))) (CC or) (NP (PRP$ its) (JJ proteolytic) (NNS derivatives)))))))))))) (. .)) )
( (S (NP-SBJ (JJ Preliminary) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN hyperactivity)) (VP (VBZ does) (RB not) (VP (VB appear) (ADVP-TMP (RB quickly)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (ADJP (NN dox) (HYPH -) (VBN reared)) (NNS mice)) (VP (VBP are) (VP (VBN shifted) (NP-1 (-NONE- *)) (PP (IN to) (NP (JJ nonmedicated) (NNS diets))) (ADVP-TMP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (NP (NNP J.) (NNP L.) (NNP J.)) (, ,) (NP (JJ unpublished) (NNS data)) (-RRB- -RRB-))))))))))) (. .)) )
( (S (NP-SBJ (DT These) (NNS data)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ neuroactive) (NN culprit)) (VP (VP (VBZ is) (ADVP-TMP (RB not) (RB immediately)) (ADJP-PRD (JJ present)) (SBAR-TMP (IN after) (S (NP-SBJ-1 (JJ transgenic) (NN APP) (NN synthesis)) (VP (VBZ is) (VP (VBN initiated) (NP-1 (-NONE- *))))))) (, ,) (CC but) (VP (VBZ requires) (NP (NP (JJ additional) (NN time)) (SBAR (WHADVP-2 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB develop) (ADVP-TMP-2 (-NONE- *T*))))))))))))) (. .)) )
( (S (ADVP (RB Alternatively)) (, ,) (NP-SBJ-1 (NN hyperactivity)) (VP (MD may) (VP (VB be) (VP (VBN caused) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (JJ neuronal) (NNS alterations))) (PP-PRP (IN due) (IN to) (NP (NP (NN transgene) (NN expression)) (PP-TMP (IN during) (NP (ADJP (JJ early) (JJ postnatal)) (NN development)))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Further) (NNS experiments)) (VP (VBP are) (VP (VBN needed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB distinguish) (PP (IN between) (NP (DT these) (NNS possibilities)))))))) (. .)) )
( (S (PP (IN In) (NP (NN summary))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG abrogating) (NP (NN Aβ) (NN production)))) (VP (VBZ halts) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (JJ pathologic) (NNS changes))) (PP-LOC (IN in) (NP (NP (DT a) (JJ transgenic) (NN mouse) (NN model)) (PP (IN of) (NP (NML (NNP Alzheimer) (HYPH -) (NN type)) (NN amyloidosis)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP (IN despite) (NP (NP (JJ dramatic) (NNS reductions)) (PP (IN in) (NP (NN Aβ) (NN synthesis))))) (, ,) (NP-SBJ (JJ neuritic) (NNS plaques)) (VP (VBP are) (NP-PRD (NP (NP (JJ stable) (NNS structures)) (ADVP (FW in) (FW vivo))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP do) (RB not) (ADVP-TMP (RB quickly)) (VP (VB disaggregate))))))) (. .)) )
( (S (NP-SBJ (NP (PRP It)) (SBAR-3 (-NONE- *EXP*))) (VP (VBZ is) (ADJP-PRD (JJ possible)) (SBAR-3 (IN that) (S (NP-SBJ (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNS therapies)) (SBAR (WHADVP-2 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VP (VP (VB limit) (NP (NN Aβ) (NN production))) (, ,) (VP (VB increase) (NP (NN Aβ) (NN degradation))) (, ,) (CC and) (VP (VBP enhance) (NP (NP (NN phagocytosis)) (PP (IN of) (NP (VBN deposited) (NN amyloid)))))) (ADVP-PRP-2 (-NONE- *T*))))))))) (VP (MD may) (VP (VB be) (VP (VBN required) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB reverse) (NP (NP (NN damage)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NN AD)))))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (SBAR-ADV (IN if) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN started) (NP-1 (-NONE- *)) (ADVP-TMP (RB early) (RB enough)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN disease)))))))) (, ,) (NP-SBJ (NP (NN secretase) (NNS inhibitors)) (ADVP (RB alone))) (VP (MD could) (VP (VB provide) (NP (NP (JJ substantial) (NN benefit)) (PP (IN in) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG slowing) (NP (NP (JJ pathogenic) (NNS processes)) (VP (VBN linked) (NP (-NONE- *)) (PP (IN to) (NP (NN amyloid) (NN deposition))))))))))) (. .)) )
( (S (PP-TMP (ADVP (RB Even)) (IN at) (NP (NP (JJR later) (NNS stages)) (PP (IN in) (NP (DT the) (NN disease))))) (, ,) (NP-SBJ (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ substantial) (JJ microglial) (NN activation))) (PP-LOC (IN in) (NP (JJ human) (NN AD) (PRN (-LRB- [) (NP (CD 40)) (-RRB- ]))))) (VP (VBZ suggests) (SBAR (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (ADVP (RB simply)) (VP (VBG slowing) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ new) (NN amyloid) (NNS deposits)))))) (VP (MD may) (VP (VB allow) (S (NP-SBJ (JJ ongoing) (NN phagocytosis)) (VP (TO to) (VP (VB diminish) (NP (JJ preexisting) (NNS lesions)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (NP (DT the) (NN development)) (PP (IN of) (NP (ADJP (JJ safe) (CC and) (JJ effective)) (NN secretase) (NNS inhibitors)))) (VP (MD will) (ADVP-TMP (RB ultimately)) (VP (VB be) (VP (VBN required) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (DT the) (JJ human) (NN brain)) (VP (VBZ has) (NP (DT the) (NN capacity) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB repair) (NP (NP (ADJP (NN amyloid) (HYPH -) (VBN associated)) (NN damage)) (PP (IN of) (NP (NN AD)))) (SBAR-TMP (IN once) (S (NP-SBJ-2 (NP (DT the) (NN progression)) (PP (IN of) (NP (NN pathology)))) (VP (VBZ is) (VP (VBN arrested) (NP-2 (-NONE- *))))))))))))))))))) (. .)) )
( (HEADING (NP (VBG Supporting) (NN Information))) )
( (HEADING (NP (NN Figure) (NN S1))) )
( (CAPTION (NP (NP (JJ Transgenic) (NN APP) (NML (NN Expression) (CC and) (NN Suppression))) (PP (IN by) (NP (NN Dox))) (PP-LOC (IN in) (NP (DT the) (CD Four) (JJ New) (NML (NN Tet) (HYPH -) (NN Off)) (NN APP) (NNS Lines))))) )
( (CAPTION (S (NP-SBJ (NP (NNP Western) (NN blotting)) (PP (IN with) (NP (ADJP (JJ human) (HYPH -) (JJ specific)) (NN antibody) (NN 6E10)))) (VP (VBZ reveals) (NP (ADJP (NN transgene) (HYPH -) (VBN derived)) (NML (JJ full) (HYPH -) (NN length)) (NN APP)) (PP (IN in) (NP (NP (JJ cortical) (NNS homogenates)) (PP (IN from) (NP (JJ untreated) (NNS animals))))) (PRN (-LRB- -LRB-) (NP (NP (JJ left) (NNS lanes)) (PP (IN of) (NP (DT each) (NN panel)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (S (NP-SBJ (DT The) (JJ new) (NNS lines)) (VP (VBP produce) (NP (NP (ADJP (RB exceptionally) (JJ high)) (NNS levels)) (PP (IN of) (NP (NN transgene) (NN expression)))))) (: ;) (S (NP-SBJ-1 (NP (DT an) (JJ equal) (NN amount)) (PP (IN of) (NP (NP (NN brain) (NN homogenate)) (PP (IN from) (NP (DT a) (JJ standard) (JJ transgenic) (NN APP) (NN line)))))) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)) (PP (IN for) (NP (NN comparison))) (PRN (-LRB- -LRB-) (NP (JJ extreme) (JJ left) (NN lane)) (, ,) (NP (JJ Standard) (NN Tg) (NN line) (NN C3) (HYPH –) (CD 3)) (: ;) (-LRB- [) (NP (CD 15) (, ,) (CD 63)) (-RRB- ]) (-RRB- -RRB-))))) (. .))) )
( (CAPTION (S (PP-TMP (IN After) (NP (NP (CD 1) (NN mo)) (PP (IN of) (NP (NN dox) (NN treatment))))) (, ,) (NP-SBJ-1 (NP (JJ transgenic) (NN protein)) (PP (IN in) (NP (DT all) (CD four) (JJ new) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS lines)))) (VP (VBZ is) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP (IN to) (NP (JJ residual) (NNS levels))) (PRN (-LRB- -LRB-) (NP (SYM +) (NN dox)) (: ;) (NP (NP (JJ right) (NNS lanes)) (PP (IN of) (NP (DT each) (NN panel)))) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 474) (NN KB)) (NN TIF) (-RRB- -RRB-) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP-LOC (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S2))) )
( (CAPTION (S (NP-SBJ (JJ Transgenic) (NN APP) (NN mRNA)) (VP (VBZ Is) (ADJP-PRD (NN Brain) (HYPH -) (JJ Specific))))) )
( (CAPTION (S (NP-SBJ-1 (NP (DT A) (NN slot) (NN blot)) (PP (IN of) (NP (NP (NN mRNA)) (VP (VBN harvested) (NP (-NONE- *)) (PP (IN from) (NP (JJ various) (NNS tissues))) (PP-LOC (IN in) (NP (NP (CD three)) (PP (IN of) (NP (NP (DT the) (CD four) (JJ new) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS lines)) (CC and) (NP (DT a) (JJ nontransgenic) (NN control)))))))))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (JJ transgenic) (NN mRNA) (NN expression))))))) (. .))) )
( (CAPTION (S (S (NP-SBJ-1 (NN Hybridization)) (VP (VBZ is) (VP (VBN seen) (NP-1 (-NONE- *)) (PP-LOC (ADVP (RB only)) (IN in) (NP (DT the) (NN brain)))))) (: ;) (S (NP-SBJ-2 (NP (DT no) (NN signal)) (PP (IN above) (NP (NN background)))) (VP (VBZ is) (VP (VBN seen) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT any) (JJ other) (NN tissue)))))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 781) (NN KB)) (NN PSD) (-RRB- -RRB-) (. .))) )
( (CAPTION (S (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP-LOC (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S3))) )
( (CAPTION (S (NP-SBJ (NP (NN Amyloid) (NN Pathology)) (PP (IN in) (NP (DT the) (NN Cortex)))) (VP (VBZ Reiterates) (NP (NP (DT That)) (PP (IN in) (NP (DT the) (NN Hippocampus))))))) )
( (CAPTION (S (NP-SBJ-1 (NN Amyloid) (NN histology)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (PP (IN on) (NP (NP (NNS sections)) (PP (IN from) (NP (NN line) (CD 107) (ADJP (JJ double) (JJ transgenic)) (NNS mice))))) (PP (IN by) (NP-LGS (NP (NNP Hirano) (NN silver) (NN stain) (PRN (-LRB- -LRB-) (NP (JJ top) (NN row)) (-RRB- -RRB-))) (, ,) (NP (NN thioflavin) (HYPH -) (NN S) (PRN (-LRB- -LRB-) (NP (JJ middle) (NN row)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN Aβ) (NN immunohistochemistry) (PRN (-LRB- -LRB-) (NP (JJ bottom) (NN row)) (-RRB- -RRB-))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN persistence)) (PP (IN of) (NP (NN pathology))) (PP-TMP (VBG following) (NP (NN transgene) (NN suppression))))))))) (. .))) )
( (CAPTION (S (PP (IN As) (PP-LOC (IN in) (NP (DT the) (NN hippocampus) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NP (NN Figure) (CD 4)) (CC and) (NP (NN text))))) (-RRB- -RRB-))))) (, ,) (NP-SBJ (NP (DT the) (NN progression)) (PP (IN of) (NP (NN amyloid) (NN pathology))) (PP-LOC (IN in) (NP (DT the) (NN cortex)))) (VP (VBZ worsens) (ADVP (RB substantially)) (PP-TMP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age))))) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT This) (NN progression)) (VP (VBZ is) (ADVP (RB completely)) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NN suppression)) (PP (IN of) (NP (DT the) (NN transgene))) (PP (IN with) (NP (NN dox))))))) (. .))) )
( (CAPTION (S (PP (IN For) (NP (NN comparison))) (, ,) (NP-SBJ-1 (JJ normal) (NN neurohistology)) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT an) (ADJP (NN age) (HYPH -) (VBN matched)) (ADJP (JJ single) (JJ transgenic) (PRN (-LRB- -LRB-) (NP (NN tTA) (RB only)) (-RRB- -RRB-))) (NN animal))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT No) (NN amyloid) (NN pathology)) (VP (VBZ has) (VP (VBN been) (VP (VBN detected) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NML (CC either) (NN APP) (CC or) (NN tTA)) (ADJP (JJ single) (JJ transgenic)) (NNS animals)) (NP-TMP (NP (QP (IN up) (IN to) (CD 15)) (NN mo)) (PP (IN of) (NP (NN age))))))))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 4.8) (NN MB)) (NN PSD) (-RRB- -RRB-) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S4))) )
( (CAPTION (S (NP-SBJ (NN Diffuse) (NNS Deposits)) (VP (VBP Do) (RB Not) (VP (VB Disperse) (PP-TMP (IN During) (NP (NN Aβ) (NN Suppression))))))) )
( (CAPTION (S (NP-SBJ-1 (NML (NNP Campbell) (HYPH –) (NNP Switzer)) (NN silver) (NN stain)) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB differentiate) (NP (VBN cored) (PRN (-LRB- -LRB-) (ADJP (JJ brown)) (-RRB- -RRB-))) (PP (IN from) (NP (ADJP (JJ diffuse) (PRN (-LRB- -LRB-) (ADJP (JJ black)) (-RRB- -RRB-))) (NNS deposits))) (PP-LOC (IN in) (NP (NML (NN line) (CD 107)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))))))) (. .))) )
( (CAPTION (S (NP-SBJ (DT This) (NN stain)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP-SBJ (NP (DT both) (NNS types)) (PP (IN of) (NP (NN deposit)))) (VP (VBP persist) (PP-TMP (IN throughout) (NP (NP (JJ long) (NNS periods)) (PP (IN of) (NP (NN transgene) (NN suppression))))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (DT The) (JJ lower) (NNS panels)) (, ,) (VP (VBG showing) (NP (NP (NML (JJ low) (HYPH -) (NN power)) (NNS images) (PRN (-LRB- -LRB-) (NP (CD 10) (SYM ×)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ frontal) (NN cortex))) (PP (IN from) (NP (DT each) (NN condition)))))) (, ,) (VP (VBP reveal) (NP (NP (JJ little) (NN change)) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ diffuse) (NN amyloid)))))) (PP-TMP (VBG following) (NP (NP (QP (IN up) (IN to) (CD 6)) (NN mo)) (PP (IN of) (NP (NN Aβ) (NN suppression)))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NML (JJ High) (HYPH -) (NN power)) (NNS images) (PRN (-LRB- -LRB-) (NP (CD 40) (SYM ×)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ upper) (NNS panels)))) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ diffuse) (NN halo)) (VP (VBG surrounding) (NP (JJ individual) (VBN cored) (NNS deposits)))) (VP (VBZ remains) (ADJP-PRD (RB relatively) (JJ unchanged)) (PP-LOC (IN in) (NP (VBN treated) (NNS mice))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (JJ Untreated) (NN tTA) (ADJP (JJ single) (JJ transgenic)) (NNS animals)) (VP (VBP are) (VP (VBN shown) (NP-1 (-NONE- *)) (PP (IN as) (NP (DT a) (JJ negative) (NN control))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Protocol)) (PP (IN for) (NP (DT the) (NML (NNP Campbell) (HYPH -) (NNP Switzer)) (NP (NNP Alzheimer) (POS 's)) (NN Method)))) (VP (VP (VBD was) (ADVP (RB kindly)) (VP (VBN shared) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NNP Robert) (NNP Switzer) (, ,) (CD III) (PRN (-LRB- -LRB-) (NP (NP (NNP NeuroScience) (NNPS Associates)) (, ,) (NP-LOC (NNP Knoxville)) (, ,) (NP-LOC (NNP Tennessee)) (, ,) (NP-LOC (NNP United) (NNP States))) (-RRB- -RRB-)))))) (, ,) (CC and) (VP (MD can) (VP (VB be) (VP (VBN downloaded) (NP-1 (-NONE- *)) (PP-LOC (IN at) (NP (NN http://www.nsalabs.com/Documents/publications/campbell-switzer_protocol.htm) (PRN (-LRB- [) (NP (CD 64) (, ,) (CD 65)) (-RRB- ])))))))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 923) (NN KB)) (NN JPG) (-RRB- -RRB-) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP-PRP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S5))) )
( (CAPTION (NP (NP (JJ Chronic) (NN Transgene) (NML (NN Suppression) (CC and) (NN Arrest))) (PP (IN of) (NP (NP (NN Aβ) (NN Aggregate) (NN Formation)) (PP (IN in) (NP (NP (DT an) (JJ Independent) (NN Line)) (PP (IN of) (NP (NML (NN Tet) (HYPH -) (NN Off)) (NN APP) (NNS Mice) (PRN (-LRB- -LRB-) (NP (NML (NN CaMKIIα) (HYPH -) (NN tTA) (SYM ×) (NN tet) (HYPH -) (NN APPswe) (HYPH /) (NN ind)) (NN Line) (CD 18)) (-RRB- -RRB-)))))))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (NP (DT The) (NN experiment)) (VP (VBN presented) (NP (-NONE- *)) (PP (IN in) (NP (DT the) (NN text))) (PP (IN for) (NP (NML (NN line) (CD 107)) (NML (NN tet) (HYPH -) (NN off)) (NN APP))))) (VP (VBD was) (VP (VBN repeated) (NP-1 (-NONE- *)) (PP (IN with) (NP (DT a) (JJ second) (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NN line) (PRN (-LRB- -LRB-) (NP (NN line) (CD 18)) (-RRB- -RRB-)))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB control) (PP (IN for) (NP (NML (NN integration) (NN site)) (NNS artifacts)))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (JJ Cortical) (NNS homogenates)) (PP (IN from) (NP (UCP (NML (JJ untreated) (NN control)) (CC and) (ADJP (ADJP (NN dox) (HYPH -) (VBN treated)) (ADJP (JJ double) (JJ transgenic)))) (NNS mice)))) (VP (VBD were) (VP (VBN immunoblotted) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NML (JJ full) (HYPH -) (NN length)) (NN APP))) (PP (IN with) (NP (DT the) (ADJP (JJ human) (HYPH -) (JJ specific)) (NN antibody) (NN 6E10))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB confirm) (NP (NN transgene) (NN suppression)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN harvest)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Immunostaining)) (PP (IN for) (NP (JJ endogenous) (NN superoxide) (NN dismutase) (PRN (-LRB- -LRB-) (NP (NN SOD1)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN included) (NP-1 (-NONE- *)) (PP (IN as) (NP (DT a) (NN loading) (NN control))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ (NP (NN Quantitation)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP (IN from) (NP (DT the) (NNP Western) (NN blot))) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (VP (VBZ shows) (SBAR (-NONE- *0*) (S (NP-SBJ-1 (NP (JJ transgenic) (NN APP) (NNS levels)) (PP (IN in) (NP (NN line) (CD 18)))) (VP (VBP are) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-EXT (IN by) (NP (QP (JJR more) (IN than) (CD 98)) (NN %))) (PP-TMP (VBG following) (NP (NP (CD 3) (NN mo)) (PP (IN of) (NP (NN dox) (NN treatment))))) (PRN (-LRB- -LRB-) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA)))) (S-FRM (NP-SBJ (NN F2) (, ,) (CD 8)) (VP (SYM =) (NP (CD 1559.7)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (DT This) (NN level)) (PP (IN of) (NP (NN suppression)))) (VP (VBD was) (ADJP-PRD (ADJP (JJ equal) (PP (IN to) (NP-1 (-NONE- *RNR*)))) (CC or) (ADJP (JJR better) (PP (IN than) (NP-1 (-NONE- *RNR*)))) (NP-1 (NP (DT that)) (VP (VBN attained) (NP (-NONE- *)) (PP (IN in) (NP (NN line) (CD 107)))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (NN 3B)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ-1 (NML (NML (JJ Serial) (NN dilution)) (NN filter) (NN trap)) (NN assay)) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB quantify) (NP (VBN aggregated) (NN Aβ)) (PP-LOC (IN in) (NP (JJ cortical) (NNS homogenates)))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP (NN Quantitation)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP (IN in) (NP (NP (NP (DT the) (JJ linear) (NN range)) (PP (IN of) (NP (DT the) (NN dilution) (NN series)))) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (-LRB- -LRB-) (NP (NN C)))))) (-RRB- -RRB-) (. .))) )
( (CAPTION (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (NP (DT the) (NN amyloid) (NN histology)) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (NP (NN Figure) (NN S5)))))))) (, ,) (NP-SBJ (NN aggregate) (NN formation)) (VP (VBD was) (ADJP-PRD (RB significantly) (VBN increased)) (PP-TMP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age))))) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA) (NML (NN F2) (, ,) (CD 18))))) (VP (SYM =) (NP (CD 12.14)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NN Aggregate) (NN formation)) (VP (VP (VBD was) (ADVP (RB completely)) (VP (VBN arrested) (NP-1 (-NONE- *)) (PP (IN by) (NP (NN transgene) (NN suppression))))) (, ,) (CC and) (VP (VBZ is) (ADJP-PRD (JJ identical)) (PP-LOC (IN in) (NP (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)) (VP (VBN treated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PP-TMP (IN for) (NP (CD 3) (NN mo))) (PP (IN as) (PP-LOC (IN in) (NP (NP (JJ untreated) (NNS animals)) (VP (VBN harvested) (NP (-NONE- *)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ (NN treatment)) (VP (VBD began) (ADVP-TMP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.5)))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-)))))))))))))) (. .))) )
( (CAPTION (FRAG (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.005)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (NP (CD 0.001)) (CC versus) (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice)))))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 962) (NN KB)) (NN TIF) (-RRB- -RRB-) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S6))) )
( (CAPTION (NP (NP (NN Arrest)) (PP (IN of) (NP (NN Amyloid) (NN Progression))) (PP (IN by) (NP (JJ Chronic) (NN Transgene) (NN Suppression))) (PP-LOC (IN in) (NP (NML (NN Line) (CD 18)) (NML (NN Tet) (HYPH -) (NN Off)) (NN APP) (NNS Mice))))) )
( (CAPTION (S (NP-SBJ (NP (NN Amyloid) (NN histology)) (PP (IN in) (NP (NP (ADJP (ADJP (JJ cortical) (PRN (-LRB- -LRB-) (NP (ADJP (JJ first) (CC and) (JJ third)) (NNS rows)) (-RRB- -RRB-))) (CC and) (ADJP (JJ hippocampal) (PRN (-LRB- -LRB-) (NP (ADJP (JJ second) (CC and) (JJ fourth)) (NNS rows)) (-RRB- -RRB-)))) (NNS sections)) (PP (IN from) (NP (JJ untreated) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))))) (VP (VBZ shows) (NP (NP (DT a) (JJ dramatic) (NN progression)) (PP (IN of) (NP (NN pathology)))) (PP-TMP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age)))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (JJ transgenic) (NN APP) (NN expression)))) (VP (VBZ arrests) (NP (DT this) (NN progression)) (, ,) (SBAR-ADV (IN although) (FRAG (PP (IN without) (NP (NP (DT any) (NN sign)) (PP (IN of) (NP (NN plaque) (NN clearance))))))) (PRN (-LRB- -LRB-) (NP (NML (NML (CD 6) (NN mo)) (SYM +) (NML (CD 3) (NN mo))) (NN dox)) (-RRB- -RRB-))) (. .))) )
( (CAPTION (NP (NP (NNP Hirano) (NN silver) (NN stain) (PRN (-LRB- -LRB-) (NP (JJ top) (NNS panels)) (-RRB- -RRB-))) (: ;) (NP (NN thioflavin) (HYPH -) (NN S) (PRN (-LRB- -LRB-) (NP (JJ bottom) (NNS panels)) (-RRB- -RRB-))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 5.8) (NN MB)) (NN PSD) (-RRB- -RRB-) (. .))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP-LOC (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Patient) (NN Summary))) )
( (HEADING (NP (NN Background))) )
( (S (NP-SBJ (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Alzheimer) (NN disease)) (-LRB- -LRB-) (NP (NN AD))))) (-RRB- -RRB-) (VP (VBP have) (VP (VBN elevated) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NP (DT a) (JJ small) (NN protein)) (VP (VBN called) (NP-3 (-NONE- *)) (S-CLR (NP-SBJ-3 (-NONE- *PRO*)) (NP-PRD (NML (NN amyloid) (HYPH -) (NN β)) (NN peptide))))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ sticks) (ADVP (RB together)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB form) (SBAR-NOM (WHNP-2 (WP what)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP are) (VP (VBN known) (NP-2 (-NONE- *)) (PP (IN as) (NP (NN amyloid) (NNS plaques))) (PP-LOC (IN in) (NP (PRP$ their) (NNS brains)))))))))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN peptide)) (VP (VP (VBZ is) (ADVP (RB normally)) (VP (VBN made) (NP-1 (-NONE- *)) (PP (IN at) (NP (JJ low) (NNS levels))) (PP-LOC (IN in) (NP (JJ healthy) (NNS individuals))))) (, ,) (CC and) (VP (VBZ is) (VP (VBN made) (NP-1 (-NONE- *)) (SBAR-TMP (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (NP (DT a) (JJR larger) (NN protein)) (VP (VBN called) (NP-4 (-NONE- *)) (S-CLR (NP-SBJ-4 (-NONE- *PRO*)) (NP-PRD (NP (NN amyloid) (NN precursor) (NN protein)) (-LRB- -LRB-) (NP (NN APP)))))) (-RRB- -RRB-) (VP (VBZ is) (VP (VBN cut) (PRT (RP down)) (NP-2 (-NONE- *)) (PP (IN in) (NP (NN size))) (ADVP-TMP-3 (-NONE- *T*))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ New) (NNS treatments)) (SBAR-2 (-NONE- *T*))) (VP (VBP are) (ADVP-TMP (RB now)) (VP (VBG being) (VP (VBN developed) (NP-1 (-NONE- *)) (SBAR-2 (WHNP-3 (WDT that)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (MD will) (VP (VB decrease) (NP (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN Aβ)))) (VP (VBN produced) (NP (-NONE- *)) (PP (IN from) (NP (NN APP)))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ clear)) (SBAR-1 (IN whether) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG lowering) (NP (DT the) (NN production)) (PP (IN of) (NP (NN Aβ))))) (VP (MD will) (VP (VB allow) (S (NP-SBJ (DT the) (NN brain)) (VP (TO to) (VP (VB heal) (NP (PRP itself)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG clearing) (NP (DT the) (NN amyloid) (NNS plaques))))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN answer)) (PP (IN to) (NP (DT this) (NN question)))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important) (PP (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG deciding) (SBAR-TMP (WHADVP-4 (WRB when)) (S (NP-SBJ-3 (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN started) (NP-3 (-NONE- *)) (ADVP-TMP-4 (-NONE- *T*)))))))) (, ,) (CC and) (VP (MD may) (ADVP (RB also)) (VP (VB determine) (SBAR (WHADJP-2 (WRB how) (JJ effective)) (S (NP-SBJ (PRP they)) (VP (VBP are) (ADJP-PRD-2 (-NONE- *T*)) (PP (IN in) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG reversing) (NP (NP (DT the) (JJ mental) (NNS symptoms)) (PP (IN of) (NP (NN AD)))))))))))))))))) (. .)) )
( (HEADING (SBARQ (WHNP-1 (WP What)) (SQ (VBD Did) (NP-SBJ (DT the) (NNS Researchers)) (VP (VB Do) (CC and) (VB Find) (NP-1 (-NONE- *T*)))) (. ?))) )
( (S (SBAR-PRP (IN Because) (S (NP-SBJ (NP (JJ new) (NNS drugs)) (VP (VBN designed) (NP (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB lower) (NP (NN Aβ) (NNS levels))))))) (VP (VBP are) (ADVP (RB still)) (PP-LOC-PRD (IN in) (NP (NN development)))))) (, ,) (NP-SBJ (PRP they)) (VP (VBP are) (RB not) (ADJP-PRD (JJ available) (PP (IN for) (NP (NN testing)))) (PP-LOC (IN in) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (DT the) (NN disease)))))) (. .)) )
( (S (ADVP (RB Instead)) (, ,) (NP-SBJ-1 (NP (JJ basic) (NNS questions)) (PP (IN about) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (DT this) (NN type)) (PP (IN of) (NP (NN treatment)))))))) (VP (MD must) (VP (VB be) (VP (VBN answered) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NNS systems)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBP mimic) (SBAR-NOM (WHADVP-3 (WRB how)) (S (NP-SBJ (DT the) (NNS drugs)) (VP (VBP work) (ADVP-3 (-NONE- *T*)))))))))))))) (. .)) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB do) (NP (DT this))))) (, ,) (NP-SBJ (DT the) (NNS authors)) (VP (VBD created) (NP (NP (NNS mice)) (SBAR (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP produce) (NP (ADJP (RB too) (JJ much)) (NN APP))))) (CC and) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBP develop) (NP (NP (DT the) (JJ same) (NN amyloid) (NNS lesions)) (SBAR (IN as) (SINV (VP (VBP do) (VP (-NONE- *?*))) (NP-SBJ (NP (JJ human) (NNS patients)) (PP (IN with) (NP (NN AD))))))))))))) (. .)) )
( (S (PP (IN Unlike) (NP (JJ normal) (NNS mice))) (, ,) (NP-SBJ (DT these) (NNS mice)) (ADVP (RB also)) (VP (VBD carried) (NP (NP (DT a) (`` “) (NN switch) ('' ”) (NN gene)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD allowed) (S (NP-SBJ (DT the) (NNS researchers)) (VP (TO to) (VP (VB turn) (PRT (RP off)) (NP (NN APP)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG feeding) (NP (DT the) (NNS mice)) (NP (JJ special) (NN food))))))))))))) (. .)) )
( (S (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG Turning) (PRT (RP off)) (NP (NN APP)) (PP-LOC (IN in) (NP (DT these) (NNS mice))))) (VP (VBD had) (NP (NP (DT the) (JJ same) (NN effect)) (PP (IN as) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG treating) (NP (PRP them)) (PP-MNR (IN with) (NP (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NNS drugs))))))))) (, ,) (CONJP (CC and) (IN so)) (S (NP-SBJ-3 (DT the) (NNS researchers)) (VP (VBD were) (ADJP-PRD (JJ able) (S (NP-SBJ-3 (-NONE- *PRO*)) (VP (TO to) (VP (VB ask) (SBAR (WHNP-2 (WP what)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD happened) (PP (IN to) (NP (DT the) (NN amyloid) (NNS plaques))) (SBAR-TMP (IN after) (S (NP-SBJ-1 (NN Aβ) (NN production)) (VP (VBD was) (VP (VBN shut) (NP-1 (-NONE- *)) (PRT (RP down))))))))))))))) (. .)) )
( (S (NP-SBJ (PRP They)) (VP (VBD showed) (SBAR (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG lowering) (NP (NN Aβ) (NN production)))) (VP (VBZ prevents) (NP (DT the) (NN amyloid) (NNS lesions)) (PP (IN from) (S-NOM (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBG getting) (S (NP-SBJ-1 (-NONE- *)) (ADJP-PRD (JJR worse))) (SBAR-TMP (IN as) (S (NP-SBJ (DT the) (NN disease)) (VP (VBZ progresses))))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ means) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN treatment)) (PP (IN with) (NP (ADJP (NN Aβ) (HYPH -) (VBG lowering)) (NNS drugs)))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ able) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB stop) (NP (DT the) (NN disease)) (PP (IN from) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG filling) (NP (DT the) (NN brain)) (PP-MNR (IN with) (NP (NNS plaques))))))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (NNS researchers)) (ADVP (RB also)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN amyloid) (NNS lesions)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD had) (VP (VBN formed) (SBAR-TMP (IN before) (S (NP-SBJ-1 (NN treatment)) (VP (VBD was) (VP (VBN started) (NP-1 (-NONE- *))))))))))) (VP (VBD remained) (ADJP-PRD (JJ intact)) (PP-TMP (IN throughout) (NP (DT the) (NN experiment))))))) (. .)) )
( (HEADING (SBARQ (WHNP-1 (WP What)) (SQ (VBP Do) (NP-SBJ (DT These) (NNS Findings)) (VP (VB Mean) (NP-1 (-NONE- *T*)))) (. ?))) )
( (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NNS treatments)) (VP (VBN designed) (NP (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB lower) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN Aβ))))))))) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (NN part)) (PP (IN of) (NP (JJ future) (NN AD) (NN treatment)))) (, ,) (SBAR-ADV (IN as) (S (NP-SBJ-1 (DT this) (NN approach)) (VP (VBZ seems) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB prevents) (NP (JJ additional) (NN amyloid) (NNS plaques)) (PP (IN from) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG forming) (PP-LOC (IN in) (NP (DT the) (NN mouse) (NN brain))))))))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP (IN by) (NP (PRP itself))) (, ,) (NP-SBJ-3 (DT this) (NN strategy)) (VP (MD may) (RB not) (VP (VB be) (ADJP-PRD (JJ able) (S (NP-SBJ-3 (-NONE- *PRO*)) (VP (TO to) (VP (VB rid) (NP (DT the) (NN brain)) (PP (IN of) (NP (NP (NNS plaques)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP have) (ADVP (RB already)) (VP (VBN formed) (PP-LOC (IN in) (NP (DT the) (NN brain))) (SBAR-TMP (IN before) (S (NP-SBJ-2 (NN treatment)) (VP (VBZ is) (VP (VBN started) (NP-2 (-NONE- *)))))))))))))))))) (. .)) )
( (S (NP-SBJ (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (JJ early) (NN treatment)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important)) (SBAR-PRP (IN for) (S (NP-SBJ (DT this) (NN approach)) (VP (TO to) (VP (VB succeed)))))))))) (. .)) )
( (SBARQ (WHADVP-1 (WRB Where)) (SQ (MD Can) (NP-SBJ (PRP I)) (VP (VB Get) (NP (JJR More) (NN Information)) (ADVP (RB Online)) (ADVP-LOC-1 (-NONE- *T*)))) (. ?)) )
( (S (NP-SBJ (NNP MedlinePlus)) (VP (VBZ has) (NP (NP (NP (JJ several) (NN Web) (NNS pages)) (PP (IN of) (NP (NP (NN information)) (PP (IN on) (NP (NNP Alzheimer) (NN disease)))))) (: :) (NP (NN http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html))))) )
( (S (NP-SBJ (NP (DT The) (NNP ADEAR) (NNP Center)) (PP (IN of) (NP (NP (NP (DT the) (NNP US) (NNP Government) (POS 's)) (NNP National) (NNP Institute)) (PP (IN on) (NP (NNP Aging)))))) (ADVP (RB also)) (VP (VBZ has) (NP (NP (NP (NN information)) (PP (IN on) (NP (NNP Alzheimer) (NN disease)))) (: :) (NP (NN http://www.alzheimers.org/))))) )
( (S (NP-SBJ (NP (NML (NP (DT The) (NNP Alzheimer) (POS 's)) (NNP Association)) (NN Web) (NN site)) (NP-1 (-NONE- *ICH*))) (VP (VBZ contains) (NP (NP (NN information)) (PP (IN on) (NP (CC both) (NN caregiving) (CC and) (NN research)))) (: :) (NP-1 (NN http://www.alz.org)))) )
( (HEADING (NP (NNS Acknowledgements))) )
( (S (NP-SBJ (PRP We)) (VP (VP (VBP thank) (NP=1 (NNP Patrick) (NNP Tremblay)) (PP-PRP=2 (IN for) (NP (NP (JJ helpful) (NN advice)) (PP (IN on) (NP (DT the) (NN tet) (NN system))) (PP-TMP (IN at) (NP (NP (DT a) (JJ critical) (NN time)) (PP (IN in) (NP (DT the) (NN project)))))))) (, ,) (CC and) (VP (NP=1 (NNP Mark) (NNP Mayford)) (PP-PRP=2 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG sharing) (NP (DT the) (NN CaMKIIα) (HYPH -) (NN tTA) (NNS mice)) (PP (IN through) (NP (NNP Jackson) (NNP Laboratory)))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VP (VBP thank) (NP=2 (NNP Fraser) (NNP Moss)) (PP=1 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG saving) (NP (JJ several) (NNS immunoblots)) (PP (IN with) (NP (NML (JJ last) (HYPH -) (NN minute)) (NNS shipments))))))) (, ,) (VP (NP=2 (NNP Andy) (NNP Groves)) (PP=1 (IN for) (NP (JJ many) (JJ thoughtful) (NNS discussions)))) (, ,) (VP (NP=2 (NNP Neil) (NNP Segil)) (PP=1 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (ADVP-MNR (RB generously)) (VP (VBG sharing) (NP (PRP$ his) (NML (NN laboratory) (CC and) (NN equipment))))))) (, ,) (VP (NP=2 (NP (NNP Beth) (NNP Olson)) (, ,) (NP (NNP Natasha) (NNP Bouey)) (, ,) (CC and) (NP (NNP Yolanda) (NNP Jackson))) (PP=1 (IN for) (NP (JJ outstanding) (NN animal) (NN care)))) (, ,) (VP (NP=2 (NNP Debbie) (NNP Swing)) (PP=1 (IN for) (NP (JJ expert) (NN microinjection)))) (, ,) (CC and) (VP (NP=2 (NNP Dave) (NNP Fromholt)) (PP=1 (IN for) (NP (NN genotyping) (CC and) (NN dissection))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB gratefully)) (VP (VP (VBP acknowledge) (NP=1 (NNP Takeda) (NNP Chemical) (NNPS Industries)) (PP=2 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG providing) (NP (NNS antibodies) (NML (NN BAN50) (, ,) (NN BA27) (, ,) (CC and) (NN BC05))))))) (, ,) (VP (NP=1 (NP (NNP Konrad) (NNP Beyreuther)) (CC and) (NP (NNP Andreas) (NNP Weidemann))) (PP=2 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG providing) (NP (NN 22C11) (NN antibody)))))) (, ,) (CC and) (VP (NP=1 (NNP Ed) (NNP Koo)) (PP=2 (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG sharing) (NP (NN CT15) (NN antibody))))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN work)) (VP (VBD was) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NP (NNS grants)) (PP (IN from) (NP (DT the) (NML (NNP Johns) (NNP Hopkins)) (NML (NP (NNP Alzheimer) (POS 's)) (NNP Disease)) (NNP Research) (NNP Center) (PRN (-LRB- -LRB-) (NP (NNP JLJ)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (NNP National) (NNP Alliance)) (PP (IN for) (NP (NP (NNP Research)) (PP (IN on) (NP (NNP Schizophrenia) (CC and) (NNP Depression))))) (PRN (-LRB- -LRB-) (NP (NNP Young) (NNP Investigator) (NNP Award)) (-LRB- [) (NP (NNP JLJ)) (-RRB- ]) (-RRB- -RRB-))) (, ,) (NP (DT the) (NNP Rose) (NNP Hills) (NNP Foundation) (PRN (-LRB- -LRB-) (NP (NNP JLJ)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNP Alzheimer) (POS 's)) (NNP Association) (PRN (-LRB- -LRB-) (NP (NNP Zenith) (NNP Award)) (-LRB- [) (NP (NN DRB)) (-RRB- ]) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNP National) (NNP Institute)) (PP (IN of) (NP (NNP Aging) (PRN (-LRB- -LRB-) (FRAG (NP (NN K01) (NN AG26144) (HYPH –) (CD 01)) (-LRB- [) (NP (NNP JLJ)) (-RRB- ])) (, ,) (FRAG (NP (NN P50) (NN AGO5146) (HYPH –) (CD 20)) (-LRB- [) (NP (NN DRB)) (-RRB- ])) (, ,) (FRAG (NP (NN R01) (NN AG006656) (HYPH –) (CD 16)) (-LRB- [) (NP (NN SGY)) (-RRB- ])) (, ,) (CC and) (FRAG (NP (NN P01) (NN AG015453)) (-LRB- [) (NP (NNP SGY)) (-RRB- ])) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (NNP National) (NNP Institute)) (PP (IN of) (NP (JJ Neurologic) (NN Disease) (CC and) (NN Stoke) (PRN (-LRB- -LRB-) (NP (NN R01) (NN NS) (CD 047225)) (-LRB- [) (NP (NNP DRB)) (-RRB- ]) (-RRB- -RRB-))))) (, ,) (CC and) (NP (DT the) (NNP National) (NNP Cancer) (NNP Institute) (PRN (-LRB- -LRB-) (NP (NNP NAJ) (CC and) (NNP NGC)) (-RRB- -RRB-))))))) (. .)) )
( (S (S (NP-SBJ (DT The) (NN funding) (NNS agencies)) (ADVP (RB generously)) (VP (VBN provided) (PP (IN for) (NP (NP (NN research) (NNS supplies)) (, ,) (NP (NN animal) (NN care)) (, ,) (CC and) (NP (NN salary) (NN support)))))) (: ;) (S (NP-SBJ (NP (DT the) (NNS funders)) (PP (IN of) (NP (DT this) (NN work)))) (VP (VBD had) (NP (NP (DT no) (NN role)) (PP (IN in) (NP (NP (NN study) (NN design)) (, ,) (NP (NP (NNS data) (NN collection)) (CC and) (NP (NN analysis))) (, ,) (NP (NN decision) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB publish))))) (, ,) (CC or) (NP (NP (NN preparation)) (PP (IN of) (NP (DT the) (NN manuscript))))))))) (. .)) )
( (HEADING (NP (NNS Abbreviations))) )
( (NP (NP (NN Aβ)) (: -) (NP (NN amyloid) (HYPH -) (NN β))) )
( (NP (NP (NN AD)) (: -) (NP (NNP Alzheimer) (NN disease))) )
( (NP (NP (NN APLP)) (: -) (NP (NN amyloid) (JJ precursor–like) (NN protein))) )
( (NP (NP (NN APP)) (: -) (NP (NN amyloid) (NN precursor) (NN protein))) )
( (NP (NP (NN CaMKIIα)) (: -) (NP (NML (NN calcium) (HYPH -) (NN calmodulin)) (NN kinase) (NN IIα))) )
( (NP (NP (NN dox)) (: -) (NP (NN doxycycline))) )
( (NP (NP (NN FA)) (: -) (NP (JJ formic) (NN acid))) )
( (NP (NP (NN GFAP)) (: -) (NP (JJ glial) (JJ fibrillary) (JJ acidic) (NN protein))) )
( (NP (NP (NN mo) (HYPH /) (NN huAPP695)) (: -) (NP (NP (NN mouse) (NN APP)) (PP (IN with) (NP (DT a) (VBN humanized) (NN Aβ) (NN domain))))) )
( (NP (NP (NN PBS)) (: -) (NP (ADJP (NN phosphate) (HYPH -) (VBN buffered)) (NN saline))) )
( (NP (NP (NN SDS)) (: -) (NP (NN sodium) (NN dodecyl) (NN sulfate))) )
( (NP (NP (NN swe) (HYPH /) (NN ind)) (: -) (NP (JJ Swedish) (HYPH /) (NNP Indiana))) )
( (NP (NP (NN tTA)) (: -) (NP (NN tetracycline) (NN transactivator))) )
( (HEADING (NP (NNS Figures) (CC and) (NNS Tables))) )
( (HEADING (NP (NN Figure) (CD 1))) )
( (CAPTION (NP (NP (NN Control)) (PP (IN of) (NP (JJ Transgenic) (NN APP) (NN Expression))) (PP (IN by) (NP (NN Dox))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ (NP (NP (NNP Western) (NN blotting)) (PP (IN for) (NP (JJ transgenic) (NN APP)))) (VP (VBG using) (NP (DT the) (ADJP (JJ human) (HYPH -) (JJ specific)) (NN 6E10) (NN antibody)))) (VP (VBZ shows) (NP (NP (NN expression)) (PP (IN of) (NP (NP (JJ full) (HYPH -) (NN length)) (NN protein))) (PP-LOC (IN in) (NP (NP (NN forebrain) (NN tissue)) (PP (IN from) (NP (NP (JJ young) (JJ predeposit) (ADJP (JJ double) (JJ transgenic)) (NNS animals) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ its) (NN suppression)) (PP-TMP (VBG following) (NP (NN dox) (NN treatment)))))))))) (. .))) )
( (CAPTION (S (S (NP-SBJ (JJ Untreated) (NNS animals)) (VP (VBP show) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN transgene) (NN expression)))))) (: ;) (S (NP-SBJ (NN protein) (NNS levels)) (VP (VBP drop) (ADVP (RB dramatically)) (PP-LOC (IN in) (NP (NP (NNS animals)) (VP (ADVP (RB acutely)) (VBN treated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PP-TMP (IN for) (NP (CD 2) (NN wk)))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (DT A) (ADJP (NN faint) (, ,) (CC but) (JJ detectable)) (NN band)) (PP (IN of) (NP (NML (JJ full) (HYPH -) (NN length)) (NN protein)))) (VP (VBZ remains) (PP-LOC-PRD (IN in) (NP (NP (RB acutely) (VBN treated) (NNS animals)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (MD can) (VP (VB be) (VP (VBN eliminated) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS mice)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox)))))))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ (NP (NP (NN Immunoblotting)) (PP (IN with) (NP (NP (DT the) (ADJP (NN N) (HYPH -) (JJ terminal)) (NN antibody)) (NP (NN 22C11))))) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (TO to) (VP (VB detect) (NP (CC both) (ADJP (JJ transgenic) (CC and) (JJ endogenous)) (NN protein))))))) (VP (VBZ shows) (SBAR (IN that) (S (NP-SBJ (NN dox) (NN treatment)) (VP (VBZ reduces) (NP (NN APP) (HYPH /) (NN APLP)) (PP (IN to) (NP (NP (NNS levels)) (VP (VBN found) (NP (-NONE- *)) (PP-LOC (IN in) (NP (JJ nontransgenic) (NNS mice)))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ (NP (NN Measurement)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP (IN from) (NP (DT the) (NNP Western) (NN blot))) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))) (-RRB- -RRB-) (VP (VBZ shows) (SBAR (-NONE- *0*) (S (NP-SBJ-1 (JJ transgenic) (NN APP) (NNS levels)) (VP (VBP are) (VP (VBN decreased) (NP-1 (-NONE- *)) (NP-EXT (QP (JJR more) (IN than) (CD 95)) (NN %)) (PP-MNR (IN by) (NP (NN dox))) (PP-LOC (IN in) (NP (ADJP (ADVP (CC both) (RB acutely) (CC and) (RB chronically)) (VBN treated)) (NNS animals))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 97.2) (NN %)) (PP (IN for) (NP (NML (NML (CD 4) (NN wk)) (SYM +) (NML (CD 2) (NN wk))) (NN dox)))) (, ,) (NP (NP (CD 98.0) (NN %)) (PP (IN for) (NP (S-TTL (NP-SBJ (-NONE- *PRO*)) (VP (VBN reared) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))) (CC versus) (ADJP-TTL (NP (CD 4) (NN wk)) (JJ untreated)))))) (: ;) (S-FRM (NP-SBJ (NP (NN ANOVA) (NN effect)) (PP (IN of) (NP (NN treatment) (NN group) (NN F4) (, ,) (CD 15)))) (VP (SYM =) (NP (CD 85.55)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN APP) (NNS levels)) (PP-LOC (IN in) (NP (NP (NML (NML (CD 4) (NN wk)) (SYM +) (NML (CD 2) (NN wk))) (NN dox)) (, ,) (S-TTL (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN reared) (NP-1 (-NONE- *)) (PP (IN on) (NP (NN dox))))) (, ,) (CC and) (NP (NP (JJ nontransgenic)) (-LRB- -LRB-) (NP (NN NTg))))) (-RRB- -RRB-)) (VP (VBD were) (RB not) (ADJP-PRD (RB significantly) (JJ different) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.9)))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP-SBJ (NP (NN Measurement)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP (IN from) (NP (NP (DT the) (NNP Western) (NN blot)) (PP (IN in) (-LRB- -LRB-) (NP (NN B)))))) (-RRB- -RRB-) (VP (VBZ shows) (SBAR (-NONE- *0*) (S (NP-SBJ (NP (JJ total) (NML (NN APP) (HYPH /) (NN APLP)) (NNS levels)) (PP (IN in) (NP (ADJP (NN dox) (HYPH -) (VBN treated)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))) (VP (VBP are) (ADJP-PRD (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (PP-LOC (IN in) (NP (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NP (NN ANOVA) (NN effect)) (PP (IN of) (NP (NN treatment) (NN group) (NN F4) (, ,) (CD 15)))) (VP (SYM =) (NP (CD 84.41)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (-RRB- -RRB-)))))) (CC and) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (JJ nontransgenic) (NNS animals) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.9)))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-)))))))))))) (. .))) )
( (CAPTION (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (IN versus) (NP (JJ untreated) (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS mice))) (, ,) (NP-ADV (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA)))))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 2))) )
( (CAPTION (S (NP-SBJ-1 (NN Aβ) (NNS Levels)) (VP (VBP Are) (ADVP (RB Dramatically)) (VP (VBN Reduced) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NN Transgene) (NN Suppression))))))) )
( (CAPTION (S (NP-SBJ-1 (NP (JJ Cortical) (NNS homogenates)) (PP (IN from) (NP (NP (JJ young) (, ,) (JJ predeposit) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)) (VP (VBN used) (NP (-NONE- *)) (PP (IN for) (NP (NNP Western) (NN blot))) (PP (IN in) (NP (NN Figure) (CD 1))) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN fractionated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NP (JJ sequential) (JJ multi-step) (NN extraction)) (PP (IN with) (NP (NP (NN PBS)) (, ,) (NP (NML (CD 2) (NN %)) (NN SDS)) (, ,) (CC and) (NP (NML (CD 70) (NN %)) (NN FA))))) (VP (VBN followed) (NP (-NONE- *)) (PP (IN by) (NP-LGS (ADJP (JJ human) (HYPH -) (JJ specific)) (NN Aβ) (NN ELISA))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB measure) (NP (ADJP (NN transgene) (HYPH -) (VBN derived)) (NN peptide)) (PP (IN in) (NP (DT each) (NN fraction))))))))))) (. .))) )
( (CAPTION (S (S (NP-SBJ-1=3 (NN Aβ40)) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)) (PP=2 (IN in) (NP (JJ white)))))) (, ,) (S (NP-SBJ=3 (NN Aβ42)) (PP=2 (IN in) (NP (JJ black)))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN Aβ) (NNS levels)) (VP (VBP are) (ADVP (RB substantially)) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (CC both) (ADJP (JJ acute) (CC and) (JJ chronic)) (NN dox) (NN treatment))) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (, ,) (S (S (S-FRM (NP-SBJ (NP (NN effect)) (PP (IN of) (NP (NML (NN treatment) (NN group)) (NN F4) (, ,) (CD 24)))) (VP (SYM =) (NP (CD 137.10) (CC and) (CD 386.01)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (IN for) (NP (NN Aβ40) (CC and) (NN Aβ42))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN Aβ) (NNS levels)) (PP (IN in) (NP (VBN treated) (NNS animals)))) (VP (VBP are) (ADJP-PRD (JJ indistinguishable) (PP (IN from) (NP (ADJP (JJ nontransgenic) (PRN (-LRB- -LRB-) (NP (NN NTg)) (-RRB- -RRB-))) (NNS animals)))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.3)))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (PP-LOC (IN In) (NP (NP (DT the) (JJ young) (NNS animals)) (VP (VBN tested) (NP (-NONE- *)) (ADVP (RB here)) (PP-TMP (JJ prior) (PP (IN to) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ visible) (NN amyloid) (NNS deposits))))))))) (, ,) (NP-SBJ-1 (JJS most) (NN Aβ)) (VP (VBZ is) (VP (VBN extracted) (NP-1 (-NONE- *)) (PP (IN into) (NP (DT the) (NN SDS) (NN fraction))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 84) (NN %)) (CC and) (NP (CD 76) (NN %))) (PP (IN of) (NP (DT all) (ADJP (JJ transgene) (HYPH -) (VBN derived)) (NN Aβ40) (CC and) (NN Aβ42)))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (PP (IN As) (PP (IN in) (NP (DT the) (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN fraction)))) (, ,) (NP-SBJ-1 (NP (NN Aβ) (NNS levels)) (PP (IN in) (NP (DT the) (NN SDS) (NN fraction)))) (VP (VBP are) (ADVP (RB significantly)) (VP (VBN lowered) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NN dox) (NN treatment))) (PP (VBN compared) (PP (IN to) (NP (JJ untreated) (NNS animals) (PRN (-LRB- -LRB-) (S (S (S-FRM (NP-SBJ (NP (NN ANOVA) (NN effect)) (PP (IN of) (NP (NN group) (NN F4) (, ,) (CD 24)))) (VP (SYM =) (NP (CD 197.57) (CC and) (CD 163.48)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (, ,) (PP (IN for) (NP (NN Aβ40) (CC and) (NN Aβ42))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (S (NP-SBJ (ADJP (RB Acutely) (VBN treated)) (NNS animals)) (VP (VBD retained) (NP (NP (DT a) (ADJP (JJ small) (PRN (-LRB- -LRB-) (SBAR (IN although) (FRAG (ADJP (JJ significant)))) (-RRB- -RRB-))) (NN amount)) (PP (IN of) (NP (JJ residual) (NN peptide)))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (VBN compared) (PP (IN to) (ADJP (JJ nontransgeinc)))))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-)) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ-1 (NP (NN Aβ) (NNS levels)) (PP-LOC (IN in) (NP (NP (NNS mice)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))))) (VP (VBD were) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NNS levels)) (ADJP (JJ indistinguishable) (PP (IN from) (ADJP (JJ nontransgenic)))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.8)))) (, ,) (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ (DT The) (ADJP (NN FA) (HYPH -) (JJ soluble)) (NN fraction)) (ADVP (RB already)) (VP (VBZ contains) (NP (NP (DT a) (ADJP (JJ small) (CC but) (JJ significant)) (NN pool)) (PP (IN of) (NP (VBN aggregated) (NN Aβ42)))) (PP-LOC (IN in) (NP (JJ untreated) (NNS animals))) (PP-TMP (IN by) (NP (NP (CD 4) (NN wk)) (PP (IN of) (NP (NN age))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)) (PP (IN versus) (NP (JJ nontransgenic))))) (: ;) (S (S-FRM (NP-SBJ (NP (NNP Tukey) (NML (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA) (NN F4) (, ,) (CD 24))))))) (VP (SYM =) (NP (CD 17.11)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (PP-TMP (IN By) (NP (NP (CD 6) (NN wk)) (PP (IN of) (NP (NN age))))) (, ,) (NP-SBJ-1 (NP (DT the) (NN amount)) (PP (IN of) (NP (NN Aβ))) (PP-LOC (IN in) (NP (DT the) (NN FA) (NN fraction)))) (VP (VBZ is) (VP (VBN increased) (NP-1 (-NONE- *)) (ADVP (RB significantly)) (S-TMP (NP-SBJ (-NONE- *PRO*)) (VP (VBG preceding) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ visible) (NNS deposits)))) (ADVP-TMP (NP (CD 2) (NN wk)) (RB later)))))) (. .))) )
( (CAPTION (S (NP-SBJ (DT The) (NN FA) (NN pool)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ only) (NN peptide) (NN fraction)) (VP (RB not) (VBN lowered) (NP (-NONE- *)) (PP (IN by) (NP-LGS (JJ acute) (NN dox) (NN treatment) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NML (CD 4) (NN wk)) (JJ untreated)) (VP (SYM =) (NP (NML (NML (CD 4) (NN wk)) (SYM +) (NML (CD 2) (NN wk))) (NN dox)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.9)) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)))) (-RRB- -RRB-)))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (JJ poor) (NN turnover)) (PP (IN of) (NP (VBN aggregated) (NN Aβ) (NNS species)))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP-SBJ (NP (NNS Measurements)) (PP (IN of) (NP (JJ total) (NN Aβ))) (, ,) (PP (VBG including) (NP (ADJP (CC both) (ADJP (JJ endogenous)) (CC and) (ADJP (NN transgene) (HYPH -) (VBN derived))) (NNS peptides)))) (, ,) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NNS animals)) (VP (VBN born) (CC and) (VBN raised) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))))) (VP (VBP harbor) (NP (NP (NN Aβ) (NNS levels)) (ADJP (JJ identical) (PP (IN to) (NP (JJ nontransgenic) (NNS animals))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.9)) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (, ,))) (S-FRM (NP-SBJ (NP (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA) (NN F4) (, ,) (CD 24)))) (VP (SYM =) (NP (CD 39.13) (CC and) (CD 35.29)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (, ,) (PP (IN for) (NP (NN Aβ40) (CC and) (NN Aβ42))) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-)))))) (. .))) )
( (CAPTION (S (SBAR-ADV (IN Whereas) (S (NP-SBJ (JJ chronic) (NN transgene) (NN suppression)) (ADVP (RB fully)) (VP (VBZ prevents) (NP (NP (NN synthesis)) (PP (IN of) (NP (DT both) (NNS peptides))))))) (, ,) (NP-SBJ (JJ acute) (NN dox) (NN treatment)) (ADVP (RB fully)) (VP (VP (VBZ suppresses) (NP (NN Aβ40) (NNS levels)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.8)))) (, ,) (NP (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-))) (, ,) (CC but) (VP (VBZ leaves) (NP (NP (DT a) (JJ small) (NN amount)) (PP (IN of) (NP (JJ nonsuppressed) (NN Aβ42)))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (DT The) (JJ residual) (NN Aβ42)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (ADJP (RB acutely) (VBN treated)) (JJ young) (NNS animals))))) (VP (VBZ derives) (PP (IN from) (NP (JJ uncleared) (NNS aggregates) (VBN extracted))) (PP-LOC (IN in) (NP (DT the) (NML (NN SDS) (CC and) (NN FA)) (NNS fractions)))) (. .))) )
( (CAPTION (S (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.005)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001))))) (PP (IN versus) (NP (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NP (NNP Tukey) (FW post) (HYPH -) (FW hoc)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA))))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 3))) )
( (CAPTION (NP (NP (JJ Robust) (NN Transgene) (NN Suppression)) (PP-LOC (IN in) (NP (NP (JJ Older) (NNS Mice)) (PP (IN with) (NP (VBG Preexisting) (NN Amyloid) (NN Pathology))))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (NP (JJ Cortical) (NNS homogenates)) (PP (IN from) (NP (NP (ADJP (NP (QP (CD 6) (HYPH -) (IN to) (CD 12)) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS animals)) (VP (VBN used) (NP (-NONE- *)) (PP (IN for) (NP (NP (NN pathology) (NNS studies)) (VP (VBN described) (NP (-NONE- *)) (ADVP (RB below)) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-))))))))) (VP (VBD were) (VP (VBN immunoblotted) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (ADJP (JJ human) (HYPH -) (JJ specific)) (NN antibody) (NN 6E10))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB examine) (NP (NN transgene) (NN suppression)) (PP (VBG following) (NP (NP (QP (CD 3) (CC or) (CD 6)) (NN mo)) (PP (IN of) (NP (NN dox) (NN treatment)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT The) (NN blot)) (VP (VBD was) (VP (VBN co-immunostained) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (JJ endogenous) (NN superoxide) (NN dismutase) (CD 1)) (-LRB- -LRB-) (NP (NN SOD1)))) (-RRB- -RRB-) (PP (IN as) (NP (NP (DT a) (NN control)) (PP (IN for) (NP (NN loading))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NN Quantitation)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP (IN from) (NP (NP (DT the) (NNP Western) (NN blot)) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (-LRB- -LRB-) (NP (NN A)))))) (-RRB- -RRB-) (. .))) )
( (CAPTION (S (NP-SBJ-1 (JJ Transgenic) (NN APP) (NNS levels)) (VP (VBP are) (ADVP (RB significantly)) (VP (VBN suppressed) (NP-1 (-NONE- *)) (PP-TMP (VBG following) (NP (NP (NML (CD 3) (CC or) (CD 6)) (NN mo)) (PP (IN of) (NP (NN dox) (NN treatment))))) (PRN (-LRB- -LRB-) (NP (NP (CD 96.9) (NN %)) (CC and) (NP (CD 97.6) (NN %))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (VBN compared) (PP (IN to) (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS animals)))))) (, ,) (S-FRM (NP-SBJ (NP (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA) (NN F3) (, ,) (CD 12))))))) (VP (SYM =) (NP (CD 107.22)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (. .))) )
( (CAPTION (S (NP-SBJ (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-1 (JJ strong) (NN transgene) (NN suppression)) (VP (VBZ is) (VP (VBN attained) (NP-1 (-NONE- *)) (PP-TMP (CC both) (IN before) (CC and) (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN amyloid) (NN pathology))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (NP (NN Figure) (CD 1)) (PP (IN for) (NP (JJ predeposit) (NNS experiments))))) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (JJ Experimental) (NN design) (. .))) )
( (CAPTION (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ chronic) (NN Aβ) (NN suppression))) (PP (IN on) (NP (NN amyloid) (NN pathology)))) (PP-TMP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN deposition)))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD compared) (NP (NP (JJ untreated) (NNS controls)) (VP (VBN harvested) (NP (-NONE- *)) (PP-TMP (IN at) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age))))) (PP (IN to) (NP (NP (NNS animals)) (VP (VP (VBN placed) (NP (-NONE- *)) (PP (IN on) (NP (NN dox))) (PP-TMP (IN at) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age)))))) (CC and) (VP (VBN harvested) (NP (-NONE- *)) (PP-TMP (IN after) (NP (NP (NML (CD 3) (CC or) (CD 6)) (NN mo)) (PP (IN of) (NP (NN treatment)))))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP-SBJ (NN Dox) (NN treatment)) (VP (VBZ leads) (PP (IN to) (NP (JJ rapid) (NN transgene) (NN suppression))) (PP-LOC (ADVP (RB even)) (IN in) (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NP (NN Immunostaining)) (PP (IN with) (NP (NN 6E10)))) (VP (VBZ shows) (NP (NML (NN APPswe) (HYPH /) (NN ind)) (NNS levels)))) (VP (VBP are) (ADVP (RB dramatically)) (VP (VBN reduced) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)) (VP (VBN treated) (NP (-NONE- *)) (PP-EXT (IN for) (NP (CD 1) (NN wk))) (PP-MNR (IN with) (NP (NN dox))) (PRN (-LRB- -LRB-) (NP (JJ upper) (NN panel)) (-RRB- -RRB-))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT A) (JJ separate) (NN blot)) (VP (VBD was) (VP (VBN immunostained) (NP-1 (-NONE- *)) (PP (IN for) (NP (ADJP (NP (NN APP) (NN C)) (HYPH -) (JJ terminal)) (NNS fragments))) (PP-MNR (IN with) (NP (NN CT15) (NN antibody))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP-SBJ-2 (NP (DT the) (NNS precursors)) (PP (IN to) (NP (NN Aβ) (NN cleavage)))) (VP (VBP are) (VP (VBN decreased) (NP-2 (-NONE- *)) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (DT the) (NML (JJ full) (HYPH -) (NN length)) (NN protein)))))))))))) (PRN (-LRB- -LRB-) (NP (JJ middle) (NN panel)) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Costaining)) (PP (IN for) (NP (NN superoxide) (NN dismutase) (CD 1)))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (DT an) (JJ internal) (NN control)) (PP (IN for) (NP (NN loading))))) (PRN (-LRB- -LRB-) (NP (NP (JJ lower) (NN panel)) (, ,) (VP (VBN taken) (NP (-NONE- *)) (PP (IN from) (NP (NP (JJ bottom) (NN half)) (PP (IN of) (NP (NN 6E10) (NN blot))))))) (-RRB- -RRB-)))) (. .))) )
( (HEADING (NP (NN Figure) (CD 4))) )
( (CAPTION (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (JJ Transgenic) (NN APP)))) (VP (VBZ Arrests) (NP (NP (NN Progression)) (PP (IN of) (NP (NN Amyloid) (NN Pathology))))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ-1 (VBN Aggregated) (NN Aβ)) (VP (VBD was) (VP (VBN quantified) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (JJ cortical) (NN tissue)) (PP (IN from) (NP (UCP (ADJP (NN dox) (HYPH -) (VBN treated)) (CC and) (NML (NN control))) (NML (NN tTA) (HYPH /) (NN APP)) (NNS mice) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-)))))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT a) (NN filter) (NN trap) (NN assay)))))) (. .))) )
( (CAPTION (S (S (NP-SBJ-1 (NP (JJ Serial) (NNS dilutions)) (PP (IN of) (NP (NN protein) (NN homogenate)))) (VP (VBD were) (VP (VBN passed) (NP-1 (-NONE- *)) (PP (IN through) (NP (DT a) (NN cellulose) (NN acetate) (NN filter)))))) (: ;) (S (NP-SBJ-2 (NP (NN protein) (NNS aggregates)) (ADJP (JJR larger) (PP (IN than) (NP (DT the) (NN pore) (NN size))))) (VP (VBD were) (VP (VBN trapped) (CC and) (VBN immunostained) (NP-2 (-NONE- *)) (PP (IN for) (NP (NN Aβ)))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ-1 (NP (NN Quantitation)) (PP (IN of) (NP (NN signal) (NN intensity))) (PP-LOC (IN in) (NP (NP (DT the) (JJ linear) (NN range)) (PP (IN of) (NP (DT each) (NML (NN filter) (NN trap)) (NN dilution) (NNS series) (PRN (-LRB- -LRB-) (NP (NP (NN arrow)) (PP (IN in) (-LRB- [) (NP (NN A)))) (-RRB- ]) (-RRB- -RRB-))))))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB compare) (NP (JJ aggregate) (NN load)) (PP (IN across) (NP (NN treatment) (NNS groups)))))))) (. .))) )
( (CAPTION (S (NP-SBJ (VBN Aggregated) (NN Aβ)) (VP (VBD increased) (ADVP-EXT (RB significantly)) (PP-TMP (IN between) (NP (NP (NML (CD 6) (CC and) (CD 9)) (NN mo)) (PP (IN of) (NP (NN age))))) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA) (NN F3) (, ,) (CD 18)))) (VP (SYM =) (NP (CD 7.85)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.002)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (DT This) (NN progression)) (PP (IN of) (NP (NN pathology)))) (VP (VBD was) (ADVP (RB completely)) (VP (VBN prevented) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NN transgene) (NN suppression))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (DT The) (NN amount)) (PP (IN of) (NP (VBN aggregated) (NN Aβ)))) (VP (VBD was) (ADJP-PRD (JJ identical)) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice))) (PP-TMP (IN at) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age))))) (PP (IN to) (NP (NP (DT that)) (PP-LOC (IN in) (NP (NP (ADJP (NP (NML (CD 9) (HYPH -) (CC or) (CD 12)) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS animals)) (VP (VBN treated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.9)))) (, ,) (NP (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (-RRB- -RRB-)))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (ADJP (JJ Single) (JJ transgenic)) (NN tTA) (NNS samples)) (VP (VBD were) (VP (VP (VBN included) (NP-1 (-NONE- *)) (PP (IN as) (NP (JJ negative) (NNS controls)))) (CC and) (VP (VBD showed) (NP-1 (-NONE- *)) (NP (NP (DT no) (NN signal)) (PP (IN above) (NP (NN background))))))) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.005)) (PP (IN versus) (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (IN versus) (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NP (NNP Student) (POS 's)) (NN t) (HYPH -) (NN test)))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (NN Amyloid) (NN pathology)) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN of) (NP (NP (JJ representative) (NNS mice)) (PP (IN from) (NP (NP (DT each) (NN treatment) (NN group)) (: :) (NP (NP (NNP Hirano) (NN silver) (NN stain) (PRN (-LRB- -LRB-) (NP (JJ top) (NN row)) (-RRB- -RRB-))) (, ,) (NP (NN thioflavin) (HYPH -) (NN S) (PRN (-LRB- -LRB-) (NP (JJ middle) (NN row)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN Aβ) (NN immunohistochemistry) (PRN (-LRB- -LRB-) (NP (JJ bottom) (NN row)) (-RRB- -RRB-)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NN Amyloid) (NN burden)) (VP (VP (VBZ increases) (ADVP (RB dramatically)) (PP (IN between) (NP (NP (QP (CD 6) (CC and) (CD 9)) (NP (NN mo))) (PP (IN of) (NP (NN age))))) (PP-LOC (IN in) (NP (JJ untreated) (NNS animals)))) (, ,) (CC but) (VP (VBZ remains) (ADJP-PRD (JJ stable)) (PP-LOC (IN in) (NP (ADJP (NN transgene) (HYPH -) (VBN suppressed)) (NNS mice))) (PP-TMP (IN over) (NP (DT the) (JJ same) (NN period))) (PRN (-LRB- -LRB-) (NP (NP (NML (NML (CD 6) (NN mo)) (SYM +) (NML (CD 3) (NN mo))) (NN dox)) (CC and) (NP (NML (NML (CD 6) (NN mo)) (SYM +) (NML (CD 6) (NN mo))) (NN dox))) (-RRB- -RRB-)))) (. .))) )
( (CAPTION (S (NP-SBJ (ADJP (JJ Single) (JJ transgenic)) (NNS animals) (PRN (-LRB- -LRB-) (S (NP-SBJ-1 (NN tTA)) (ADVP (RB only)) (VP (VBN shown) (NP-1 (-NONE- *)) (ADVP (RB here)))) (-RRB- -RRB-))) (VP (VBP show) (NP (NP (DT no) (NN sign)) (PP (IN of) (NP (NN amyloid) (NN pathology)))) (PP-TMP (IN at) (NP (NP (DT any) (NN age)) (VP (VBN tested) (NP (-NONE- *)))))) (. .))) )
( (HEADING (NP (NN Figure) (CD 5))) )
( (CAPTION (S (NP-SBJ (NN Aβ) (NN ELISA)) (VP (VBZ Confirms) (NP (NP (NN Arrest)) (PP (IN of) (NP (NN Progression)))) (PP (IN without) (NP (NP (NN Clearance)) (PP (IN of) (NP (NN Peptide))))) (PP-LOC (IN in) (NP (NP (NNS Mice)) (PP (IN with) (NP (VBG Preexisting) (NNS Aggregates)))))))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Aβ) (NNS levels)) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (NP (NML (CD 6) (HYPH -) (CC and) (CD 9)) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NML (NN tTA) (HYPH /) (NN APP)) (NML (NN line) (CD 107)) (NNS mice) (PRN (-LRB- -LRB-) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (NP (NN Figure) (CD 4))))) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (DT those)) (PP-LOC (IN in) (NP (NP (ADJP (NP (NML (CD 9) (HYPH -) (CC and) (CD 12)) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS animals)) (VP (VBN treated) (NP (-NONE- *)) (PP-MNR (IN with) (NP (NN dox))) (PP-TMP (IN from) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD 6) (NN mo)))))))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (ADJP (JJ Single) (JJ transgenic)) (NN APP) (NNS samples)) (VP (VBD were) (VP (VBN included) (NP-1 (-NONE- *)) (PP (IN as) (NP (JJ negative) (NNS controls))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (JJ Cortical) (NNS homogenates)) (VP (VBD were) (VP (VBN fractionated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (JJ sequential) (JJ multi-step) (NN extraction))) (PP-MNR (IN with) (NP (NP (NP (NN PBS)) (, ,) (NP (NML (CD 2) (NN %)) (NN SDS)) (, ,) (CC and) (NP (NML (CD 70) (NN %)) (NN FA))) (VP (VBN followed) (NP (-NONE- *)) (PP (IN by) (NP-LGS (ADJP (JJ human) (HYPH -) (JJ specific)) (NN Aβ) (NN ELISA)))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB measure) (NP (ADJP (NN transgene) (HYPH -) (VBN derived)) (NN peptide)) (PP (IN in) (NP (DT each) (NN fraction)))))))) (. .))) )
( (CAPTION (S (S (NP-SBJ-1=2 (NN Aβ40)) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)) (PP=3 (IN in) (NP (JJ white)))))) (, ,) (S (NP-SBJ=2 (NN Aβ42)) (PP=3 (IN in) (NP (JJ black)))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (CC and) (LS B) (-RRB- -RRB-)) (NP-SBJ-1 (NP (JJS Most) (NN Aβ)) (PP-LOC (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (ADJP (NN plaque) (HYPH -) (VBG bearing)) (NNS mice)))))) (VP (VBZ is) (VP (VBN extracted) (NP-1 (-NONE- *)) (PP (IN into) (NP (DT the) (NML (NN FA) (CC and) (NN SDS)) (NNS fractions))))) (. .))) )
( (CAPTION (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ Consistent) (PP (IN with) (NP (NN amyloid) (NN burden) (PRN (-LRB- -LRB-) (NP (NP (NNS Figures) (CD 4)) (CC and) (NP (NN Figure) (NN S3))) (-RRB- -RRB-)))))) (, ,) (NP-SBJ (NP (ADJP (NP (NN SDS) (HYPH -) (CC and) (NN FA)) (HYPH -) (VBN extracted)) (NN Aβ) (NNS levels)) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice)))) (VP (VBD were) (ADJP-PRD (ADJP (RB significantly) (JJR higher)) (PP (IN than) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA))) (PP (IN for) (NP (NML (NN SDS) (CC and) (NN FA)) (NNS fractions))))))) (S-FRM (NP-SBJ (NN F3) (, ,) (CD 18)) (VP (SYM =) (NP (QP (CD 4.72) (SYM –) (CD 12.92))))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.02)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NML (CD 3) (CC or) (CD 6)) (NN mo)) (PP (IN of) (NP (NN transgene) (NN suppression)))) (VP (VBD held) (NP (NN Aβ)) (PP (IN at) (NP (NP (NNS levels)) (ADJP (JJ equivalent) (PP (IN to) (NP (NP (DT those)) (VP (VBN harbored) (NP (-NONE- *)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (NN treatment)) (VP (VBD was) (VP (VBN started) (NP-1 (-NONE- *)) (ADVP-2 (-NONE- *T*)))))))))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM >) (NP (CD 0.2)) (PP (VBN compared) (PP (IN to) (NP (NML (CD 6) (NN mo)) (JJ untreated) (NNS mice)))) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.005)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (IN versus) (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NP (NN Significance)) (PP (IN for) (NP (NP (NN APP)) (CC versus) (NP (ADJP (NP (CD 9) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))))) (VP (VBZ is) (VP (VBN based) (NP-1 (-NONE- *)) (PP (IN on) (NP (NP (NNP Student) (POS 's)) (NN t) (HYPH -) (NN test))))) (. .))) )
( (CAPTION (S (S (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP-SBJ (DT The) (NN PBS) (NN fraction)) (VP (VBZ represents) (NP (NP (QP (JJR less) (IN than) (CD 0.1)) (NN %)) (PP (IN of) (NP (JJ total) (NN Aβ) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB note) (NP (DT the) (NN change)) (PP (IN in) (NP (NN y) (HYPH -) (NN axis))) (PP (IN from) (-LRB- [) (NP (NN A) (-RRB- ]) (CC and) (-LRB- [) (NN B))))) (-RRB- ]) (-RRB- -RRB-))))))) (, ,) (CC but) (SINV (ADVP (RB only) (RB here)) (VB do) (NP-SBJ (NP (NN Aβ) (NNS levels)) (PP-LOC (IN in) (NP (DT the) (ADJP (NN dox) (HYPH -) (VBN treated)) (NNS mice)))) (VP (VBP differ) (PP (IN from) (NP (DT those))) (PP-LOC (IN in) (NP (JJR younger) (JJ untreated) (NNS mice))))) (. .))) )
( (CAPTION (S (SBAR-ADV (IN Although) (S (NP-SBJ-1 (DT both) (NNS peptides)) (VP (VBP appear) (S (NP-SBJ-1 (-NONE- *)) (ADJP-PRD (JJ elevated))) (PP (IN in) (NP (DT the) (VBN treated) (NNS groups))) (PP (VBN compared) (PP (IN to) (NP (DT the) (JJ untreated) (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS mice))))))) (, ,) (NP-SBJ (RB only) (NN Aβ40)) (VP (VBZ reaches) (NP (JJ statistical) (NN significance)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (CD 0.05))) (, ,) (NP (NP (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)) (VP (VBN applied) (NP (-NONE- *)) (PP (IN to) (NP (NP (JJ significant) (NN effect)) (PP (IN of) (NP (NN group) (NN ANOVA))) (PP (IN for) (NP (NN Aβ40))))))) (S-FRM (NP-SBJ (NN F3) (, ,) (CD 18)) (VP (SYM =) (NP (CD 4.60)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.02)))) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (S (NP-SBJ-1 (DT A) (JJ similar) (NN trend)) (VP (VBD was) (VP (VBN seen) (NP-1 (-NONE- *)) (PP (IN for) (NP (NN Aβ42))) (, ,) (SBAR-ADV (WHADVP-2 (WRB where)) (S (NP-SBJ (NN ANOVA)) (VP (VBD yielded) (NP (DT a) (JJ significant) (NN effect)) (PP (IN of) (NP (NN group))) (PP (IN for) (NP (ADJP (NN PBS) (HYPH -) (JJ soluble)) (NN Aβ42))) (ADVP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN F3) (, ,) (CD 18)) (VP (SYM =) (NP (CD 3.75)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.03)))) (-RRB- -RRB-)))))))) (, ,) (S (ADVP (RB however)) (NP-SBJ (DT this)) (VP (VBD was) (PP-PRD (IN due) (ADVP (RB only)) (IN to) (NP (NP (NNS differences)) (PP (IN between) (NP (DT the) (JJ untreated) (ADJP (NP (NML (CD 6) (HYPH -) (CC and) (CD 9)) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (NNS groups))))))) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM •)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)) (PP (IN versus) (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NNP Tukey) (ADJP (FW post) (HYPH -) (FW hoc)) (NN test)))) (: ;) (S-FRM (LST (SYM •••)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (PP (IN versus) (NP (ADJP (NP (CD 6) (HYPH -) (NN mo)) (HYPH -) (JJ old)) (JJ untreated) (NNS mice))) (, ,) (NP-ADV (NP (NNP Student) (POS 's)) (NN t) (HYPH -) (NN test)))) (. .))) )
( (HEADING (NP (NN Figure) (CD 6))) )
( (CAPTION (S (NP-SBJ (JJ Neuritic) (CC and) (JJ Glial) (NN Pathology)) (VP (VBP Are) (ADJP-PRD (JJ Unchanged)) (PP-TMP (VBG following) (NP (NN Transgene) (NN Suppression)))))) )
( (CAPTION (S (NP-SBJ (NP (JJ Dystrophic) (NNS neurites)) (CC and) (NP (VBN activated) (NNS astrocytes))) (VP (VBP surround) (NP (JJS most) (JJ compact) (NNS plaques)) (PP-LOC (IN in) (NP (NML (NN tet) (HYPH -) (NN off)) (NN APP) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (NP-SBJ (ADJP (NN Dark) (HYPH -) (VBN stained)) (, ,) (ADJP (NN ubiquitin) (HYPH -) (VBN filled)) (NML (NML (NNS neurites)) (CC and) (NML (JJ reactive) (NNS astrocytes)))) (VP (VBP form) (NP (NP (DT a) (NN halo)) (SBAR-2 (-NONE- *ICH*))) (PP-LOC (IN around) (NP (VBN cored) (, ,) (JJ fibrillar) (NNS deposits))) (PP-TMP (IN by) (NP (NP (CD 6) (NN mo)) (PP (IN of) (NP (NN age))))) (SBAR-2 (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ worsens) (PP (IN with) (NP (NN time)))))) (PP-LOC (IN in) (NP (JJ untreated) (NNS mice)))) (. .))) )
( (CAPTION (S (NP-SBJ (DT Both) (ADJP (NN plaque) (HYPH -) (VBN associated)) (NNS pathologies)) (VP (VBP are) (VP (VBN arrested) (, ,) (SBAR-ADV (IN although) (FRAG (RB not) (VP (VBN reversed)))) (NP-1 (-NONE- *)) (, ,) (PP (IN by) (NP-LGS (NN transgene) (NN suppression))))) (. .))) )
( (CAPTION (NP (NP (NNP Hirano) (NN silver) (NN stain) (PRN (-LRB- -LRB-) (NP (JJ top) (NN row)) (-RRB- -RRB-))) (: ;) (NP (NN GFAP) (NN immunohistochemistry) (PRN (-LRB- -LRB-) (NP (JJ middle) (NN row)) (-RRB- -RRB-))) (: ;) (NP (NN ubiquitin) (NN immunohistochemistry) (PRN (-LRB- -LRB-) (NP (JJ bottom) (NN row)) (-RRB- -RRB-))) (. .))) )
( (HEADING (NP (NN Figure) (CD 7))) )
( (CAPTION (S (NP-SBJ (NN Transgene) (NN Suppression)) (VP (VBZ Attenuates) (NP (NN Hyperactivity)) (PP-LOC (IN in) (NP (NML (NN tTA) (HYPH /) (NN APP)) (NNS Mice)))))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP-SBJ (NP (DT A) (NML (CD 48) (HYPH -) (NN h)) (NN measure)) (PP (IN of) (NP (NN ambulation)))) (VP (VBZ records) (NP (JJ extreme) (NN hyperactivity)) (PP-LOC (IN in) (NP (JJ untreated) (ADJP (JJ double) (JJ transgenic)) (NNS mice))) (PP (VBN compared) (PP (IN to) (NP (ADJP (ADJP (JJ single) (JJ transgenic)) (CC and) (ADJP (JJ nontransgenic))) (NNS controls)))) (PRN (-LRB- -LRB-) (NP (NN line) (CD 107)) (-RRB- -RRB-))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (DT This) (NN phenotype)) (VP (VBZ is) (ADVP (RB completely)) (VP (VBN eliminated) (NP-1 (-NONE- *)) (PP (IN by) (S-NOM-LGS (NP-SBJ (-NONE- *PRO*)) (VP (VBG rearing) (NP (DT the) (ADJP (JJ double) (JJ transgenic)) (NNS mice)) (PP (IN on) (NP (NN dox)))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP-SBJ-1 (NP (DT The) (JJ same) (NNS data)) (VP (VBN shown) (NP (-NONE- *)) (PP (IN in) (-LRB- -LRB-) (NP (NN A))))) (-RRB- -RRB-) (VP (VBP are) (VP (VBN replotted) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB magnify) (NP (NP (NNS data)) (PP (IN from) (NP (UCP (NML (JJ untreated) (NN control)) (CC and) (ADJP (NN dox) (HYPH -) (VBN treated))) (NNS groups))))))))) (. .))) )
( (CAPTION (S (LST (-LRB- -LRB-) (LS C) (CC and) (LS D) (-RRB- -RRB-)) (NP-SBJ-1 (NP (NN Activity) (NNS levels)) (PP (IN in) (NP (NP (DT the) (VBN combined) (NN control) (NNS groups)) (PP (IN of) (-LRB- -LRB-) (NP (NN A) (-RRB- -RRB-) (CC and) (-LRB- -LRB-) (NN B)))))) (-RRB- -RRB-) (VP (VBP are) (ADVP-LOC (RB here)) (VP (VBN separated) (NP-1 (-NONE- *)) (PP (IN by) (NP (NN genotype))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN None)) (PP (IN of) (NP (DT the) (UCP (ADJP (JJ single) (JJ transgenic)) (CC or) (NML (JJ nontransgenic) (NN control))) (NNS groups)))) (VP (VBP display) (NP (DT the) (NN hyperactivity) (JJ present)) (PP-LOC (IN in) (NP (JJ untreated) (NML (NN tTA) (HYPH /) (NN APP)) (NNS animals)))) (. .))) )
( (CAPTION (S-IMP (ADVP (RB Again)) (, ,) (NP-SBJ (-NONE- *PRO*)) (VP (VBP note) (SBAR (-NONE- *0*) (S (NP-SBJ-1 (DT the) (NN y) (HYPH -) (NNS axes)) (VP (VBP have) (VP (VBN been) (VP (VBN enlarged) (NP-1 (-NONE- *)) (PP (IN for) (NP (NN detail))) (PP (VBN compared) (PP (IN to) (-LRB- -LRB-) (NP (NN A)))))))))) (-RRB- -RRB-) (. .))) )
( (HEADING (NP (NNS Footnotes))) )
( (FRAG (NP (NN Citation)) (: :) (CIT (NNP Jankowsky) (NNP JL) (, ,) (NNP Slunt) (NNP HH) (, ,) (NNP Gonzales) (NNP V) (, ,) (NNP Savonenko) (NNP AV) (, ,) (NNP Wen) (NNP JC) (, ,) (FW et) (FW al.) (-LRB- -LRB-) (CD 2005) (-RRB- -RRB-)) (NP (NP (JJ Persistent) (NN amyloidosis)) (PP-TMP (VBG following) (NP (NP (NN suppression)) (PP (IN of) (NP (NN Aβ) (NN production))))) (PP (IN in) (NP (NP (DT a) (JJ transgenic) (NN model)) (PP (IN of) (NP (NNP Alzheimer) (NN disease)))))) (. .)) )
( (CIT (NNP PLoS) (NNP Med) (CD 2) (-LRB- -LRB-) (CD 12) (-RRB- -RRB-) (: :) (NN e355) (. .)) )
